MOHFormulary Drug List

Transcription

1 MOFormulary Drug List

2 Table of Content Introdaction Message of Minister of ealth...5 Deputy Minister of ealth for Supply and Engineering Affairs...7 Use of Formulary...9 Drug Control olicies and Guidelines...10 Reporting of Adverse Drug Reaction (ADR) olicy...20 Medication Error olicy...26 Drug roduct Quality Reporting olicy...43 New Changes and Addition to The Formulary...46 Deleted Items...48 Crash Cart Drugs for ediatrics...50 Crash Cart Medication to Maintain Cardiac Output and for ost Resuscitation Stabilization for ediatric...51 Crash Cart Drugs for Adults...51 Adults Supplementary Drugs (Available in The Ward)...53 Therapeutic Listing of Drugs...54 Drugs used as Antidotes rimary ealth Care Centers Medication List Adverse Drug Reaction Form Medication Error Report Form Drug Quality Report Form Formulary Addition Request Form Automatic Stop of Medication Form Direct urchase Order Form Key Word Index Alphabetical Drug Groups Index Alphabetical Drug Index

3 Message of Minister of ealth In the Name of GOD The Most Merciful, The Most Compassionate In Its ursuit of ealthcare Excellence The Ministry of ealth Is Committed to rovide The ighest Quality and Standards of atient Care and Safety to The eople of This Beloved Country. The Objective of The MO Formulary System Is to rovide Safe, Appropriate and Therapeutically Effective Drug Therapy Consistently Throughout The MO Facilities in Turn Resulting in Minimizing Variation and Enhancing Standardization. This Latest Edition of MO Formulary Contains Updated 2014 Listings as Well as Easy-To-Follow Information and Necessary rocedures to Assist ealthcare rofessionals in Obtaining Specific harmacy Services. Quality of Care Is aramount to The Ministry of ealth and as Such This Formulary Booklet as Been Developed for The ealthcare rofessional to Use as A Tool to rovide Optimum Care to Our recious atients. In Conclusion, I Would Like to Extend My eartfelt Thanks and Appreciation to The Dedicated and ardworking Members of The harmacy and Therapeutic Committee. Abdullah Al Rabeeah, MD, Frcsc Minister of ealth Kingdom of Saudi Arabia 4 5

4 Deputy Minister of ealth for Supply and Engineering Affairs According to The Recommendation of The Minister of ealth About Reviewing The Ministry of ealth Formulary and aving an Easy ortable Edition, It Is Our leasure to Introduce The MO Formulary Drug List Revised Second Edition. This Edition Is Carefully and Extensively Reviewed and Modified By The &T Committee. Our Aim Is to Keep This Formulary Updated By Adding New Drugs That Are Approved By The &T Committee and Constantly Updating The List of Crash Cart and Emergency Drugs. The Formulary of The MO Is Classified According to The harmacological Groups. any Update in The Formulary Regarding Eddition or Deletion Will Be Available on The MO Website. at The End We ope That All These Efforts in Successfully Utilizing This Formulary Will Bare Fruit in elping The Medical Staff erform The Ideal Medical Care, Finally I Wish to Thank The Minister of ealth Dr. Abdullah Bin Abdul Aziz Al Rabeeah, Who Supported Us in Our Efforts to Complete This Formulary. We ighly Appreciate Efforts ut Forth in This Issue God bless you, Salah Fahad Al-Mazroua Deputy Minister of ealth for Supply and Engineering Affairs 6 7

5 INTRODUCTION USE of FORMULARY MO Formulary Drug List Is Divided Into Three Sections. The First Section Is a Compilation of Selected olicies, Guidelines, And Medical Supply Directory The Second Section Is The Therapeutic Listing of All Medications Approved for Using in MO ospitals Each Individual Drug Is Arranged in A Consistent Format That Will rovide The Following Information for Quick Reference When Considering a rescription. Chapter 1 GASTROINTESTINAL SYSTEM Code No. Item Dosage Form Strength ANTACIDS Aluminum hydroxide + Magnesium hydroxide Tablet C urchasable Item ( laned Item ) N Non urchasable Item ( Non lanen Item ) C C C/1 N Medication Under Controled olices Through rescriping, Dispensing and Administration Medication laned to Be Dispensed at rimary ealth Care centers Referral rimary ealth Care Centers Medication laned to Be Dispensed at ospital Narcotic Medication The third section is the appendix included approved abbreviations, MO forms, key ward index, and alphabetical index. 8 9

6 INTRODUCTION DRUG CONTROL OLICIES AND GUIDELINES The harmacy and Therapeutics Committee The harmacy and Therapeutics Committee is a standing medical committee of healthcare professionals MO hospitals, The committee is composed chiefly of physicians, pharmacists and nurses with broad representation from physician specialty groups in the hospital. urposes The primary purposes of the harmacy and Therapeutics Committee are: Advisory The committee recommends the adoption of, or assists in the formulation of policies regarding evaluation, selection, and therapeutic use of drugs in the hospital. Educational The committee recommends or assists in the formulation of programs designed to meet the continuing needs of the professional staff (physicians, nurses, pharmacists, and other healthcare practitioners) on matters related to, drugs and drug use. Scope of Functions : The harmacy and Therapeutics Committee functions are: To serve in an advisory capacity to the medical staff and hospital administration in all matters pertaining to the use of drugs.. to develop a formulary of drugs accepted for use in the hospital and provide for its constant revision; the selection of items to be included in the formulary will be based on objective evaluation of their respective therapeutic merits, safety, and cost; the committee strives to minimize duplication of the same basic drug type, drug entity, or drug product. To establish programs and procedures that help ensure cost-effective drug therapy. to establish or plan suitable educational programs for the hospital s professional staff on matters related to drug use. To participate in quality-assurance activities related to the distribution, administration, and safe use of medications. To review adverse drug reactions and medication errors INTRODUCTION occurring in the hospital and recommend corrective action. To initiate and/or direct drug-use review programs and ensure follow-up of the results. To advise the pharmacy in the implementation of effective drug distribution and control procedures. To make recommendations concerning those drugs to be stocked in hospital patient-care areas. To develop and/or approve policies and procedures relating to the selection, distribution, handling, use, and administration of drugs and diagnostic testing materials. The Formulary System The ospital formulary system is an ongoing process whereby the medical staff working through the harmacy and Therapeutics Committee evaluates and selects those drugs it considers to be the most beneficial in patient care, a formulary represents a continually revised compilation of pharmaceuticols that reflects the current clinical judgment of the medical and pharmacy staff. Drugs evaluated and recommended as such are called formulary drugs and are the only agents that shall be routinely stocked in the pharmacy. Formulary Additions A request for inclusion of a drug in the hospital formulary shall be made by. submitting a Formulary Addition Request along with supporting literature and a signed disclosure of dual interest to the harmacy and Therapeutics (&T Committee). This addition request form is available from MO forms. Requests for addition to the formulary are evaluated on the basis of a literature review of the drug s safety and efficacy, as well as the availability of similar drugs already on the formulary. Generally, each addition is balanced by deletion of an existing product. Individuals requesting an addition to the formulary are asked to present their application to the harmacy and Therapeutics Committee for final decision. Generally, one to two applications for addition of drugs are discussed by the &T Committee at its regular meetings. The committee will make one of the following decisions regarding the request: approval (with or without restriction) denial deferment (until pertinent information becomes available)

7 INTRODUCTION The following rules and guidelines apply to formulary additions. 1. As per Saudi Ministry of ealth directive, only drugs which belong to one of the following categories may be considered for inclusion into formulary: A. medications registered for use in the Saudi Arabia B. medications available for free sale in USA, Canada or European Union from manufacturers registered within the Kingdom s Ministry of ealth C. FDA-approved drug entities from manufacturers not registered with the S.FDA, but available in USA; Canada,European Union. 2. Drugs with unknown formula or composition shall not be admitted to the hospital formulary. Fixed dosage form combinations of two or more agents shall be regarded as undesirable. Such combinations may only be considered when a therapeutic advantage is demonstrated and there are no known disadvantages. 3. A drug may be approved for addition to the formulary for one or more of the following reasons: A. It is the only drug effective for the purpose indicated. (Therapeutic efficacy will be based on Statistically Significant Controlled Studies reported in the medical literature.) B. It is superior to other formulary drugs in use because of: greater efficacy for most patients or for selected patients, taking into consideration variations in patient response decreasedtoxicity or greater patient tolerance easier method of administration C. It possesses equal efficacy and safety as a currently used formulary product but is more economical. Deletion of a Drug Suggestions for deletion of drugs from the formulary may be submitted to the &T Committee by any member of the medical, pharmacy, or nursing staff. In order to control growth of the hospital formulary, some additions will balanced by deletions of another drug. & T committie shall periodically review its stocks and various therapeutic classes on an ongoing basis to effect deletion of duplicate drugs whose usage is low or those which can readily be replaced by less costly but equally INTRODUCTION efficacious alternatives. Deletion of products due to unavailability as a result of discontinuation by the manufacturer, Saudi MO restriction, etc will be noted at the harmacy and therapeutics Committee meetings and recorded in the minutes. All medical, nursing; pharmacy, and other related healthcare providers shall be informed appropriately to minimize impact on patient care. Generic Substitution The formulary system which admits a drug under the nonproprietary name implies permitted substitution of chemically and pharmacologically equivalent products (generics). Restricted Drugs In order to promote and ensure rational use of drugs, &T Committee approves specific usage criteria that must be met prior to dispensing certain drugs. These drugs are referred to as priveleged drugs in the formulary and the prescribing bounded by one of the following types: by indications by specialty by a group of patients by protocol or guidelines It is the responsibility of the physician to ensure that all specific criteria are met before prescribing the drug. The pharmacist, upon receiving an order for a use priveleged drug, shall review and may call the physician for verification of the usage criteria before dispensing. lease consult privileged drug list. Nonformulary Drugs Drugs which are not currently approved by the &T Committee for use at MO hospitals are termed as nonformulary. Only those drugs which are listed in the formulary of the MO will be stocked in the pharmacy and accordingly prescribed by the medical staff. owever, in special clinical situations an attending physician may request procurement of a specific drug if, in his opinion: none of the currently available formulary products meet the therapeutic needs of the patient all acceptable therapeutic alternatives listed in the formulary have been tried and failed v the nonformulary product is superior to the available alternatives

8 INTRODUCTION rocedure for Requesting a Nonformulary Drug 1. supporting literature to his/her Section ead or Department Chair for approval. on ce signed, the Form and literature are sent to the ead of harmacy for approval. 2. The ead of harmacy may consult experts within the hospital or the &T Committee Chair for their opinion of the request. 3. If the ead of harmacy approves the request, he will then arrange procurement of the medication. The time required to make this drug available depends on its local availability. 4. A nonformulary drug is only to be used by the requesting physician for a single patient and is not intended for use by the general staff for the general patient population. roper documentation of use will be maintained by the pharmacy. 5. The requesting physician is required to complete a Form followup letter describing the treatment outcome with the nonformulary drug. 6. A summary of all nonformulary drug requests will be presented periodically to the harmacy and Therapeutics Committee for review. Investigational Drugs An investigational drug is defined as an agent, the use of which has not been approved on a commercial basis by a regulatory body in Saudi Arabia. The Clinical Research Committee, reviews protocols involving drug use in patients. The Investigational Drug Services Section of harmacy Services shall act as the center for procurement, storage, and distribution of investigational drugs and will provide information regarding their preparation and use. An investigational drug shall only be used under the direct supervision of the principal investigator, who shall be a member of the medical staff and who shall assume responsibility for securing the necessary consent from the patient(s) and/or the patient(s) family members, monitoring the therapeutic and adverse side effects of the drug and informing the patient(s) and patient(s) family members beforehand of the possible risks and benefits of the drug therapy. The principal investigator alone is responsible for signing the appropriate release forms, if any, for obtaining the investigational drug from the manufacturer. Signed consent forms must be placed in the patient s chart. harmacy INTRODUCTION will dispense the drug and maintain pertinent records upon receipt of the physician s order, assuming that a signed patient consent form has been placed in the patient s chart. Compassionate Use of an Investigational Drug or a Licensed Drug enicillin or enicillin Derivative Administration To ensure safe penicillin therapy, patients must be tested prior to administration of any penicillin or penicillin derivative. These policies conform to the Saudi Ministry of ealth guidelines and are outlined below. 1. The prescribing physician determines if a patient needs an intradermal skin test or not as per the following guidelines. A. Oral Therapy: Compulsory skin testing is not required, but is left to the discretion of the physician who, before writing a prescription for a penicillin derivative, will ensure that the patient has no allergies to it. If the patient s history is not clear, the physician may ask for a skin test. B. arenteral Therapy: A skin test must be done. If penicillin therapy is to be restarted 30 days or more after the last therapeutic dose or skin test, then a repeat skin test is required. 2. If the physician determines that a skin test is necessary, it must be specified clearly on the prescription order form (eg, administer skin test ). 3. Written permission for administration of the skin test and or penicillin therapy must be obtained from the patient or legal guardian, using Form (Consent for enicillin Administration). 4. Only after the test is negative or the physician is assured that no penicillin allergy exists, will the prescription be forwarded to the pharmacy. 5. The pharmacy will assume that the above procedures have been implemented and will automatically dispense any penicillin derivative prescription it receives without verification of skin test result

9 INTRODUCTION Adverse Drug Reactions An adverse drug reaction reporting program is established at MO to ensure patient safety. The data from the program is reviewed on a regular basis by the harmacy and Therapeutics Committee. An adverse drug reaction is any response to a drug which is noxious and unintended at doses within the manufacturer s recommended dosage range. In the event of an adverse drug reaction (ADR), the procedures outlined below should be followed. 1. The practitioner who ordered the drug is to be notified and appropriate medical treatment is to be administered to the patient. 2. Documentation of the reaction is to be entered in the patient s medical record (eg, nurses notes and physicians orders) and an ADR-alert form is to be completed. 3. The ADR-alert form is to be filled out by any member of the healthcare team who observes the reaction. The form should be imprinted with the patient s nameplate in the space provided. The ADR-alert form can then be forwarded to the harmacy, DrugInformation Center. 4. Upon receipt of the ADR form, the DrugInformationCenter will coordinate the evaluation of a suspected ADR. 5. To ensure that information supplied by the ADR is used effectively towards the goal of improving quality patient care, the results are evaluated, compiled, and reported quarterly to the harmacy and Therapeutics Committee. Signature Cards harmacy maintains electronic and hard copy databases to identify the signatures of all prescribers with clinical privileges. All practitioners are required to submit a completed New Staff Information Form bearing their representative signature to the harmacy Department via Medical and Clinical Operations. INTRODUCTION rescription Writing Drugs are dispensed only upon a written order of an authorized prescriber. Specific and detailed prescription policies are outlined under the inpatient and outpatient medication systems and narcotic and controlled medication section. in order to minimize errors, prescriptions should be written clearly as per the following guidelines. 1. rescriptions should be written in the Agree 100 n/o. 2. For pediatric patients, chemotherapeutic medications, and other critical care drugs in which dose calculation and administration are routinely dependent on patient weight or body surface area (BSA), the doses should be written as mg, ml_, or mcg per kg or per square meter of BSA. atient weight, BSA (wherever applicable), and frequency of dosing should also be a part of the order writing. Example: Digoxin: 10 mcg per kg daily.o. = 40 mcg daily.o. (wt= 4 kg) Vincristine: 1 mg per m 2 I.V. = 2 mg (BSA = 2 m 2 ) 3. In the interest of minimizing errors, the use of abbreviations is discouraged. on ly abbreviations excellent by the &T Committee for medications or their administration are acceptable for prescription writing. The Forms of the Formulary: 1. Adverse Drug Reaction Form 2. Medication Error Report Form 3. Drug Quality Report Form 4. Formulary Addition Request Form Drug Evaluation & Economic Analysis 5. Automatic Stop of medication Form 6. Direct urchase Order Form Note: To print any form please check the attached CD or visit

10 INTRODUCTION Institute for Safe Medication ractices ISM s List of igh-alert Medications Classes/Categories of Medications adrenergic agonists, IV (e.g., EINErine, henylephrine, norepinephrine) adrenergic antagonists, IV (e.g., propranolol, metoprolol, labetalol) anesthetic agents, general, inhaled and IV (e.g., propofol, ketamine) antiarrhythmics, IV (e.g., lidocaine, amiodarone) antithrombotic agents, including: anticoagulants (e.g., warfarin, low-molecular-weight heparin, IV unfractionatedheparin) Factor Xa inhibitors (e.g., fondaparinux) direct thrombin inhibitors (e.g., argatroban, bivalirudin, dabigatran etexilate, lepirudin) thrombolytics (e.g., alteplase, reteplase, tenecteplase) glycoprotein IIb/IIIa inhibitors (e.g., eptifibatide) cardioplegic solutions chemotherapeutic agents, parenteral and oral dextrose, hypertonic, 20% or greater dialysis solutions, peritoneal and hemodialysis epidural or intrathecal medications hypoglycemics, oral inotropic medications, IV (e.g., digoxin, milrinone) insulin, subcutaneous and IV liposomal forms of drugs (e.g., liposomal amphotericin B) and conventional counterparts (e.g., amphotericin B desoxycholate) moderate sedation agents, IV (e.g., dexmedetomidine, midazolam) moderate sedation agents, oral, for children (e.g., chloral hydrate) INTRODUCTION neuromuscular blocking agents (e.g., succinylcholine, rocuronium, vecuronium) parenteral nutrition preparations radiocontrast agents, IV sterile water for injection, inhalation, and irrigation (excluding pour bottles) in containers of 100 ml or more sodium chloride for injection, hypertonic, greater than 0.9% concentration epoprostenol (Flolan), IV magnesium sulfate injection methotrexate, oral, non-oncologic use opium tincture oxytocin, IV nitroprusside sodium for injection potassium chloride for injection concentrate potassium phosphates injection promethazine, IV vasopressin, IV or intraosseous ISM Narcotics/opioids IV transdermal oral (including liquid concentrates, immediate and sustainedrelease formulations) 18 19

11 INTRODUCTION INTRODUCTION Medication Safety olicy No. MO/MS/0006/01 Issue Date: 4/1434ijri Revision Date: 1/1437ijri Reporting of Adverse Drug Reaction (ADR) olicy 1. urpose 1. 1 To establish a comprehensive policy & procedure for : 1. 2 The identification and review of the significant ADRs that will lead to meaningful opportunities to improve the safe and appropriate use of drugs The provision of the means by which caregiver as Medical, harmacy, Nursing and other staff can participate in the MO ospitals/c Centers ADR Reporting. 2. Definition 2. 1 Adverse Drug Reaction definition by 2. 2 World ealth Organization (WO): World health organization defines adverse drug reaction is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or the modification of physiological function Saudi Food & Drug Authority (SFDA): Adverse Drug Reaction is defined as a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man American Society of ospital harmacy: AS defines a significant adverse drug reaction as any unexpected, unintended, undesired or excessive response to a drug that includes: Require discontinuing the drug (therapeutic or diagnostic) Requires changing the drug therapy Requires modifying the dose (expect for minor dosage adjustments) Necessitates admission to hospital rolongs stay in a health care facility Necessitates supportive treatment Significantly complicates diagnosis Negatively affects prognosis Or result in temporary or permanent harm, disability, or death ADR:Adverse drug reaction 4. reventable ADR: an ADR that resulted from a deviation in the medication use process that could be reasonably anticipated based upon existing policies and procedures, patient data, medical literature or accepted medical practice. 5. Forms Attachment: Adverse Drug Reaction Report Form, General Administration of harmaceutical Care, Ministry of ealth 6. olicy 6. 1 All ADRs should be documented on the Ministry of ealth authenticated Medication Error Form (see attached form: Adverse Drug Reaction Form) All ADRs should be documented timely and forwarded to the Medication Safety officer at harmacy Department within 24hrs All ADRs report form should be send to the General Administration of harmaceutical Care, Ministry of ealth All adverse drug reactions must be reported to the harmacy Department which meet the (SFDA) requirements : What should be reported according to the Saudi Food & Drug Authority (SFDA) requirements: All Adverse Drug Reaction that might be related to use of medicines, vaccines, herbal products, and cosmetics All suspected reactions for new drugs including minor ones All serious and /or unexpected reactions for well-known drugs Any increased in frequency of a given reaction All suspected ADRs associated with drug-food or drug herb or food supplement interactions All reactions in special populations such as pregnant and breast feeding women, children and elderly When suspected ADRs are associated with drug withdrawals Any other situation where you believe it needs to be reported ADRs information should be used by the M.O. ospital/ rimary ealthcare Centers to improve the care. 7. rocedures 7. 1 If any caregiver in the MO ospitals/c Centers notices that a patient experiences an adverse drug reaction (ADR), he/ she must assess the patient, including vital signs.

12 INTRODUCTION 7. 2 The caregiver should record the assessment in the patient s medical record The caregiver should notify the patient s attending physician for any needed immediate action. The physician may need to change the therapy and/or provide necessary treatment The caregiver should notify the nursing shift manager. A clear label/note on the medical record should be affixed to indicate that the patient has allergy from such medication The caregiver should utilize the ADR Report form (see attachment) and complete the following information: atient demographics Suspected drug information Concomitant drugs Adverse drug reaction description Outcome data Classification of adverse drug reaction according to: The Naranjo causality scale for adverse drug reaction, (see the Naranjo table and scoring in the attachedadverse Drug Reaction Form page 3) Adverse drug reaction severity (minor, moderate, and severe) 7. 6 Name,rofession,address, phone, and fax 7. 7 The caregiver who notify the ADR should sign the ADR Report form and write the date. The caregiver should send the complete form to Medication Safety officer in the harmacy Department If the caregiver while documenting need clarification of any item that should be completed,he/she may ask the Medication Safety officer to assist him in how to complete documentation of all the required information The Medication Safety officer is responsible to send the completed form (and enter the data in the electronic form in MO website) to the General Administration of harmaceutical Care, National Drug Information Center, Medication Safety Department using the Fax No or phacare-ncdi@moh. gov.sa, if Medication Safety officer need to contact the authorized pharmacist he/she should contact through telephone no Ext The Medication Safety officer is responsible to keep all the original completed ADRs Form in confidential manner. The Medication Safety officer is responsible to aggregate the data INTRODUCTION of all the ADR reported and formulate a Monthly ADR Summary Report The Director of harmacy or designee shall review all Monthly ADR Summary Report The Medication Safety officer is responsible to submit the Monthly ADR Summary Report to : Quality Department TC Committee atient Safety Committee Medication Safety Committee Note: Also The Medication Safety officer is responsible to submit Report of independent case (considered as sentinel event) to them An investigation of the ADRs,specially preventable ADRs causes and contributing factors should be performed and documented by the Medication Safety officer in coordination by the affected Department(s)/assigned team,or RCA investigation if the case is considered as sentinel event Necessary action(s) should be taken with follow-up as necessary to prevent ADRs,specially preventable ADRs occurrence. DEFINITION(s): 1. Adverse Drug Reaction by (World ealth Organization (WO)): World health organization defines adverse drug reaction is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or the modification of physiological function. 2. Saudi Food & Drug Authority (SFDA): Adverse Drug Reaction is defined as a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man. 3. With significance to the specific guidelines the definition for ADR is as follows: A. Food and Drug Administration (FDA): Adverse Drug Reaction is serious adverse event (event relating to drugs or device) as in which the patient outcome is death, life threatening (real risk of dying), hospitalization (initial or prolonged), disability, (signification, persistent, or permanent), congenital anomaly, or required intervention to prevent permanent impairment or damage. B. American Society of ospital harmacy. AS defines a significant adverse drug reaction as any unexpected, unintended, undesired or excessive response to a drug that

13 INTRODUCTION includes: i. Require discontinuing the drug (therapeutic or diagnostic) ii. Requires changing the drug therapy. iii. Requires modifying the dose (expect for minor dosage adjustments). iv. Necessitates admission to hospital v. rolongs stay in a health care facility. vi. Necessitates supportive treatment. vii. Significantly complicates diagnosis. viii. Negatively affects prognosis. ix. or result in temporary or permanent harm, disability, or death. C. Saudi Food & Drug Authority (SFDA) requirements: What should be reported: i. All Adverse Drug Reaction that might be related to use of medicines, vaccines, herbal products, and cosmetics. ii. All suspected reactions for new drugs including minor ones. iii. All serious and /or unexpected reactions for well-known drugs. iv. Any increased in frequency of a given reaction v. All suspected ADRs associated with drug-food or drug herb or food supplement interactions. vi. All reactions in special populations such as pregnant and breast feeding women, children and elderly. vii. When suspected ADRs are associated with drug withdrawals. viii. Any other situation where you believe it needs to be reported. INTRODUCTION TABLE NARANJO CAUSALITY SCALE FOR ADVERSE DRUG REACTIONS No. Question / Scoring Yes / No / Do not know or unavailable Yes No NA Are there previous conclusive reports on this reaction? Did the adverse event appear after the suspected drug was given? Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? Did the adverse reaction appear when the drug was re-administered? Are there alternative causes that could have caused the reaction? Did the reaction reappear when a placebo was given? Was the drug detected in any body fluid in toxic concentrations? Was the reaction more severe when the dose was increased/increasing or less severe when the dose was decreased? Did the patient have a similar reaction to the same or similar drugs in any previous exposure? TOTAL Scoring: >9 = definite adverse drug reaction (ADR) 5-8 = probable ADR 1-4 = possible ADR 0 = doubtful ADR

14 INTRODUCTION Medication Safety olicy no. MO/MS/0007/01 Issue Date: 1/1434 Revision Date: 1/1436 Medication Error olicy 1. urpose 1. 1 To provide a method for the documentation of all medication errors in a manner that allows reviewingthe types and causes with the aim of preventing or minimizing the events. 2. Definition 2. 1 Medication Error : Any preventable event that may cause or lead to inappropriate use or patient harm while the medication is in the control of the health care professional, patient or consumer. Such event may be related to professional practice, healthcare products, procedures, and systems, including prescribing; order communication; product labeling; pre-packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use. 3. Forms Attachment: Medication Error Reporting Form, General Administration of harmaceutical Care, Ministry of ealth 4. olicy 4. 1 All medication errors should be documented on the Ministry of ealth authenticated Medication Error Form (see attached form: Medication Error Reporting Form) All medication errors should be documented timely and forwarded to the Medication Safety officer at harmacy Department within hrs All completed medication errors report form should be send to the General Administration of harmaceutical Care, Ministry of ealth The medication errors are reporting for the purpose of taking preventive measure and improving the quality of pharmaceutical careservices The Medication Errors Reports will not be used to criticize or speculate on actions of the staff involved All Medication Errors Reports should be handled and maintained in a confidential manner Medication errors information should be used by the M.O. ospital/rimary ealthcare Centers to improve the care INTRODUCTION 5. rocedures 5. 1 If any caregiver observing, or involved in or discovering medication error, he/she shall attend to the victim, i.e. patient, visitor or hospitals employee etc. and call for help as needed The caregiver should notify his/her Supervisor or Department Director /ead as soon as possible after the occurrence or discovery of the medication error and if the occurrence is severe, take immediate action The attending physician must be notified immediately to take action The Immediate Supervisor or Employer must be notified to assess the outcome and to take action The patient shall be monitored for unwanted side effects Documenting The Medication Error: The individual discovering the error must initiate documenting the medication error using the Medication Error Reporting Form. If he/she do not document his/her Immediate Supervisor should ask him/her to document it The following information in the Medication Error Report Form must be documented by the individual discovering the error: atient s information Date Error Occurred Time Error Occurred Location (Ward/Unit) Date/Time Error Reported Date Error Discovered Time Error Discovered Error Committed by Error Discovered by Dosage Form Route of Administration ackage Container Error Criteria Stage(s) involved Brief Description of Error The following information in the Medication Error Report Form must be documented by the Immediate Supervisor or Employer: Outcome of Error Cause of error/ Contribution factor

15 INTRODUCTION Immediate Action Taken Immediate Supervisor or Employer should sign the and forward it to the harmacy Department The following information should document by the Immediate Supervisor or Employer in case of error reached the patient that required physician intervention: hysician Follow-up The completed Medication Error Report Form should be delivered to the Medication Safety officer in the harmacy Department The following information in the Medication Error Report Form must be documented by Medication Safety officer at the harmacy Department: Recommendations Medication Safety officer at the harmacy Department should document his/her suggestions to prevent recurrence of error based on his/her assessment of the action taken and document that and sign the Medication error form The Medication Safety officer is responsible to send the completed form (and enter the data in the electronic form in MO website) to the General Administration of harmaceutical Care, National Drug Information Center, Medication Safety Department using the Fax No or phacare-ncdi@moh. gov.sa, if Medication Safety officer need to contact the authorized pharmacist he/she should contact through telephone no Ext The Medication Safety officer is responsible to keep all the original completed Medication Error Reporting Form in confidential manner. The Medication Safety officer must not respond to any request from any employee asking for photocopying any Medication Error Reporting Form to prevent using it against anycare provider for disciplinary action The Medication Safety officer is responsible to aggregate the data of all the medication errors reported and formulate a Monthly Medication ErrorsSummary Report The Director of harmacy or designee shall review all Monthly Medication Errors Summary Report The Medication Safety officer is responsible to submit the Monthly Medication Errors Summary Report to : Quality Department TC Committee INTRODUCTION atient Safety Committee Medication Safety Committee Note:Also The Medication Safety officer is responsible to submit Report of independent case (considered as sentinel event) to them An investigation of the medication errorscauses and contributing factors should be performed and documented by the Medication Safety officer in coordination by the affected Department(s)/assigned team,or RCA investigation if the case is considered as sentinel event Necessary action(s) should be taken with follow-up as necessary to decrease reoccurrence and to prevent medication error occurrence

16 INTRODUCTION ospital harmaceutical Care Department Region MEDICATION ERROR REORT FORM ANONYMOUS (lease fill all applicable information and forward the form to the Medication Safety officer at harmacy Department within hrs) FILE NO. NAME: AGE SEX: M F NATIONALITY CONSULTANT IN-CARGE DEFINITIONS: 1. Medication error is any preventable event that may cause or lead to inappropriate medication use or to patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice; health care products, procedures, and systems, including prescribing; order communication; product labelling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; or use. A broader definition is any error that occurs in the medication-use process. 1 INTRODUCTION clutter), Staffing shortages that result in excessive workload and fatigue, Intimidating behaviors, Out-of-date drug references, Use of error-prone abbreviations, and Medication-related device hazards Near Miss: A medication error that was detected and corrected before it reached the patient1, and according to ISM definition Close call (near miss) is an event, situation, or error that took place but was captured before reaching the patient. for example, penicillin was ordered for a patient allergic to the drug; however, the pharmacist was alerted to the allergy during computer order entry, the prescriber was called, and the penicillin was not dispensed or administered to the patient, or the wrong drug was dispensed by pharmacy, and a nurse caught the error before it was administered to the patient According to definition of near miss from ISM; Category A is Risk, and Category B is Near miss. 5. According to definition of sentinel event from MO policy and procedure. Category G,, and I is Sentinel Event and should be reported within 24 hours Total Quality Department at ospital or rimary Care Centre for all discovered medication errors, Medication Error Report should be completed and forwarded after all necessary information has been gathered to harmacy Department within hours. 2. Risk: azardous conditions that could lead to an error, such as; roducts with look-alike packaging or names, Ambiguous product labels, Error-prone medication delivery devices (e.g., pumps), Error-prone functions in computerized prescriber order entry system, Unsafe environmental conditions (e.g., noise, poor lighting, 30 31

17 INTRODUCTION National Coordinating Council for Medication Error Reporting and revention (NCCMER) 3. Index for Categorizing Medication Errors INTRODUCTION National Coordinating Council for Medication Error Reporting and revention (NCCMER) Index for Categorizing Medication Errors Algorithm 32 33

18 INTRODUCTION INTRODUCTION ISM Key System Elements of Medication Use 6 3. Communication (e.g., Failure to question ambiguous Use electronic prescribing systems that (Cause of error/ Contribution factor: (May underline more than one), ISM ASSESS ERR) communication dynamics among colleagues, team dynamics, communication of or unclear orders or pursue safety concerns because of intimidation by prescriber connect to the pharmacy computer and electronic MAR Use carefully designed, standard Element Examples of Safety roblems Examples of Safety Strategies drug orders) Methods of communicating drug orders and other drug Illegible handwritten orders Error-prone presentation of medication orders on MARs or preprinted orders rohibit error-prone abbreviations, symbols, and dose expressions on 1. atient information (e.g., Untimely access to lab studies Gain electronic access to lab values information are standardized patient profiles orders, MARs, labels, computer screens age, sex, diagnoses, Failure to adjust doses for Communicate patient allergies to and automated to minimize Incomplete medication orders (see Chapter 8) pregnancy, allergies, height, patients with hepatic or renal pharmacy before medications are the risk for error. (missing dose or route, orders Discourage spoken (including weight, lab values, impairment dispensed and administered to resume same medication telephone) orders except in diagnostic study results, atient allergies unknown List allergies and diagnoses on order upon transfer or to take at-home emergencies, and prohibit them for vital signs, ability to pay for Teratogenic medication given to forms and medication administration medications upon admission) cancer chemotherapy prescriptions, patient pregnant patient records (MARs) Abbreviations misunderstood Read back spoken orders to confirm identity) Failure to notice significant lace allergy alert bracelets on (e.g., U misread as a zero) understanding Essential patient information respiratory depression in hospitalized patients Spoken orders misheard Require complete, reconciled orders is obtained, readily available patients receiving IV opioids Use two unique identifiers (or bar Failure to transmit all orders or (not resume orders) upon admission, inuseful form, and atient misidentified coding) to confirm institutional patient prescriptions to the pharmacy transfer, and discharge considered when atient unable to pay for identity Establish a procedure that specifies the prescribing, dispensing, and prescriptions Take MAR to the bedside during drug steps practitioners should take when administering medications. atient weight unavailable for administration; consult patient drug there is disagreement about the safety proper dosing profile prior to pharmacy dispensing of an order Require special monitoring for high-risk Send all orders to the pharmacy, even if patients (those with obesity, asthma, or the medication prescribed is available sleep apnea) receiving IV opioids on the unit or the order does not contain Assess patient s ability to pay for a medication prescriptions and refer to case 2. Drug information (e.g., maximum dose, typical dose, route, precautions, contraindications, special warnings, drug interactions, cross-allergies) Essential drug information is readily available in useful form to those ordering, dispensing, or administering medications. Incomplete information about the patient s at-home medications Knowledge deficit leading to dispensing or administration of the wrong dose or use of the wrong route Lack of staff awareness of special precautions or special monitoring needed with new medication Computer warnings about unsafe doses overlooked or ignored Serious drug interaction unknown or overlooked management/social services if problems are uncovered rovide up-to-date, timely drug information (textbooks and online at all computer terminals) ave staff pharmacists in patient care units for consultation and education rovide readily accessible dosing charts, protocols, guidelines, and checklists for high-alert medications (Chapter 14) Establish maximum doses for high-alert medications; list applicable doses on preprinted orders; build alerts into computer systems to warn staff if doses exceed safe limits ave a pharmacist review all prescriptions and drug orders before administration (except in an emergency) Establish a reconciliation process for verifying patient s at-home medication list and verifying medication lists upon each transfer of care 4. Drug names, labels, and packages Readable labels that clearly identify drugs and doses are on all medication containers, and drugs remain labeled up to the point of administration. Strategies are undertaken to minimize the possibility of errors with products that have similar or confusing labels, packages, or drug names. roduct misidentification due to look-alike drug labels and packages or look-alike/ sound-alike drug names Confusing or ambiguous labels on medications Unlabeled medications or syringes Unlabeled solutions or syringes on a sterile field oorly positioned labels that obscure vital information Doses dispensed in bulk supplies without patient-specific labels Mislabeled medications Consider the potential for look-alike appearance or label ambiguity of commercial containers For institutional use, dispense medications in labeled, unit dose form Label all containers, with drug name and strength most prominent Within institutions, keep oral medications in original packaging until administered at the bedside Store drugs with look-alike names or packages in separated areas or in separated drawers of automated dispensing equipment Use warning labels to alert staff to unusual strengths and special precautions Ensure that pharmacy labels are easy to read and understand Require prescribers to include the indication for prn medications to differentiate them from drugs with look-alike names 34 35

19 INTRODUCTION INTRODUCTION 5. Drug standardization, Multiple concentrations of IV Standardize concentrations of insulin, 6. Medication delivery ump programming errors Examine new devices for the potential storage, and distribution solutions leading to potential heparin, morphine, and vasopressor devices (e.g., infusion Accidental administration of an for errors before purchase and use (e.g., storage of unit stock use of the wrong concentration drips (adult and pediatric) to a single pumps, implantable pumps, oral solution by the IV route via Limit the variety of infusion pumps to medications and Nurse preparation of IV concentration oral and parenteral syringes, devices with Luer connections promote staff proficiency pharmacy-dispensed solutions Use commercially available premixed IV glucose monitors) Rapid free-flow of solution when rohibit the use of infusion pumps medications, preparation of Failure to properly dilute solutions whenever possible The potential for human tubing is removed from the without free-flow protection IV medications, use of concentrated medications and Limit nurse preparation of IV solutions error is mitigated through pump Train staff adequately about use of new standard concentrations, electrolytes before to emergency situations careful procurement, Failure to notice incorrect devices and ensure competency before pharmacy delivery services) administration Dispense medications from the maintenance, use, and default setting on pump, leading independent use Intravenous solutions, drug Selection of the wrong drug or pharmacy according to realistic time standardization of devices to dosing errors Require one nurse to set up a pump and concentrations, and dose caused by unsafe storage frames for stat, urgent, and routine used to prepare and deliver Unfamiliarity with medication another to independently double-check administration times are of medications in the pharmacy medications medications. delivery devices, leading to the solution, settings, line attachment, standardized whenever or on patient care units Store high-alert drugs in the pharmacy misuse and patient before infusing IV solutions possible. Storage of hazardous until needed for a specific patient, or Line mix-ups (e.g., connecting that contain high-alert medications Medications are provided to chemicals, fixatives, and secure and restrict access if they are an IV solution to an epidural Label the distal ends of all tubing if patient care units in a safe developers with medications, available on the unit line) patients are receiving solutions via and secure manner and leading to mix-ups Remove concentrated forms of Insufficient supply of infusion multiple routes (e.g., IV, intra-arterial, available for administration Missing medications because of electrolytes from patient care units pumps to meet patient needs enteral, epidural, bladder instillation) within a time frame that problems with pharmacy rovide all stock medications in unit End users (often nurses) not Use specially designed oral syringes to meets essential patient distribution or nursing dose form (no bulk supplies) involved in purchase decisions administer oral solutions to prevent needs. transmission of orders Remove discontinued medications from regarding medication delivery inadvertent connection to an IV port Unit-based floor stock is Nonstandard medication the unit in a timely manner devices urchase and use pumps that offer restricted. administration times Do not borrow medications from patient technology that can intercept and Delay in therapy due to untimely supplies prevent wrong-dose or infusion rate delivery of new medications or rohibit nursing access to the pharmacy errors failure of nursing transmission after hours; establish a night cabinet of the order with a restricted supply of medications Unsafe nursing access to for use when pharmacy is closed pharmacy after hours 36 37

20 INTRODUCTION INTRODUCTION 7. Environmental factors and Drug mix-ups due to lack of Ensure adequate space, storage, and 8. Staff competency and Delays and errors due to Organize all orientation schedules staffing patterns (e.g., space or cluttered work spaces lighting in stock medication areas, education (e.g., orientation, misunderstanding between according to individual learning needs physical surroundings, Drug mix-ups due to crowded including automated dispensing in-service training, nursing and pharmacy, and assessments physical health of staff, and disorganized storage of cabinets certifications, annual stemming from lack of Arrange staffing so that trainers have organization of unit, lighting, medications in refrigerators rovide work spaces that are free of competencies, skills labs, knowledge of each discipline s reduced workload to avoid overload of noise, foot traffic, storage, Misinterpretation of spoken/ distractions for transcription of simulation of events, off-site practice patterns and normal duties ergonomics, workload, telephone orders because of medication orders education) environments Require new nurses to spend time in the staffing patterns, work noise and distractions Arrange areas for IV and oral dose ractitioners receive Inappropriate medication doses pharmacy to become familiar with drug schedules) Errors in preparation or drug preparation so that they are isolated sufficient orientation to or errors in patient assessment dispensing processes Medications are prescribed, mix-ups due to poorly lighted from noise, foot traffic, and other medication use and undergo and monitoring due to lack of Require new pharmacists to spend time transcribed, prepared, and work spaces and drug storage distractions baseline and annual knowledge about particular on patient care units to become familiar administered in a physical cabinets Make computer screens and patient competency evaluation of patient populations with drug administration processes environment that offers Interruptions during medication monitors adjustable for staff comfort knowledge and skills related Errors related to task overload rovide staff education about new adequate space and lighting administration or preparation and safety during use to safe medication practices. and rushed procedures for medications before they are used and allows practitioners to causing mental slips and other urchase refrigerators that are of ractitioners involved in those with added responsibility Require pharmacy to affix special alerts remain focused on errors adequate size for organized storage of medication use are provided of training new staff or provide nurses with other important medication use. Inadequate staffing patterns medications with ongoing education Medication errors by new or information about nonformulary drugs The complement of qualified, leading to task overload and Establish a realistic staffing plan to about medication error reassigned ( floated ) staff who when dispensing these medications well-rested practitioners rushed procedures safely provide care to patients during prevention and the safe use are required to perform Ensure that reassignment to other matches the clinical Staff member fatigue causing staff illnesses, vacations, and of drugs that have the unfamiliar tasks or give clinical areas ( floating ) is not workload without impaired judgment and flawed fluctuations in patient acuity greatest potential to cause unfamiliar medications without permitted until staff have undergone compromising patient safety. performance of job functions Schedule adequate staffing to allow for harm if misused. proper orientation, education, or orientation and competency verification Mental overload and error staff meals and breaks supervision Include in job descriptions and potential due to inadequate Manage and monitor individual staff Errors with new medications performance evaluations specific breaks schedules to allow adequate rest given to patients without full accountability standards for patient/ Lack of staffing contingency between shifts and to prohibit shifts knowledge of the preparation, medication safety that do not include the plans to cover illness and longer than 12 hours dose, route, action, or effects to absence of errors or a numeric error vacations Minimize the use of transient agency anticipate threshold uman resources required for staff Errors (including near misses) rovide staff with ongoing education new services not fully Communicate plans for new services to that are not reported, with about medication errors that have considered all involved staff, and carefully consider consequent loss of knowledge occurred within the organization and in the resources necessary to handle about the causes of errors and other organizations, as well as additional work volume without their prevention strategies to prevent these errors compromising patient safety rovide staff with the necessary support and time to attend internal and external education programs related to medication use and error prevention 38 39

21 INTRODUCTION INTRODUCTION 9. atient education (e.g., atients might feel Teach patients how to actively 10. Quality process and risk Lack of leadership and Clearly articulate patient/medication drug information sheets, uncomfortable reminding staff participate in proper identification management (e.g., culture, budgetary support for safety in the organization s mission/ dosing schedules for complex medication to verify their identity atients might be reluctant to before accepting medication or undergoing procedures leadership, error reporting, safety strategies, safety redundancies) medication safety Disincentives (shame, blame, fear of disciplinary action, vision statements Train midlevel managers to effectively evaluate competency and handle regimens, discharge ask questions about the rovide patients/families with the brand A nonpunitive, documentation of errors in difficult behavior without allowing the instructions, tips for medications they are receiving and generic names of each medication systems-based approach to personnel files) encourage presence or absence of errors to be a avoiding errors, consumer atients might not understand administered, the general purpose, the error reduction is in place underreporting of errors factor representation in drug safety efforts) information given to them orally because of medical jargon or prescribed dose, and important adverse effects and supported by management, senior administration, and the Culture of secrecy and blame prevents disclosure of errors to patients and families romote a culture where human error is anticipated and accountability for medication safety is shared among atients are included as other language barriers Consult a pharmacist for assistance, board of trustees. Inaccurate error rates organizational leaders and professional active partners in their care Low health literacy or poor especially if patients are, or will be, ractitioners are stimulated determined by using error staff without blame through education about reading skills might prevent taking more than five medications at to detect and report errors, reports, with a romote and reward reporting of errors their medications and ways to avert errors. patients from understanding printed information or directions home Encourage patients to ask questions and interdisciplinary teams regularly analyze errors that have occurred within the counterproductive goal of reducing the number of error reports and hazardous conditions that could lead to errors, and expect a sustained, not reduced, error-reporting rate for using medications about their drug therapy organization and in other Ineffective error prevention Disclose all errors that reach a patient atients often lack resources Fully investigate and resolve all patient organizations for the strategies focused on individual Include discussions about errors and for questions about drug questions or concerns about drug purpose of redesigning performance improvement their prevention in all staff meetings as a therapy after discharge atients might not remember all therapy before drug administration rovide patients with written materials systems to best support safe practitioner performance. Simple redundancies that rather than system improvements Lack of understanding of standing agenda item Convene an interdisciplinary team to routinely review errors and other safety the medications and doses they that use lay terminology (eighth-grade support a system of medication administration as a data to identify system-based causes are taking, which increases the reading level or lower) for high-alert independent double checks system and ways to safeguard and facilitate implementation of risk of errors in prescribing medications prescribed at discharge or an automated verification the system as a whole system-based enhancements medications upon admission atients lack information about Instruct patients on when and whom to call with concerns or questions about process are used for vulnerable parts of the medication-use process to Lack of automated or manual double checks for critical steps in the medication-use process Invite patients and community representatives to participate in medication safety discussions, and the causes of medication errors their drug therapy after discharge detect and correct errors Failure of manual double solicit their input and how to prevent them Encourage patients to keep a written before they reach patients. checks, often because they are Disseminate information regularly record of all their prescription and not performed independently throughout the organization about nonprescription medications, herbal products, and vitamins, and to show the Misplacement or misuse of double checks in place of system enhancements that errors and safety strategies Recalculate all doses for chemotherapy and pediatric medications to verify the list to health care providers during each would prevent error prescriber s order inpatient and outpatient visit erform an independent double check (manual or automated) to verify the drug, dose, concentration, infusion rate, patient, route, and line attachment before administering selected high-alert medications such as IV insulin, IV chemotherapy, and IV opioids (including those used in patient-controlled analgesia) Use bar-coding technology during drug administration 40 41

22 INTRODUCTION INTRODUCTION References 1. Smetzer JL and Cohen MR., Definitions. Ch: Medication Error Reporting Systems, Editing: Cohen MR Medication Errors, 2nd Edition, harmacy Library, accessed 21/8/ Smetzer JL and Cohen MR. Reportable Events, Conditions, and riorities, Ch: Medication Error Reporting Systems, Editing: Cohen MR Medication Errors, 2nd Edition, harmacy Library, accessed 21/8/ Smetzer JL and Cohen MR. Categorizing Reports, Ch: Medication Error Reporting Systems, Editing Cohen MR Medication Errors, 2nd Edition, harmacy Library, accessed 21/8/ ISM survey helps define near miss and close call. ISM Medication Safety Alert Acute Care. September 24, Sentinel Event olicy and rocedures, MO Smetzer JL and Cohen MR. Defining Systems, Ch: Causes of Medication Errors, Editing Cohen MR Medication Errors, 2nd Edition, harmacy Library, accessed 21/8/ Medication Safety olicy no. MO/MS/0008/01 Issue Date: 5/1434 ijri Revision Date: 5/1436 ijri Drug roduct Quality Reporting olicy 1. urpose 1. 1 To establish a comprehensive policy & procedure for : 1. 2 Reporting any Drug roduct quality related problem which occur in the Ministry of ealth facilities to ensure that the required safety, effectiveness and quality of drug products is maintained throughout the entire medication supply system up to the point of use. 2. Definition 2. 1 Drug roduct The finished dosage form that contains a drug substance, generally, but not necessarily in association with other active or inactive ingredients (OTC) Over-the-Counter Drugs An OTC drug defined as safe and effective for use by the general public without a doctor s prescription. 3. Forms 3. 1 Attachment: Drug Quality Report Form, General Administration of harmaceutical Care, Ministry of ealth olicy 4. 1 If the medication did not seemed right to any Medical, harmacy, Nursing and other staff he/she should report that Any drug product (OTC or prescription) problem noted when the drug is received, used, or dispensed should be reported. Drug product problems may include: Efficacy ackaging hysical, chemical or microbiological changes Size / volume Suspected mislabeled drugs Inaccurate or unreadable product labels/labeling (including the package insert) ackaging that is torn or punctured Sterile containers or vials that are punctured or leaking ackaging or product mix-ups

23 INTRODUCTION Abnormal odor or taste Capsule leakage Chipped, cracked, or splitting tablets Tablet or capsule discolorations Broken, cracked, or chipped syringes Suspected product contamination Sterile syringes with floating objects or growth s with foreign floating objects or growth Container closure defects Leaking vials 4. 3 All drug product problems should be documented in the official Drug Quality Report Form (see attached form: Drug Quality Report Form), The report must be completed, in a timely manner It s important to : Fill the Drug Quality Report Form out completely as possible Attach additional information, if needed The Medication Safety officer is responsible to communicatethe competed Drug Quality Reports to General Administration of harmaceutical Care, Ministry of ealth in an organized and systematic way. 5. All the competed Drug Quality Reports should be handled by the Medication Safety officer in confidential and secure manner. 6. rocedures 6. 1 If any Medical, harmacy, Nursing and other staff notes any quality related problem while receiving, using, or dispensing any drug product (OTC or prescription), he/she should report that using the official Drug Quality Report Form (see attached form) The one noting quality related problem may contact their pharmacists first if they have drug quality concerns or complaints. harmacists can provide essential information regarding the product and the product labeling The one noting quality related problem should fill the Drug Quality Report Form out completely as possible with regard to suspect product information and contact information. If the one noting quality related problem while documenting need clarification of any item that should be completed,he/she may ask the Medication Safety officer to assist him in how to complete documentation of all the required information. INTRODUCTION 6. 4 The completed Drug Quality Report Formshould be delivered to the Medication Safety officer in the harmacy Department within 24 hours in the event that a product defect is suspected to be a widespread problem which may bedetrimental to patients, the Medication Safety officer notifies the harmacy Director for further action to be taken. harmacy inventory and purchasing staff are also informed in order to implement measures such as a recall, if necessary The Medication Safety officer is responsible to send the completed form (and enter the data in the electronic form in MO website) to the General Administration of harmaceutical Care, National Drug Information Center, Medication Safety Department using the Fax No or phacare-ncdi@moh. gov.sa, if Medication Safety officer need to contact the authorized pharmacist he/she should contact through telephone no Ext The Medication Safety officer is responsible to keep all the original completed Drug Quality Report Form in confidential and secure manner. The Medication Safety officer must not respond to any request from any employee asking for photocopying any Drug Quality Report Form The Medication Safety officer is responsible to aggregate the data of all the medication errors reported and formulate a Monthly Drug Quality Summary Report The Director of harmacy or designee shall review all Monthly Drug Quality Summary Report The Medication Safety officer is responsible to submit the Monthly Drug Quality Summary Report to : TC Committee Medication Safety Committee An investigation of the drug product quality related problem should be performed and documented by the Medication Safety officer. Necessary action(s) should be taken with follow-up as necessary

24 INTRODUCTION New Changes and Addition to The Formulary Code No. Item Specification Dosage Form Strength Budesonide 3mg Capsules Capsule 3 mg Milrinone 1mg/ml (10ml) rocainamide cl 1 Gm (10 ml) ropranolol cl Ampoule 1mg/ml (5ml) Sodium Nitroprusside Ampoule or 10mg/ml (5ml) 50 mg Candesartan Tablets 8mg Candesartan Tablets 16mg Telmisartan Tablets 40mg Olmesartan Tablets 20mg Nitroglycerin Ampoule or 5mg/ml (10ml) Dobutamine cl Ampoule or 250 mg/10ml Noradrenaline Acid Tartrate Ampoule 1mg/ml (4mg/Amp (4ml)) Diphenhydramine cl 50mg/ml romethazine cl Ampoule 50 mg/ 1ml Bromhexine cl Tablets 8mg Bromhexine cl Syrup 4mg/5ml Betahistine Tablet 16 mg Dihydrochloride henytoin Sodium 250 mg (5ml) Raltegravir Tablet 400 mg Glimepiride Tablet 2mg Vasopressin Ampoule 20 U/ml 1ml Iodine Vaginal Dish Vaginal Dish 10% Cholecalciferol Capsule 1000 Iu (Vitamin D3) Cholecalciferol Capsule 5000 Iu (Vitamin D3) Biotin Tablet 10 mg Arginine cl Oral owder owder Jar 100 Gm 100 Gm Arginine cl 10% Iv 300 ml Bottle 100mglml Sodium Benzoate Oral Bottle 500 Gm owder INTRODUCTION Sod henyl Acetate+Sod Ampoule 10% Benz 10% Carglumic Acid Tablet 200 mg henyl Butyrate Tablet 500 mg Riboflavine B2 Tablet 100 mg Diclofenac Gel 1-3% Indomethacin Ampoule 1mg Lornoxicam Ampoule 8 mg Cortamiton Cream 10% Ampoule, mg/ Atropine Sulfate refilled ml,0.05mg/ml 5ml Syringe Calamine Lotion Chlorhexidine 2 % and Stick 2% & 70% Alcohol 70% Didecyl Dimethyl Spray Ready to % ml Ammonium Bromide Use Didecyl Dimethyl Concentrated % 2-5 L Ammonium Bromide Solutions eracetic Acid Solution (3-5 %)1-2 L Iodophor 7,5 % & 7.5% & 70% Solution Isopropyle Alcohol 70% ( ml) Adrenalin refilled Syringe 300 Mcg (Epinephrine) Tetrastarch (ydroxyethyl Infusion 6% 500 ml Starch Waxy Maiez) 10%( ml) / Urea Lotion Bottle Omalizumab 150mg Telaprevir Tablet 375mg Sodium Chloride Nasal Drops 0.9% ml Tretinoin Liquid 0.05% ml / Bottle Tretinoin Gel % Gm / Tube 0.025% Gm / Tretinoin Cream Tube 46 47

25 INTRODUCTION INTRODUCTION Deleted Items Sodium Bicarbonate owder Container 5 Kg Code No. Item Specification Dosage Form Strength eparin Calcium for Ampoule 5,000 I.U. Subcutaneous Injection Desmopressin Acetate Tablet 200 Mcg Desmopressin Acetate Nasal Spray 10 Mcg 5-6 ml Ritodrine cl Tablet 10 mg Ritodrine cl Ampoule 50 mg ydrxoy Ethyl Starch Infusion 6 % 500 ml/ Bottle olymyxin B+ Neomycin Eye Dropper ml 5ml Bottle Ketoconazole Tablet 200 mg henol Crystals owder 100 Gm Container Chlorhexidine Gluconate + Container 1.5% + 15% )1 Liter) Cetrimide Solution Ethyl Alcohol Container 95% 25 Liters/ Container Formaldehyde Solution Container 1 Liter/ Container (Formalin) Glutaraldehyde With Activator Buffer for Container 2 % 5 Liters/ Container Adjusting The h at ydrogen eroxide (20 Bottle 6% 500 ml/ Bottle Volume) Isopropylalcohol Absolute Container (99%), 25 Liters/Container Cefaclor Suspension 250 mg / 5 ml Cefaclor Tablet or Capsule 250 mg Tropisetron Capsule 5 mg Oxytetracyclin Capsule 250 mg Tobramycin Sulfate Ampoule or 80 mg Roxithromycin Tablet or Capsule 150 mg Coal Tar Ointment 5 % Coal Tar Shampoo 1% Dithranol Ointment % Dithranol Ointment 0.1% Famotidine Tablet 20 mg Nizatidine Tablet 150 mg Sulfacetamide Eye Dropper Calamine Gentian Violet Crystals (Medical) otassium Chloride owder Container owder Container owder Container 1 Kg 100 Gm 1 Kg 48 49

26 INTRODUCTION Crash Cart Drugs for ediatrics S/N Name of Drugs Qty Qty remixed /Amp Bag/Syg 1 Adenosine 3mg/ml (2ml) Iv Vail Amiodarone 1.5mg/ml (150mg/100ml) remixed Bag 2 3 *If Not Available Amiodarone 50mg/ml (3ml Ampoule) Iv Inj. Atropine Sulphate 0.05mg/ml 5ml refilled Syringe *If Not Available Atropine Sulphate 0.1mg/ml ml refilled Syringe. 4 Calcium Chloride 10% (10ml) refilled Syringe Epinephrine 1:10,000(0.1mg/ml) 5ml refilled 5 -- Syringe. 5 *If Not Available Epinephrine 1:10,000(0.1mg/ml) ml refilled Syringe. Glucose 10%, 10ml Ampoule *If Not Available Glucose 10%, 250ml lastic 2 -- Bottle Lidocaine 2% 20mg/ml, 100mg/5ml refilled 2 -- Syringe Magnesium Sulfate (10mg/ml) 1G/100ml remixed Bags 1 2 *If Not Available Magnesium Sulfate 10% (20ml). rocainamide cl 100mg/1ml (1G/Vail (10ml)) -- 2 Iv Injection. Sodium Bicarbonate 1Meq/ml (10ml) refilled 2 -- Syringe. *If Not Available: Sodium Bicarbonate 8.4% 2 -- (50ml) refilled Syringe. Naloxone 1mg/ml, 2ml refilled Syringe. *If Not Available Naloxone 0.4mg/ml 2 2 1ml Ampoule S/N INTRODUCTION Crash Cart Medication to Maintain Cardiac Output and for ost Resuscitation Stabilization for ediatric Name of Drugs Dobutamine 500mg/250ml D5w remixed Bag *If Not Available Dobutamine l250mg/ 10ml Iv. Dopamine 800mg/250ml D5w remixed Bag *If Not Available 40mg/ml (5ml) Iv Ampoule. Epinephrine 1:1,000(1mg/ml) 5ml refilled Syringe *If Not Available Epinephrine 1:1,000(1mg/ml) 1ml Ampoule Milrinone 200Mcg/ml, 20mg/100ml D5w remixed Bag. *If Not Available Milrinone 1mg/ml (10ml) Norepinephrine 1mg/ml (4mg/Amp (4ml)) Iv Ampoule. Qty remixed Bag/Syg Qty Vail/Amp Sodium Nitroprusside 10mg/ml (5ml) Iv Vail -- 2 S/N 1 2 Name of Drugs Crash Cart Drugs for Adults Amiodarone (1.8mg/ml) 360mg/200ml D5w remixed Bag *If Not Available 50mg/ml(3ml Ampoule) Iv Injection. Atropine Sulphate 0.1mg/ml (10ml) refilled Syringe. *If Not Available : Atropine Sulphate mg/ml (10ml Ampoule) Qty remixed Bag/Syg Qty / Amp Calcium Chloride 10% (10ml) refilled Syringe

27 INTRODUCTION INTRODUCTION 4 Dextrose 50% (50ml) refilled Syringe. *If Not Available Dextrose 50% 50ml Iv Vail. 1 2 Adults Supplementary Drugs (Available in The Ward) 5 Dobutamine 500mg/250ml D5w remixed Bag. *If Not Available Dobutamine l250mg/10ml Iv Ampoule Dopamine 800mg/250ml D5w remixed Bag. *If Not Available Dopamine 40mg/ml (200mg/5ml) Iv Vail. 1 2 Epinephrine 1:10,000(0.1mg/ml) 10 ml refilled Syringe *If Not Available Epinephrine 1:10,000(0.1mg/ml) 10ml Ampoule. Norepinephrine 1mg/ml, 1ml Ampoule, {4mg/Amp 2 2 (4ml)} Iv Ampoule. rocainamide cl 100mg/1ml {1G/Vail (10ml)}Iv 2 2 Injection. Sodium Bicarbonate 1Meq/ml 8.4% (50ml) refilled Syringe. 2 2 *If Not Available: Sodium Bicarbonate 8.4% (50ml) Iv. Magnesium Sulfate (40mg/ml) 2Gm/50ml remixed Bag 1 2 *If Not Available Magnesium Sulfate 10% (10ml) Vail 12 Vasopressin 20U/ml 1ml Lidocaine 2% 20mg/ml 100mg/5ml refilled 2 -- Syringe S/N Name of The Drugs Qty remixed Qty /Amp Bag/Syg 1 Calcium Gluconate 10% (10ml) Iv Ampoule. 2 2 Dextrose 10% 500ml Iv in Bottle. 2 3 Digoxin 0.25mg/ml (2ml) Iv Injection. 2 4 Furosemide 10mg/ml (2ml) Iv Ampoule. 2 5 ydrocortisone 100mg Iv Ampoule. 5 6 Isoproterenol cl 1:5000 (0.2mg/ml) 1ml Ampoule. 2 7 Nitroglycerin (100Mcg/ml) 25mg/250ml remixed Bag. 2 5 *If Not Available Nitroglycerin 5mg/ml (10ml) Iv 8 henytoin 250mg Iv (5ml) 5 9 ropranolol 1mg/ml Iv (5ml) 2 10 Diphenhydramine 50mg/ml 5 (1 ml Fill in 2 ml Cartridge) 11 Diltiazem 5mg/ml (10ml) *If Not Available Verapamil 2.5 mg/ml (5mg/2ml) Sodium Chloride 0.9% 10ml reservative Free 2 14 Lidocaine Infusion 2G/500ml D5w remixed Bag Epinephrine 1:1,000 (1mg/ml) 10ml refilled Syringe *If Not Available Epinephrine 1:1, (1mg/ml) 1ml Ampoule

28 GASTROINTESTINAL SYSTEM GASTROINTESTINAL SYSTEM Chapter 1 Gastrointestinal System antoprazoole Sodium Sesquihydrate Antidiarrheal Drugs 40 mg N G I T SYSTEM 1 Code No. Item Specification Dosage Form Strength 01. Gastrointestinal System Antacids Aluminum ydroxide Tablet N C Magnesium ydroxide Aluminum ydroxide Magnesium ydroxide Suspension 100 ml C (Low Sodium) Antispasmodics Loperamide cl Capsule 2 mg Kaolin + ectin Suspension 9.88Gm + 22 mg/ 5ml 60ml/ Bottle Drugs for Inflammatory Bowel Diseases 400 mg Mesalazine Tablets 500 mg Mesalazine Suppository mg Sulfasalazine, 500 mg/ Tablets 500 mg Tablet G I T SYSTEM yoscine Butylbromide Tablet 10 mg C rednisolone Enema With A Nozzle 20 mg 100 ml yoscine Butylbromide Suppository 10 mg Budesonide 3mg Capsules Capsule 3 mg N yoscine Butylbromide for Ampoule 20 mg C Injection yoscine Syrup 5mg/5ml C Butylbromide Mebeverine cl Tablet 200 mg C Mebeverine cl Tablet 135 mg Ulcer-ealing Drugs Receptor Antagonists Ranitidine Tablet 150 mg C Ranitidine cl Ampoule 50 mg Chelates and Complexes Sucralfate Tablet 1 Gm N roton ump Inhibitors Tablet or Omeprazole 20 mg C Capsule Lansoprazole Tablet 30 mg N Esomeprazole Tablet 20 mg Magnesium Trihydrate Laxatives Bulk-Forming Laxative Bulk-Forming Laxative ack 7 or 15 Gm C Stimulant Laxatives Bisacodyl Tablets 5 mg C Bisacodyl Suppository 5 mg Bisacodyl Suppository 10 mg C Docusate Sodium Tablets 100 mg Docusate Sodium Oral Solution 12.5 mg / 5ml N Glycerin Adults Suppository 2 g C Glycerin ediatric Suppository 900 mg C Suppository Senna Tablets 5-10 mg C Osmotic Laxatives Gm/ ml Lactulose Syrup C (300 ml) hosphate Enema Enema 60 ml N hosphate Enema Enema ml Omeprazole Sodium 40 mg 54 55

29 GASTROINTESTINAL SYSTEM CARDIOVASCULAR SYSTEM G I T SYSTEM 1 olyethylene Glycol, G Oral owder, Sodium Bicarbonate mg, Sachet, Oral N Sodium Chloride 350 owder mg, otassium Chloride 46.6 mg / Sachet Antiflatulent Drugs Simethicone Tablets mg C Simethicone Oral Dropper 40mg/ 0.6ml C 30ml/ Bottle Chapter 2 Drugs Used in the Treatment of Diseases of The Cardiovascular System Code No. Item Specification Dosage Form Strength 02. Drugs Used in The Treatment of Diseases Of The Cardiovascular System ositive Inotropic Drugs Cardiac Glycosides Digoxin Tablets 125 Mcg Digoxin Tablets 250 Mcg C V SYSTEM reparations for emorrhoids Soothing reparations With Corticosteroids Antihemorrhoidal Ointment or Gm/ Tube C Without Steroid Cream Antihemorrhoidal Suppository C Without Steroid Rectal Sclerosants Oily henol Injection Ampoule 5% 5ml N Oral Elixir 50 Mcg/ml Digoxin With Dropper ml/ Bottle Digoxin Ampoule 100 Mcg N Digoxin Ampoule 500 Mcg/ 2ml hosphodiesterase Type-3 Inhibitors 1mg/ml Milrinone N (10ml) Diuretics Drugs Affecting Intestinal Secretions Thiazides and Related Diuretics Multienzyme Chlorthalidone Tablets 50 mg (ancreatic Enzymes : rotease U ; Lipase 5,000-10,000 U and Amylase 5,000-10,000 U) /Capsule or Capsule or Enteric Coated Tablet I.u I.u I.u C/ ydrochlorothiazide Tablets 25 mg C Indapamide (Sustainad Tablet 1.5 mg C Release) Metolazone Tablet 2.5 mg Metolazone Tablet 5 mg Enteric Coated Tablet Metolazone Tablet 10 mg Drugs Acting on The Gall Bladder Loop Diuretics Ursodeoxycholic Acid Tablet 250 mg Furosemide Tablets 40 mg C Ursodeoxycholic Acid Suspension 250 mg/ 5 ml N Furosemide Tablets 500 mg N Furosemide Oral Solution 5 mg / 5 ml ml Furosemide Ampoule 10 mg/ml (20 mg/ 2 ml) C Furosemide for Injection Ampoule or 10 mg/ml (250 mg/ 25 ml) otassium-sparing Diuretics and Combined Diuretics 56 57

30 CARDIOVASCULAR SYSTEM CARDIOVASCULAR SYSTEM Spironolactone Tablets 25 mg C Mexiletine cl Ampoule 250 mg N C V SYSTEM 2 25 mg / 5 ml Spironolactone Oral Solution N 100 ml Triamterene + 50 mg Tablets N ydrochlorothiazide 25 mg Amiloride cl Tablets 5 mg + 50 mg ydrochlorothiazide Osmotic Diuretics Infusion 20% 250 ml Mannitol Bottle Glass Bottle Antiarrhythmic Drugs Supraventricular Arrhythmias 3mg /ml Adenosine (2ml ) Beta-Adrenoceptor Blocking Drugs ropranolol cl Tablets 10 mg ropranolol cl Tablets 40 mg C ropranolol cl Syrup 20 mg/5 ml N 100 ml ropranolol cl Ampoule 1mg/ml (5ml) N Atenolol Tablets 50 mg N Atenolol Tablets 100 mg C Esmolol cl Ampoule or 100 mg Labetalol cl Tablets 100 mg Labetalol cl Ampoule or 5 mg/ ml (100 mg/ 20 ml) C V SYSTEM Supraventricular and Ventricular Arrhythmias Amiodarone cl Tablets 200 mg Amiodarone cl for 50mg/ml (3ml Ampoule C Injection Ampoule) Disopyramide Capsule 100 mg N hosphate Disopyramide Ampoule 50 mg N hosphate rocainamide cl Tablets 250 mg N rocainamide cl Tablet 500 mg N (Sustainad Release) rocainamide cl 1 Gm (10 ml) C Carvedilol Tablets 6.25 mg C Bisoprolol Fumarate Tablets 2.5 mg N Carvedilol Tablets 25 mg C Bisoprolol Fumarate Tablets 5 mg C Metoprolol Tartrate Tablets 50 mg Metoprolol Tartrate Ampoule 5 mg Sotalol ydrochloride Tablets 80 mg N Antihypertensive Drugs Vasodilator Antihypertensive Drugs Diazoxide Ampoule 300 mg N Diazoxide Suspension 250 mg/ 5 ml30 ml/ Quinidine Sulfate Tablets 200 mg Bottle Quinidine Gluconate 800 mg N Ventricular Arrhythmias ydralazine clmesilate Tablets 25 mg Bretylium Tosylate Ampoule 500 mg N refilled 1% 100 mg Lidocaine cl C Syringe ml/ Syringe refilled 2%, 100 mg Lidocaine cl C Syringe ml/ Syringe Dihydralazine Mesilate Ampoule 20 mg or ydralazine cl Ampoule or 10mg/ml Sodium Nitroprusside N (5ml) 50 mg Centrally Acting Antihypertensive Drugs Lidocaine cl remixed Bag 2 Gm in 500 ml D5w C Clonidine cl Tablets 100 Mcg N Methyldopa Tablets 250 mg C Lidocaine cl, %, 1 G N reservative Free Mexiletine cl Capsule 200 mg N Alpha-Adrenoceptor Blocking Drugs razosin cl Tablets 1 mg C razosin cl Tablets 5 mg C 58 59

31 CARDIOVASCULAR SYSTEM CARDIOVASCULAR SYSTEM Tamsulosin cl (Modified Release) Tablets 400 Mcg C/ Diltiazem 5mg/ml (10ml) N heochromocytoma hentolamine Mesylate Ampoule or 10 mg N Diltiazem cl Tablet 90 mg (Sustainad Release) Nimodipine Tablets 30 mg C V SYSTEM Angiotensin-Converting Enzyme Inhibitors Captopril Tablets 25 mg C Captopril Suspension 25 mg/5 ml 100 ml Enalapril Maleate Tablets 10 mg C Lisinopril Tablets 10 mg C Fosinopril Tablets 10 mg N erindopril Tablets 4-5 mg C Angiotensin Ii Receptor Antagonist Valsartan Tablets 80 mg C Losartan otassium Tablets 50 mg C Irbesartan Tablets 150 mg C Telmisartan Tablets 80 mg Telmisartan Tablets 40mg C Candesartan Tablets 8mg C Candesartan Tablets 16mg C Olmesartan Tablets 20mg C Nitrates, Calcium-Channel Blockers, and eripheral Vasodilators Nitrates Nitroglycerin (24-our Effect Dose) Nitroglycerin Nitroglycerin Isosorbide Dinitrate Transdermal 10 mg atch Sublingual mg C Tablet Ampoule or 5mg/ml C (10ml) Sublingual 5 mg C Tablet Isosorbide Dinitrate Tablets 10 mg Isosorbide Dinitrate Tablet or mg C (Sustainad Release) Capsule Ivabradine Tablet 5 mg Calcium-Channel Blockers Diltiazem cl Tablets 60 mg Verapamil cl Tablets 40 mg Verapamil cl Tablets 80 mg Verapamil cl Tablet 120 mg N (Sustainad Release) Verapamil cl Oral Solution 40 mg / 5 ml N 100 ml Verapamil cl Ampoule 5 mg Tablet or Amlodipine Besilate 5 mg C Capsule Felodipine Retard Tablets 5 mg N (Modified Release) Nifedipine Retard Tablet or mg C (Modified Release) Capsule Nifedipine Retard Tablet or mg (Modified Release) Capsule Amlodipine Besilate Capsule 10 mg N Felodipine Retard Retard Tablet 10 mg N (Modified Release) Nifedipine Retard Tablet or mg (Modified Release) Capsule eripheral Vasodilators Cinnarizine Capsule 75 mg entoxifylline Capsule 400 mg apaverin 300 mg N Sympathomimetics Inotropic Sympathomimetics Ampoule or Dobutamine cl 250 mg/10ml 500 mg in remixed Dobutamine cl 250 ml D5w C Bag Bag Ampoule or Dopamine cl 200 mg C V SYSTEM

32 CARDIOVASCULAR SYSTEM CARDIOVASCULAR SYSTEM C V SYSTEM mg in remixed Dopamine cl 250 ml D5w C Bag Bag Isoprenaline cl 200 Mcg/ ml Ampoule C (Isoproterenol cl) (5 ml) Vasoconstrictor Sympathomimetics Noradrenalin Acid Ampoule Tartrate Adrenalin refilled (Epinephrine) Syringe Adrenalin refilled (Epinephrine) Syringe Adrenalin refilled (Epinephrine) Syringe Racemic Epinephrine Oral Inhalor 1mg/ml (4mg/ C Amp (4ml)) 150 Mcg 300 Mcg 1:10,000 C (1mg/ml) 2.25% 15-30ml Ephedrine mg / Ampoule ydrochloride ml Ephedrine 3 mg/ ml in Ampoule N ydrochloride 10 ml Low Molecular Wieght eparin (Treatment Dose) Dvt, ulmonary Embolism refilled Tinzaparin Sodium I.U. Syringe refilled Enoxaparin 6000 I.U. N Syringe refilled Dalteparin 7500 I.u N Syringe Low Molecular Wieght eparin (Treatment Dose) Cardiac Treatment Myocardial Infarction, Unstable Coronary Artery Disease, Acute Coronary Syndrome refilled Enoxaparin 8,000 I.U. Syringe refilled Dalteparin I.u N Syringe I.u / Tinzaparin Sodium N Low Molecular Wieght eparin (rophylaxis Dose) igh Risk refilled Enoxaparin I.U. Syringe C V SYSTEM henylephrine cl Ampoule 10 mg Anticoagulants and rotamine Dalteparin refilled Syringe 5000 I.u N eparin Sodium Ampoule 5000 I.u ml Tinzaparin Sodium refilled Syringe I.u N eparin Sodium (Bovine) 25,000 I.U. / 5 ml Low Molecular Wieght eparin (rophylaxis Dose)Moderate Risk Warfarin Sodium Tablets 1 mg Warfarin Sodium Tablets 2 mg Enoxaparin refilled Syringe 2000 I.u Warfarin Sodium Tablets 5 mg Anagrelide Capsule 500 Mcg Tinzaparin Sodium refilled Syringe 3500 I.u N Rivaroxaban Tablet 10 mg rotamine Sulfate Ampoule 1% 50 mg/ 5ml Dalteparin Antiplatelet Drugs refilled Syringe 2500 I.U. N Dabigatran Tablet or Capsule 75 mg Acetyl Salicylic Acid (Enteric Coated) Tablet mg C Dabigatran Dabigatran Tablet or Capsule Tablet or Capsule 110 mg 150 mg Clopidogral Tablets 75 mg C Tirofiban 250 Mcg / ml ydrochloride 50ml Dipyridamol Ampoule 20mg N 62 63

33 CARDIOVASCULAR SYSTEM CARDIOVASCULAR SYSTEM Fibrinolytic Drugs Factor Ix Fraction for Alteplase 50 mg Injection, Which Is C V SYSTEM Reteplase Set 10 mg Streptokinase 250,000 I.U Streptokinase 750,000 I.U Antifibrinolytic Drugs and emostatics Antifibrinolytic Drugs and emostatics Ethanolamine Ampoule 250 mg N Tranexamic Acid Tablets 500 mg N Aminocaproic Acid Tablets 500 mg N Tranexamic Acid Syrup 500 mg / 5 ml N Aminocaproic Acid Syrup 1250 mg / 5 N ml ml Ampoule Aminocaproic Acid 4 Gm Or Tranexamic Acid Ampoule 500 mg Antihemophilic Agent Recombinant mg Factor Viia Recombinant mg Factor Viia Recombinant mg Factor Viia Factor Viii (Stable Lyophilized 250 I.U. Concentrate) Factor Viii (Stable Lyophilized 1000 I.U. Concentrate) Recombinant 250 I.U. Factor Viii Sterile and Free of I.U. N epatitis, iv and Any Other Infectious Disease Agent Lipid-Lowering Drugs Sachet, Oral Cholestyramine 4 Gm/ acket owder Capsule or Gemfibrozil 600 mg C/1 Tablet Simvastatin Tablet 10 mg C ravastatin Tablet 20 mg N Atorvastatin Tablet 10 mg N Simvastatin Tablet 20 mg Atorvastatin Tablet 20 mg Simvastatin Tablet 40 mg N Atorvastatin Tablet 40 mg N Rosuvastatin Tablet 10 mg C Rosuvastatin Tablet 20 mg C Local Sclerosants Ampoule or Ethanolamine Oleate 5% (5 ml) Antioxidant Agent Ascorbic Acid Tablet 500 mg (Vitamin C) Trimetazidine Dihdrochloride Tablet 35 mg (Modified Release) ulmonary Arterial ypertension Iloprost Ampoule 10 Mcg C V SYSTEM Recombinant Factor Viii 500 I.U. N Sildenafil Tablet 20 mg N Bosentan Tablet 62.5 mg Recombinant Factor Viii 1000 I.U Bosentan Tablet 125 mg 64 65

34 RESIRATORY SYSTEM RESIRATORY SYSTEM Chapter 3 Drugs Used in The Treatment of Diseases of The Respiratory System Ipratropium Bromide Nebulization Solution (Unit Dose Ampoule) 0.025% 2 ml 500 Mcg C/1 RESIRATORY SYSTEM 3 Code No. Item Specification Dosage Form Strength 03. Drugs Used in The Treatment of Diseases Of The Respiratory System Bronchodilators Selective Beta2-Adrenoceptor Stimulants 2 mg/5 ml, Salbutamol Syrup ml Salbutamol Metered 100 Mcg/uff Inhaler Dose Inhalations (200 Doses) C C Tiotropium Theophylline Theophylline Anhydrous Theophylline Anhydrous (Sustained Release) Inhalation owder, ard Capsule Capsule or Tablet Tablet or Capsule 18 Mcg mg N 300 mg mg RESIRATORY SYSTEM Salbutamol Nebulization Solution 0.5% 20 ml/ Bottle C Theophylline Syrup Base/5 ml ml/ Long Acting 2 Agonists (Laba) With Corticosteroids Bottle Salmeterol + Fluticasone ropionate Metered Dose Inhalations Inhaler 25 Mcg + 50 Mcg 120 Doses Aminophylline Ampoule 250 mg 10 ml Corticosteroids 50 Mcg Fluticasone ropionate Inhaler Doses Salmeterol + Fluticasone ropionate Metered Dose Inhalations Formoterol Budesonide Turbuhaler Salmeterol + Fluticasone ropionate Salmeterol + Fluticasone ropionate Antimuscarinic Ipratropium Bromide, Metered Dose Inhalation Inhaler Turbuhaler Diskus Inhaler Inhaler 25 Mcg Mcg 120 Doses 4.5 Mcg Mcg 120 Doses 50 Mcg Mcg 60 Doses 25 Mcg Mcg 120 Doses 20 Mcg/uff 200 Doses C C/1 125 Mcg Fluticasone ropionate Inhaler C/1 Doses Budesonide 200 Mcg Inhaler C Turbuhaler Doses rednisolone Syrup 15 mg/ 5ml C Nebulization Budesonide Solution Cromoglycate Sodium Cromoglycate Inhaler 500 Mcg / 2 C/1 ml 5 mg 112 N Doses Antihistamines and Allergic Emergencies Nonsedative Antihistamines Non Sedating Antihistamine Tablet (Cetirizine, or Loratadine, or Astemizole) Tablet 10 mg C 66 67

35 RESIRATORY SYSTEM RESIRATORY SYSTEM Non Sedating Antihistamine Tablet (Cetirizine, or Syrup 5 mg / 5 ml 100 ml N Cough Suppressants, Expectorants, Mucolytic and Decongestants Bromhexine cl Tablets 8mg Loratadine) Sedative Antihistamines Bromhexine cl Syrup 4mg/5ml 15 mg/ 5 ml RESIRATORY SYSTEM 3 Chlorpheniramine Tablet 4 mg C Maleate 2 mg / 5 ml Chlorpheniramine Syrup (100 ml/ C Maleate Bottle) Diphenhydramine cl Syrup 12.5 mg / 5 ml (100 ml/ N Bottle) Diphenhydramine cl Capsule 25 mg N Dextromethorphan Syrup ml/ C Bottle Cough Syrup ediatric ml Syrup C Expectorant Bottle Diphenhydramine cl, Ammonium Chloride Syrup 100 ml/ Bottle C and Sodium Citrate seudoephedrine cl Syrup 60 ml -100 ml C 30 mg + Antihistamine RESIRATORY SYSTEM Diphenhydramine cl 50mg/ml N romethazine cl Tablet 10 mg C seudoephedrine cl 60 mg + Antihistamine Capsule or Tablet C romethazine cl Syrup 5 mg / 5 ml 100 ml C Leukotriene Receptors Antagonist Montelukast Sodium Granules 4 mg romethazine cl Ampoule 50 mg C ydroxyzine Tablet 10 mg Chewable Montelukast Sodium 5 mg C/1 Tablet Montelukast Sodium Tablet 10 mg ydroxyzine Tablet 25 mg N Natalizumab 20mg/ml 15ml ydroxyzine Syrup 2 mg / ml Bottle N Meclozine + Vitamin B6 Tablet 25 mg + 50 mg C Anaphylaxis Adrenaline cl Ampoule 1:1,000 (1 mg /ml) 1 ml Allergen Immunotherapy Omalizumab 150mg ulmonary Surfactants Beractant, hospholipid 200 mg umactant hospholipid 100 To N 68 69

36 CENTRAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM C N S SYSTEM 4 Chapter 4 Drugs Acting on The Central Nervous System Code No. Item Specification Dosage Form Strength 04. Drugs Acting on The Central Nervous System ypnotics and Anxiolytics ypnotics Nitrazepam Tablet 5 mg N Nitrazepam Suspention 2.5 mg / 5 ml N 150 ml Temazepam Capsule 15mg N 200 mg / 5 ml Chloral ydrate Syrup 100 ml Zolpidem Tartrate Tablet 10 mg Anxiolytics Diazepam Tablet 2 mg Diazepam Tablet 5 mg Diazepam Syrup 2 mg / 5 ml N 100 ml Diazepam Ampoule 10 mg C Diazepam Rectal Tube 5 mg C Diazepam Rectal Tube 10 mg Diazepam Suppository 10 mg N Midazolam Ampoule 5 mg Midazolam Syrup 2 mg / ml 120 ml Alprazolam Tablet 250 Mcg Alprazolam Tablet 500 Mcg Riluzole Tablet 50 mg Lorazepam Tablet 1 mg Chlordiazepoxide cl Tablet 25 mg N Lorazepam 2 mg Lorazepam 4 mg N Barbiturates Amobarbital 500 mg N Antipsychotic and Antimanic Drugs Antipsychotic Drugs Chlorpromazine cl Tablet 25 mg Chlorpromazine cl Tablet 100 mg Chlorpromazine cl Ampoule 25 mg Clozapine Tablet 25 mg Clozapine Tablet 100 mg Flupenthixol Tablet 500 Mcg N Flupenthixol Ampoule 20 mg Flupenthixol Ampoule 40 mg N Decanoate Fluphenazine Ampoule 25 mg Decanoate aloperidol Tablet 1.5 mg C/ aloperidol Tablet 5 mg aloperidol Tablet 10 mg aloperidol Dropper 10 mg / 5 ml N 15 ml aloperidol Ampoule 5 mg C/ aloperidol Decanoate Ampoule 50 mg N Risperidone Tablet 2 mg Risperidone Tablet 4 mg Risperidone Oral Solution 5 mg / 5 ml 100 ml/bottle Risperidone 25mg Risperidone 37.5 mg Risperidone 50 mg p Sulpiride Tablet or 50 mg Capsule Sulpiride Tablet or 200 mg Capsule Trifluoperazine cl Tablet or 1 mg Capsule Trifluoperazine cl Tablet or 2 mg Capsule Trifluoperazine cl Tablet or 5 mg Capsule Trifluoperazine cl Tablet or 15 mg Capsule Olanzapine Tablet 5 mg Olanzapine Tablet 10 mg Olanzapine 10 mg C N S SYSTEM 4

37 CENTRAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM Zuclopenthixol Acetate (I.m) Ampoule 50 mg Escitalopram Tablet 10 mg C/ Fluvoxamine Maleate Tablet 100 mg Aripiprazole Tablet 10 mg Aripiprazole Tablet 15 mg Quetiapine Tablet 100 mg Quetiapine Tablet 200 mg Norepinephrine Serotonin Re-Uptake Inhibitors (Nsri) Mirtazapine Tablet 30 mg Venlafaxine cl Tablet or 75 mg (Sustained Release) Capsule C N S SYSTEM Quetiapine Tablet 300 mg Zuclopenthixol Tablet 10 mg aliperidone Tablet 3 mg aliperidone Tablet 6 mg aliperidone Tablet 9 mg N Antimanic Drugs Lithium Carbonate Tablet mg Antidepressant Drugs Tricyclic and Related Drugs Venlafaxine cl Tablet or mg (Sustained Release) Capsule Duloxetine Capsule 60 mg Central Nervous System Stimulants Methylphenidate Tablet 10 mg Methylphenidate cl Tablet 18 mg Drugs Used in Nausea and Vertigo Antihistamines Dimenhydrinate Tablet 50 mg N C N S SYSTEM Amitriptyline cl Tablet 10 mg C Amitriptyline cl Tablet 25 mg C Betahistine Dihydrochloride Tablet 8 mg C/ Amitriptyline cl Tablet 50 mg Amitriptyline cl Syrup 10 mg /5 ml N 200 ml Clomipramine cl Capsule or 10 mg Tablet Clomipramine cl Capsule or 25 mg Tablet Clomipramine cl Capsule 50 mg N Imipramine cl Tablet 10 mg C Betahistine Tablet 16 mg C/1 Dihydrochloride Metoclopramide and Domperidone Metoclopramide cl Tablet 10 mg C Metoclopramide cl Ampoule 10 mg C Metoclopramide cl Suppository 10 mg C Domperidone Tablet 10 mg C Domperidone Suspension 5 mg/ 5 ml 200 ml/ Bottle Doxepin Tablet 10 mg N Imipramine cl Tablet 25 mg C Related Antidepressants Maprotiline cl Tablet 25 mg Trazodone Tablet 100 mg Monoamine-Oxidase Inhibitors Moclobemide Tablet 150 mg N Selective Serotonin Re-Uptake Inhibitors Fluoxetine Capsule 20 mg C Fluvoxamine Maleate Tablet 50 mg C Citalopram Tablet 20 mg C ydrobromide Specific 5-t3 Serotonin Antagonists Ondansetron Tablet 4 mg Granisetron Tablet 1 mg N Ondansetron Ampoule 4 mg Tropisetron Ampoule 5 mg N Granisetron Ampoule 3 mg N Ondansetron Syrup 4 mg / 5 ml 50 ml/ Bottle Analgesics Nonopioid Analgesics Acetyl Salicylic Tablet 500 mg Acid (Aspirin) aracetamol Tablet 500 mg C 72 73

38 CENTRAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM aracetamol or Bag 10 mg / ml (1 Gm) Buprenophine Sublingul Tablet 80 mg N C N S SYSTEM mg / 5 ml aracetamol Syrup ml/ C (Alcohol Free) Bottle 500 mg / 5 ml aracetamol Dropper C 15 ml aracetamol Suppository mg C aracetamol Suppository mg aracetamol + Codeine Tablet 300mg + 30 mg aracetamol + Codeine Tablet 300mg + 8 C + Caffeine mg + 30 mg Opioid Analgesics Morphine Sulfate Tablet 10 mg N (Sustained Release) Morphine Sulfate Tablet 30 mg (Sustained Release) 10 mg/5 ml Morphine Sulfate Solution 100 ml Morphine Sulfate Ampoule 10 mg C concentrated 100 mg / 5 ml Morphine sulphate N oral solution 120 ml Immediate Morphine sulphate 10 mg N release tablet Codeine hosphate Tablet 30 mg N Codeine hosphate Syrup 25 mg / 5 ml N 100 ml Methadone cl Tablet 5 mg p Nalbuphine cl Ampoule mg ethidine cl Ampoule 50 mg ethidine cl Ampoule 100 mg Fentanyl Citrate atch 25 Mcg/r p Fentanyl Citrate atch 50 mg/r p Fentanyl Citrate Ampoule 0.1 Mcg Tramadol cl Capsule 50 mg Tramadol cl Ampoule 100 mg Buprenorphine Sublingul 2 mg N Tablet Fentanyl Citrate 500 Mcg Antimigraine Drugs Ergotamine Tartarate Tablet 1 mg Sumatriptan Tablet 50 mg N Sumatriptan Tablet 100 mg C Sumatriptan refilled 6 mg N Syringe Antiepileptics Carbamazepine Tablet 200 mg C Carbamazepine Sustained Release 200 mg N Tablet Carbamazepine Syrup 100 mg/5 ml Liquid, 100 ml/ Bottle Ethosuximide Tablet 250 mg 250 mg / 5 ml Ethosuximide Syrup ml Lamotrigine Tablet 25 mg N Lamotrigine Tablet 50 mg Lamotrigine Tablet 100 mg henobarbital Tablet 10 mg henobarbital Tablet 30 mg henobarbital Tablet 50 mg henobarbital Tablet 100 mg henobarbital Alcohol-Free 15 mg / 5 ml N Liquid ml henobarbital Ampoule mg henobarbital Ampoule or 200 mg rimidone Tablet 250 mg N henytoin Sodium Capsule 50 mg N henytoin Sodium Capsule 100 mg C henytoin Sodium 250 mg (5ml) Sodium Valproate Tablet 200 mg C Sodium Valproate Tablet 500 mg C (Slow Release) C N S SYSTEM

39 CENTRAL NERVOUS SYSTEM CENTRAL NERVOUS SYSTEM Sodium Valproate Syrup mg / 5 ml Rivastigmine Transdermal atch 4.6mg N ml/ Bottle Clonazepam Tablet 500 Mcg N Rivastigmine Transdermal atch 9.5 mg N C N S SYSTEM Clonazepam Tablet 2 mg Clonazepam Oral Dropper 12.5 mg / 5 ml 10 ml/ Bottle Clonazepam Ampoule 1 mg N Gabapentin Capsule 300 mg regabalin Capsule 75 mg C regabalin Capsule 150 mg regabalin Capsule 300 mg Vigabatrin Tablet 500 mg araldehyde Ampoule 100% 5 ml N Drug for Smoking Cessation Bupropion Tablet 150 mg Nicotine (24-our Transdermal mg C/1 Effect Dose) atch Nicotine (24-our Transdermal mg C/1 Effect Dose) atch Nicotine (24-our Transdermal mg C/1 Effect Dose) atch Varenicline Tablet 0.5 mg C/ Varenicline Tablet 1 mg C/1 C N S SYSTEM Topiramate Tablet 25 mg Nicotine Lozenge Tablet 0.5 mg C/ Topiramate Tablet 100 mg Topiramate Capsule 15 mg N Levetiracetam Syrup 500 mg / 5 ml 300 ml Levetiracetam Tablet 500 mg Drugs Used in arkinsonism and Related Disorders Dopaminergic Drugs ramipexole Tablet 0.25 mg Amantadine cl Capsule 100 mg Selegiline cl Tablet 5 mg N Antimuscarinic Drugs Benzhexol cl Tablet 2 mg Benzhexol cl Tablet 5 mg Benztropine Mesylate Tablet 500 Mcg N Benztropine Mesylate Tablet 2 mg Benztropine Mesylate Ampoule 2 mg p rocyclidine ydrochloride Tablet 5 mg rocyclidine ydrochloride Ampoule 10 mg N Drugs for Dementia N-Methyl-D-Aspartate Receptor Antagonist Memantine cl Tablet 10 mg 76 77

40 ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG 5 Chapter 5 Drugs Used in The Treatment of Infections Code No. Item Specification Dosage Form Strength 5. Drugs Used in The Treatment of Infections Antibacterial Drugs enicillins enicillin Benzathine ,000,000 I.U. C (enicillin G) enicillin Benzathine ,200,000 I.U. (enicillin G) henoxymethyl enicillin (enicillin V Tablet 250 mg C otassium) henoxymethyl enicillin (enicillin V Suspension 250 mg / 5 ml C 100 ml/ Bottle otassium) enicillinase-resistant enicillins Cloxacillin or or mg Flucloxacillin Sodium Ampoule Cloxacillin or Capsule 250 mg C Flucloxacillin Sodium Cloxacillin or Capsule 500 mg Flucloxacillin Sodium Cloxacillin or or mg Flucloxacillin Sodium Ampule Cloxacillin or Flucloxacillin Sodium Suspension 125 mg / 5 ml 100 ml/ Bottle Broad-Spectrum enicillins Amoxicillin Trihydrate Capsule 250 mg C Amoxicillin Trihydrate Capsule 500 mg Amoxicillin Trihydrate Suspension 250 mg / 5 ml C 100 ml Amoxicillin Trihydrate Dropper 500 mg/ 5 ml N 15 ml Amoxicillin Trihydrate + Clavulanate Tablet 250 mg + 125mg C otassium Amoxicillin Trihydrate 500 mg Clavulanate Tablet 125mg otassium Amoxicillin Trihydrate 875 mg Clavulanate Tablet 125mg otassium Amoxicillin Trihydrate + Clavulanate otassium Suspension 125 mg + 31 mg / 5 ml 100 ml C Amoxicillin Trihydrate 400 mg Clavulanate Suspension otassium Amoxicillin Trihydrate Clavulanate otassium mg / 5 ml 100 N ml 500 mg mg Ampicillin Sodium 500 mg Ampicillin Sodium 1 Gm Antipseudomonal enicillins iperacillin + 2 Gm Tazobactam 0.25 Gm iperacillin + 4 Gm Tazobactam 0.5 Gm Cephalosporins and Cephamycins Tablet or Cefuroxime 250 mg Capsule Cefuroxime Suspension 250 mg / 5 ml Cefotaxime Sodium 1 Gm Ceftazidime 1 Gm entahydrate Ceftriaxone Sodium 1 Gm Cefuroxime Sodium 750 mg Cephalexin Capsule 250 mg Monohydrate Cephradine Capsule 250 mg N Cephalexin Suspension 125 mg / 5 ml Monohydrate Cephradine Suspension 125 mg / 5 ml N Cephradine 500 mg Cephradine 1 Gm N ANTI-INFECTIOUS DRUG

41 ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG 5 Cefepime Gm ydrochloride Cefepime Gm ydrochloride Cefixime Suspension 100 mg / 5 ml N Carbapenem 500 mg Imipenem + Cilastatin 500 mg Meropenem 1 Gm Meropenem 500 mg Tetracyclines Tablet or Tetracycline 250 mg Capsule Tetracycline 250 mg N Tablet or Doxycycline cl 100 mg C Capsule Tablet or Minocycline cl 100 mg Capsule Tigecycline 50 mg Aminoglycosides Ampoule Gentamicin Sulfate 20 mg Or Ampoule Tobramycin Sulfate 20 mg N Or Ampoule Gentamicin Sulfate 80 mg Or Ampoule Amikacin Sulfate 100 mg Or Ampoule Amikacin Sulfate 500 mg or Neomycin Sulfate Tablet 500 mg N Macrolides Erythromycin Ethylsuccinate or Tablet 250 mg C Stearate Erythromycin Suspension 200 mg/5 ml C Ethylsuccinate 100 ml Erythromycin Lactobionate or 1 Gm Tablet or Azithromycin 250 mg C Capsule Tablet or Clarithromycin 250 mg C Capsule 200 mg / 5 ml Azithromycin Suspension C 15 ml 125 mg / 5 ml Clarithromycin Suspension N 60 ml Clindamycin Clindamycin Capsule 300 mg N Clindamycin Ampoule 300 mg hosphate Other Antibiotics Spectinomycin cl 2 Gm Spiramycin Tablet 750,000 Unit N Spiramycin Tablet 1,500,000 Unit Vancomycin cl 500 mg Colistin Sulphomethate 1-2 Million I.U Sodium Linezolid Tablet 600 mg Linezolid remixed 600 mg / Bag 300 ml/ Bag Linezolid Suspension 100 mg/ 5 ml 150ml Bottle Sulfonamides and Trimethoprim Trimethoprim Tablet Sulfamethoxazole Trimethoprim Suspension Sulfamethoxazole Trimethoprim Ampoule Sulfamethoxazole 160 mg + C 800 mg 40 mg mg/5 ml C 50 ml Bottle 80 mg mg Sulfadiazine Tablet 500 mg N Antituberculous Drugs Capsule or Cycloserine 250 mg Tablet Ethambutol cl Tablet 400 mg C Gluceptate Ethionamide Tablet 250 mg ANTI-INFECTIOUS DRUG 5

42 ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG Isoniazid Tablet 100 mg C Isoniazid Syrup 50 mg/5 ml N 100 ml Antibiotics for Urinary Tract Infections Tablet or Nitrofurantoin 100 mg C Capsule ANTI-INFECTIOUS DRUG 5 Ampoule or Isoniazid 50 mg N ara-amino Salicylate Tablet 500 mg Sodium yrazinamide Tablet 500 mg C Rifampicin Capsule 150 mg Rifampicin Capsule 300 mg C Rifampicin Syrup 100 mg / 5 ml C 100 ml Rifampicin 300 mg N Rifampicin + Isoniazid Tablet 300 mg mg Kanamycin 1 Gm N rothionamide Tablet 250 mg N Streptomycin Sulfate 1 Gm C Thiacetazone Tablet 50 mg N Thiacetazone Tablet 75 mg N Rifabutine Tablet 150 mg N Capreomycin 1Gm N Antileprotic Drugs Clofazimin Capsule 50 mg Dapsone Tablet 100 mg Quinolones Ciprofloxacin Tablet 250 mg N Nitrofurantoin Suspension 25 mg / 5 ml Norfloxacin Tablet 400 mg N Antifungal Drugs olyene Antifungals Amphotericin B mg Liposomal Amphotericin B 50 mg Nystatin Tablet 500,000 I.U. N Nystatin Suspension 100,000 I.U. / 1 ml C ml Imidazole Antifungals Tablet or Fluconazole 50 mg Capsule Tablet or Fluconazole 150 mg Capsule 50 mg / 5ml Fluconazole Suspension 35 ml Fluconazole 50 mg Itraconazole Capsule 100 mg Voriconazole 200 mg Voriconazole Tablet 200 mg Miconazole Oral Gel 2% (20-40 Gm) ANTI-INFECTIOUS DRUG Ciprofloxacin Tablet 500 mg C Ciprofloxacin (As Infusion 200 mg/ 100 Lactate) Solution ml Bottle Ofloxacin Tablet 200 mg Moxifloxacin Tablet 400 mg ydrochloride Levofloxacin Tablet 500 mg Levofloxacin Tablet 750 mg Moxifloxacin ydrochloride Levofloxacin (Infusion in D5w) 400 mg remixed 500 mg / N Infusion 100 ml Other Antifungals Griseofulvin Tablet 500 mg N Micronized Griseofulvin 125 mg / 5 ml Suspension Micronized 100 ml Terbinafine Tablet 250 mg C/ Echinocandins Caspofungin Acetate 50 mg Micafungin Sodium 50 mg N Antiviral Drugs Drugs for erpes Simplex and Varicella-Zoster Viruses Acyclovir Tablet 200 mg C 82 83

43 ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG Acyclovir Tablet 800 mg Emtricitabine Capsule 200 mg Acyclovir Suspension 200 mg / 5 ml 125 ml Bottle Emtricitabine Oral Solution 10 mg /ml 170 ml N ANTI-INFECTIOUS DRUG Acyclovir 250 mg Valacyclovir Tablet 500 mg Drugs for uman Immunodeficiency Virus Nucleotide Reverse Transcriptase Inhibitors Zidovudine Capsule 100 mg Zidovudine Syrup 50 mg / 5 ml 200 ml/ Bottle Zidovudine 200 mg Zidovudine Tablet 300 mg Didanosine Enteric Coated Capsule 400 mg Enteric Non-Nucleoside Reverse Transcriptase Inhibitors Efavirenz Tablet 600 mg Efavirenz Syrup 30 mg/ ml Bottle Etravirine Tablet 100 mg rotease Inhibitors (is) Lopinavir + Ritonavir Tablet Lopinavir + Ritonavir Oral Solution 200 mg + 50 mg 80 mg + 20 mg / 1 ml (160 ml/ Bottle) Nelfinavir Tablet 250 mg N ANTI-INFECTIOUS DRUG Didanosine Coated Capsule 125 mg Nelfinavir Oral Suspension 50 mg / 5 ml 144 ml N Didanosine owder for Oral Solution Oral Solution 2 Gm Darunavir Tablet 300 mg N Darunavir Tablet 400 mg Lamivudine Syrup 50 mg / 5ml (240 ml) Darunavir Tablet 600 mg Ritonavir Tablet 100 mg Lamivudine Tablet or Capsule 100 mg Lopinavir + Ritonavir Tablet 100 mg + 25 mg Lamivudine Tablet or Capsule 150 mg N Raltegravir Tablet 400 mg Atazanavir Capsule 150 mg Zidovudine + Lamivudine Abacavir Sulfate + Lamivudine + Zidovudine Tenofovir Disoproxil Fumurate Tenofovir Disoproxil Fumurate + Emtricitabine Tenofovir Disoproxil Fumurate + Emtricitabine + Efavirenz 300 mg + Tablet 150 mg 300 mg + Tablet 150 mg + N 300 mg Tablet 300mg 300 mg + Tablet 200 mg 245 mg + Tablet 200 mg + N 600 mg Atazanavir Capsule 200mg Indinavir Capsule 400 mg N Drugs for Fusion or Entry Inhibitors: Enfuvirtide 90 mg Drugs for Cytomegalovirus Ganciclovir 500 mg Valganciclovir cl Tablet 450 mg Foscarnet Infusion 24 mg/ml 250 N ml/ Bottle Drugs for Respiratory Syncytial Virus Ribavirin for Aerosol Inhalation or Nebulization 6 Gm N 84 85

44 ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG ANTI-INFECTIOUS DRUG Ribavirin Capsule 200 mg alivizumab 100 mg Drugs for Viral epatitis Entecavir Tablet 0.5 mg Adefovir Dipivoxil Tablet 10 mg Raltegravir Tablet 400 mg N Antiprotozoal Drugs Antimalarials Artemisinin Capsule 250 mg N Artesunate Tablet 50 mg N Artesunate Ampoule 60 mg Chloroquine 250 mg, ( Tablet C hosphate mg Base) Chloroquine 50 mg/ 5 ml Syrup C hosphate ml Chloroquine Ampoule mg Base Mefloquine cl Tablet 250 mg rimaquine hosphate Tablet 7.5 mg C rimaquine hosphate Tablet 15 mg C roguanil cl Tablet 100 mg yrimethamine + Tablet 25 mg + C Sulfadoxine 500 mg yrimethamine Tablet 25 mg Quinine Sulphate Tablet 300 mg Quinine 300 mg / ml Ampoule Dihydrochloride (2ml) Artemether + 20 mg Tablet C Lumefantrine 120 mg Artesunate + 50 mg Sulfadoxine + Tablet mg + 25 mg yrimehamine Artesunate mg Sulfadoxine + Tablet mg + 25 mg yrimehamine Artmether Ampoule 20 mg Artesunate Suppository 400 mg N Amebicides, Trichomonacides and Antigiardial Drugs Diloxanide Furoate Tablet 500 mg C Metronidazole Tablet 500 mg C Metronidazole Suspension 125 mg/5 ml C 100 ml Metronidazole Iv Bottle or Bag 500 mg p Infusion Leishmaniacides Stibogluconate Ampoule or Sodium (Organic 600 mg C entavalent Antimony) Drugs for neumocystis neumonia entamidine mg N Isethionate Anthelmintics Drugs for Threadworms, Roundworms and ookworms Mebendazole Tablet 100 mg C Mebendazole Suspension 100 mg/ C 5 ml 30 ml Levamizole Tablet 40 mg N Taenicides and Schistosomicides Niclosamide Tablet 500 mg N raziquantel Tablet 600 mg C Drugs for ydatid Disease, Tapeworms Albendazole Tablet 200 mg Albendazole Tablet 400 mg Filaricides (Elephantiasis) Ivermectin Tablet 10 mg Albendazole Tablet 200mg Tablet or Doxycycline cl 100 mg C Capsule Albendazole Tablet 400 mg Diethylcarbamazine Tablet 50 mg N Citrate Artemether Ampoule 80 mg Artesunate Suppository 50 mg C/ Artesunate Suppository 100 mg N Artesunate Suppository 200 mg N ANTI-INFECTIOUS DRUG 5

45 ENDOCRINE SYSTEM ENDOCRINE SYSTEM Chapter 6 Drugs Used in The Treatment of Disorders of The Endocrine System Insulin Mixed (30% Aspart,70 % rotamine Aspart) refilled en Oral ypoglycemic Agents 100 I.U./ml (3 ml) C/1 Code No. Item Specification Dosage Form Strength Glibenclamide Tablet 5 mg C 06. Drugs Used in The Treatment of Disorders of The Sitagliptin hosphate Tablet 100 mg C/1 Endocrine System Gliclazide Tablet 80 mg C Drugs Used in Diabetes Glipizide Tablet 5 mg N ENDOCRINE SYSTEM Insulin uman Soluble Insulin (Regular) uman Isophane Insulin (Nph) Mixed uman Insulin % Soluble, 70 % Isophane Insulin Glulisine refilled en Insulin Aspart refilled en 100 I.U./ ml (10 ml) 100 I.U./ ml (10 ml) 100 I.U./ml (10 ml) 100 I.U./ml (3 ml) 100 I.U./ml (3 ml) C C C C/1 C/ Glimepiride Tablet 2 mg C/ Gliclazide Mr (Modified Tablet 30 mg C Released) Metformin cl Tablet 500 mg C Metformin cl Xr Tablet 750 mg C (Modified Released) Vildagliptin Tablet 50 mg C/ Drugs for ypoglycemia Glucagon 1 mg Glucagon refilled 1 mg Syringe Repaglinide Tablet 2 mg N ENDOCRINE SYSTEM Insulin Glargine 100 I.U./ ml (10 ml) C/ Nateglinide Tablet 120 mg N Thiazolidinedione Insulin Lispro Insulin Aspart Insulin Detmir Insulin Lispro refilled en Insulin Detmir refilled en Insulin Glargine refilled en Insulin Mixed (50% Lispro, 50 % rotamine Lispro) refilled en Insulin Mixed (25% Lispro, 75 % rotamine refilled en Lispro) 100 I.u/ ml (10 ml) 100 I.u/ ml (10 ml) 100 I.U./ ml (10 ml) 100 I.U./ml (3 ml) 100 I.U./ml (3 ml) 100 I.U./ ml (3 ml) 100 I.U./ml (3 ml) 100 I.U./ml (3 ml) N C/1 C/1 N C/1 C/1 C/1 C/1 C/1 C/ ioglitazone Tablet 15 mg C/ Thyroid and Antithyroid Drugs Thyroid ormones Thyroxine Sodium Tablet 25 Mcg C Thyroxine Sodium Tablet 50 Mcg C Thyroxine Sodium Tablet 100 Mcg C Levothyroxine Sodium Ampoule Mcg Liothyronine T3 Tablet 25 Mcg N Liothyronine T3 Tablet 50 Mcg N Antithyroid Drugs Carbimazole Tablet 5 mg C ropylthiouracil Tablet 50 mg yperparathyroidism Cinacalcet Tablet 30 mg ydrochloride Cinacalcet Tablet 60 mg ydrochloride 88 89

46 ENDOCRINE SYSTEM ENDOCRINE SYSTEM Corticosteroids Fludrocortisone Acetate Tablet 100 Mcg ypothalamic and ituitary ormones and Antiestrogens Antiestrogens rednisolone Tablet 5 mg C Clomiphene Citrate Tablet 50 mg rednisolone Tablet mg C Dexamethasone Tablet 500 Mcg Dexamethasone Ampoule 5 mg p C Anterior ituitary ormones Tetracosactrin Ampoule 250 Mcg N (Corticotrophin) ENDOCRINE SYSTEM ydrocortisone Tablet 10 mg Ampoule ydrocortisone 100 mg C or Ampoule Methylprednisolone 40 mg Or Ampoule Methylprednisolone 500 mg C Or Sex ormones Estrogens for ormone Replacement Therapy Tablet- Conjugated Estrogen Mcg Calendar N Norgestrel 150 Mcg ack Tablet- Estradiol Valerate + 1 mg Calendar N Norgestrel 500 Mcg ack Tetracosactrin (Corticotrophin) uman Chorionic Gonadotrophin uman Chorionic Gonadotrophin uman Menopausal Gonadotrophins, Follicle Stimulating ormone + Luteinizing ormone Somatropin (uman Growth ormone) Urofollitrophine F.s.h Ampoule 1 mg Ampoule 1500 U p Ampoule 5000 I.U. 75 I.U Ampoule I.U. en Iu Ampoule or 75 I.U. ENDOCRINE SYSTEM Estradiol Valerate Tablet 1 mg N (Recombinant uman Estradiol Valerate Ampoule 10 mg N Follicle Stimulating I.U Ethinyl Estradiol Tablet 10 Mcg ormone) Follitropin rogestogens Dydrogesterone Tablet 10 mg C/ ydroxyprogesterone Ampoule 250 mg exanoate Medroxyprogesterone Tablet 5 mg C Acetate Norethisterone Tablet 5 mg C rogesterone Ampoule 50 mg N rogesterone Ampoule 100 mg N rogesterone Vaginal 50 mg N essary Androgens Testosterone Depo Ampoule 250 mg (Recombinant uman Follicle Stimulating I.U. N ormone) Follitropin (Recombinant uman Follicle Stimulating en I.U. ormone) Follitropin Alfa ypothalamic ormones Corticorelin (Corticotrophin- Ampoule 100 Mcg N Releasing Factor, Crf) refilled Triptorelin Acetate 3.75 mg Syringe Finasteride Tablet 5 mg 90 91

47 ENDOCRINE SYSTEM Gonadorelin (Gonadotrophin- or Mcg Releasing ormone, Ampoule Lhrh) rotirelin (Thyrotrophin Ampoule 200 Mcg N Releasing ormone, Trh) osterior ituitary ormones Vasopressin Ampoule 20 U/ml 1ml C ENDOCRINE SYSTEM Gonadorelin Analogues Goserlin Acetate Ampoule 3.6 mg 200 Mcg Nafarelin Nasal Spray N 30-Dose Unit Leuprolide Depo Ampoule mg Acetate Or Leuprolide Depo Ampoule mg Acetate Or ENDOCRINE SYSTEM 6 Disintegrating Desmopressin MELT 60 Mcg Tablet Disintegrating Desmopressin MELT 20 Mcg Tablet Nasal 0.1 mg./ ml., Desmopressin Acetate Solution 2.5 ml Drugs Affecting Bone Metabolism Bisphosphonate and Other Drugs Affecting Bone Metabolism Disodium Etidronate Ampoule 300 mg N Disodium 15 mg N amidronate Alendronate Sodium Tablet 10 mg N Strontium Ranelate Sachet 2 Gm Zoledronic Acid 4 mg Zoledronic Acid remixed 5 mg 100m Infusion Alendronate Sodium Tablet 70 mg C/ Calcitonin and arathyroid ormone Calcitonin Ampoule 100 I.U. (Salmon) - (Salcatonin) Teriparatide en 250 Mcg Other Endocrine Drugs Other Endocrine Drugs Bromocriptine Tablet 2.5 mg Cabergoline Tablet 0.5 mg ituitary Gonadotrophins Inhibitors Danazol Capsule 100 mg ENDOCRINE SYSTEM

48 GENITOURINARY SYSTEM GENITOURINARY SYSTEM GENITOURINARY SYSTEM 7 Chapter 7 Drugs Used in Disorders of The Obstetrics, Gynecology and Genitourinary Disorders Code No. Item Specification Dosage Form Strength 07. Drugs Used in Obstetrics, Gynecology And Genitourinary Disorders Drugs Used in Obstetrics rostaglandins and Oxytocics Vaginal Dinoprostone 3 mg Tablet Cervical Gel 500 Mcg / Dinoprostone Disposable N 2.5 ml Syinge Dinoprostone for Extra Ampoule 5 mg Amniotic Misoprostol Tablet 200 Mcg Oxytocin Ampoule 5 I.U Methylergonovine Tablet 125 Mcg Maleate Methylergonovine Ampoule 200 Mcg C Maleate Sulprostone Ampoule 500 Mcg N Alprostadil (rostaglandin E1) Ampoule 500 Mcg ediatric Dose Carboprost Ampoule 250Mcg Tromethamine Myometrial Relaxants Drugs for Seizure revention in Eclampsia remixed (10 mg / ml) Magnesium Sulfate N Bag 1G/100 ml Treatment of Vaginal and Vulval Conditions Antifungal Drugs Imidazole Derivative (Clotrimazole, Vaginal mg C Econazole, Tablet Miconazole) Imidazole Derivative (Clotrimazole, Vaginal Econazole, cream Miconazole) Econazole Nitrate essary 150 mg N Miconazole Nitrate essary 1.2 G N CLOTRIMAZOLE vaginal 500mg with N tablets applicator Nystatin essary or Vaginal 100,000 I.U. C Tablet Iodine Vaginal Dish Vaginal Dish 10% Bottle C Drugs for Genitourinary Disorders Drugs for Urinary Retention Distigmine Bromide Tablet 5 mg Drugs for Urinary Frequency and Incontinence Flavoxate Tablet 100 mg Tolterodine Tartrate Tablet 2 mg Oxybutynin cl Xl Tablet 5 mg N GENITOURINARY SYSTEM 7

49 MALIGNANCY AND IMMUNOSURESSION MALIGNANCY AND IMMUNOSURESSION Chapter 8 Drugs Used in The Treatment of Malignant Disease and Immunosuppression Antimetabolites Cytarabine for Injection Cytarabine for Injection Ampoule or Ampoule or 500 mg 100 mg MALIGNANCY AND IMMUNOSURESSION 8 Code No. Item Specification Dosage Form Strength 08. Drugs Used in The Treatment of Malignant Disease and Immunosuppression Cytotoxic Drugs Alkylating Drugs Busulfan Tablet 2 mg Carmustine 100 mg N Chlorambucil Tablet 2 mg Chlorambucil Tablet 5 mg N Cyclophosphamide Tablet 25 mg N Cyclophosphamide Tablet 50 mg Cyclophosphamide 100 mg N Cyclophosphamide 200 mg Cyclophosphamide 500 mg Thalidomide Capsule 100 mg Thalidomide Capsule 200 mg Ifosfamide 1 Gm Mechlorethamine cl 10 mg N Melphalan Tablet 2 mg Drugs for Urothelial Toxicity Mesna Ampoule 400 mg Cytotoxic Antibiotics Bleomycin 15 mg Dactinomycin 500 Mcg Daunorubicin cl 20 mg Doxorubicin cl 10 mg Doxorubicin cl 50 mg Epirubicin cl 10 mg Epirubicin cl 50 mg Mitomycin 2 mg N Mitomycin 10 mg N Mitomycin 20 mg N Mitoxantrone 20 mg ydrochloride 50 mg/ ml Fluorouracil (5-10 ml) Mercaptopurine Tablet 50 mg Methotrexate Tablet 2.5 mg Methotrexate, 50 mg reservative-free Methotrexate 500 mg Thioguanine Tablet 40 mg N Fludarabine hosphate 50 mg Capecitabine Tablet 150 mg Capecitabine Tablet 500 mg emetrexed 500 mg Folinic Acid Rescue Leucovorin Calcium Tablet 15 mg N Ampoule or Leucovorin Calcium 50 mg / 5ml Leucovorin Calcium 3-5 mg N Vinca Alkaloids and Etoposide Etoposide Capsule 50 mg N Etoposide 100 mg/ 5ml Vinblastine Sulfate 10 mg Vincristine Sulfate 1 mg Other Antineoplastic Drugs Cisplatin 50 mg Asparaginase ,000 U N (Crisantaspase) 750 I.u /ml egaspargase ( 5 ml) Lenalidomide Tablet 25 mg Dacarbazine 200 mg ydroxurea Capsule 500 mg rocarbazine Capsule 50 mg p aclitaxel 30 mg aclitaxel 300 mg MALIGNANCY AND IMMUNOSURESSION

50 MALIGNANCY AND IMMUNOSURESSION MALIGNANCY AND IMMUNOSURESSION MALIGNANCY AND IMMUNOSURESSION Vinorelbine 50 mg Cyproterone Acetete Tablet 50 mg Bicalutamide Tablet 50 mg N Bicalutamide Tablet 150 mg Miltefosine Topical 0.06 N Solution Gemcitabine 200 mg Gemcitabine 1 Gm N Carboplatin 150 mg N Carboplatin 450 mg Lomustine Capsule 100 mg Imatinib Mesilate Capsule 100 mg Dasatinib Monohydrate Tablet 50 mg Dasatinib Monohydrate Tablet 70 mg Nilotinib Tablet 200 mg Sorafenib Tablet 200 mg Docetaxel 20 mg Docetaxel 80 mg Irintecan 100 mg N ydrochloride Oxaliplatin 50 mg Oxaliplatin 100 mg Bevacizumab 100 mg Bevacizumab 400 mg Bortezomib 3.5 mg Trastuzumab 150 mg Trastuzumab 440 mg Cetuximab 100 mg rotein Kinase Inhibitors Drugs Affecting The Immune Response Immunosuppressants Azathioprine Tablet 50 mg Azathioprine 50 mg N Leflunomide Tablet 20 mg Antithymocyte 25 mg Globulin (Atg) Cyclosporin Capsule 25 mg Cyclosporin Capsule 50 mg Cyclosporin Capsule 100 mg Cyclosporin Oral Solution Cyclosporin Ampoule 500 mg/ 5 ml 50 ml/ Bottle 50 mg/ml (5ml) Muromonab-Cd3 Ampoule 5 mg N Basiliximab 20 mg N Immunostimulants Interferon Alpha 3,000,000 U N Interferon Alpha 5,000,000 U N Mycophenolate Mofetil Capsule 250 mg Mycophenolate Mofetil Capsule 500 mg Mycophenolate Tablet 180 mg N Sodium Mycophenolate Tablet 360 mg Sodium Tacrolimus Capsule 0.5 mg Tacrolimus Capsule 1 mg Tacrolimus Capsule 5 mg Sirolimus Tablet 1 mg MALIGNANCY AND IMMUNOSURESSION Erlotinib ydrochloride Erlotinib ydrochloride Coated Tablet Coated Tablet 25 mg 100 mg Interferon Beta 1A 6,000,000 I.U. N Interferon Beta 1A or refilled (30 Mcg) 6,000,000 I.U. Syringe Coated Erlotinib ydrochloride Tablet ormone Antagonists 150 mg Interferon Beta 1B 9,600,000 I.U. (44Mcg) Interferon Beta 1A 12,000, Letrozole Coated Tablet 2.5 mg I.U

51 MALIGNANCY AND IMMUNOSURESSION NUTRITION AND BLOOD SUBSTITUTES egylated Interferon Alpha 2 A egylated Interferon Alpha 2 B 180 Mcg 80 Mcg N Chapter 9 Drugs Affecting Nutrition and Blood MALIGNANCY AND IMMUNOSURESSION 8 egylated Interferon Mcg Alpha 2 B egylated Interferon Mcg N Alpha 2 B Fingolimod 0.5 mg Capsule 0.5 mg N Bacillus Calmette mg Gue Rin Telaprevir Tablet 375 mg Sex ormones and ormone Antagonists in Malignant Disease rogestogens Megestrol Acetate Tablet 40 mg ormone Antagonists Tamoxifen Citrate Tablet 10 mg Anastrozole Tablet 1 mg Aminoglutethimide Tablet 250 mg N Flutamide Tablet 250 mg N Octreotide Ampoule 100 Mcg Code No. Item Specification Dosage Form Strength 09. Drugs Affecting Nutrition and Blood Anemias and Some Other Blood Disorders Iron mg Tablet or Ferrous Salt Elemental N Capsule Iron mg Tablet or Ferrous Salt Elemental C Capsule Iron 75 mg Ferrous Sulphate Drops Bottle C 15-30ml 50 mg / ml Iron Saccharate Ampoule ( 2 ml) Iron and Folic Acid reparations Used in regnancy mg Ferrous Sulfate or Iron Tablet Fumarate + Folic Acid Mcg NUTRITION AND BLOOD SUBSTITUTES Octreotide for Injection 20 mg N Folic Acid Terlipressin Acetate 1 mg N Drugs Used in Megaloblastic Anemia Cyanocobalamin (Vit B12) Ampoule 1 mg Folic Acid Tablet 1 mg C Folic Acid Tablet 5 mg Drugs Used in Renal Anemia Epoetin (Recombinant uman Erythropoietins) refilled Syringe 1000 I.U. N Epoetin (Recombinant uman Erythropoietins) refilled Syringe 2000 I.U Epoetin (Recombinant uman Erythropoietins) refilled Syringe I.U

52 NUTRITION AND BLOOD SUBSTITUTES NUTRITION AND BLOOD SUBSTITUTES NUTRITION AND BLOOD SUBSTITUTES 9 refilled Bottle Darbepoetin 40 Mcg Sodium Chloride 0.45 % 500 ml Syringe Or Bag refilled Sodium (Chloride Darbepoetin 60 Mcg % 10ml N Syringe reservative Free) refilled Sodium Chloride Bottle Darbepoetin 80 Mcg % 500 ml C Syringe (Normal Saline) Or Bag Methoxy olyethylene refilled Sodium Chloride Mcg iggy Bag 0.9% 100 ml p Glycol-Epoetin Beta Syringe (Normal Saline) Methoxy olyethylene refilled Sodium Chloride Mcg iggy Bag 0.9% 50 ml p Glycol-Epoetin Beta Syringe (Normal Saline) refilled Sodium Chloride Ampoule 3% 10 ml Erthyropoietin I.U. Syringe Sodium Chloride Flush refilled % 10 ml refilled (Normal Saline) Syringe Erthyropoietin I.U. Syringe Sodium Chloride Flush refilled % 5 ml refilled (Normal Saline) Syringe Erthyropoietin I.U. Syringe Sodium Chloride Flush refilled % 3 ml Drugs Used in Neutropenia (Normal Saline) Syringe Sodium Chloride or Bag 14.3 or 20% erfilled Syr / 300 Mcg/ Filgrastim G-Csf Dextrose + Sodium 0.5 ml Bottle 5 % % Chloride (1/5 Normal Or Bag 250 ml Saline) Orlenograstim (G-Csf) N I.U. Dextrose + Sodium Bottle 5 % % Fluids and Electrolytes Oral Electrolytes and otassium Removal Chloride (1/4 Normal Saline) Or Bag 500 ml otassium Chloride Tablet 600 mg Dextrose + Sodium 5 % % otassium Salt Oral Solution 5Mmol/5ml N Chloride (1/4 Normal Bottle or Bag 250 ml olystyrene Saline) Sulphonate Resins owder Jar 450 Gm/ Jar Dextrose + Sodium Bottle 5% % (Sodium) Chloride (1/2 Normal Or Bag 250 ml olystyrene Saline) Sulphonate Resins owder Jar 300 Gm/ Jar Dextrose + Sodium Bottle 5% % (Calcium) Chloride (1/2 Normal Or Bag 500 ml Electrolyte Oral Saline) Sachet C Dextrose + Sodium Rehydration Salt (Ors) Bottle 5% % Sodium Bicarbonate Tablet 325 mg Chloride (Normal Or Bag 250 ml Intravenous Solutions and Electrolytes Saline) Dextrose + Sodium 40 Mmol Bottle 5% % Sodium Acetate N Chloride (Normal C (20ml) Or Bag 500 ml Saline) Bottle % Sodium Chloride Or Bag 500 ml NUTRITION AND BLOOD SUBSTITUTES 9

53 NUTRITION AND BLOOD SUBSTITUTES NUTRITION AND BLOOD SUBSTITUTES Dextrose + Sodium Chloride (1/5 Normal Saline) Dextrose + Sodium Bottle or Bag 10 % % 250 ml 10 % Sodium Bicarbonate Sodium Bicarbonate refilled Syringe refilled Syringe 8.4 % 50 ml C 1Meq/ml (10ml) Chloride (1/4 Normal Bottle or Bag 0.225% Ammonium Chloride Solution 5Mmol/ml N Saline) Dextrose + Sodium Chloride (1/2 Normal Saline) Bottle or Bag ml 10 % % 250 ml Water for Injection Ampoule 5-10 ml C (Sterile) Water for Injection Bottle or Bag 500 ml/glass or lastic Ringer s Solution Bottle or Bag 500 ml Bottle NUTRITION AND BLOOD SUBSTITUTES 9 Ringer s Lactate Bottle or Bag 500 ml C Solution Sodium hosphate 3 Mmol hosphate and 4 Mmol N Sodium/ ml (15 ml) Dextrose iggy Bag 5 % 50 ml Dextrose iggy Bag 5 % 100 ml Dextrose Bottle or Bag 5% 250 ml C Dextrose Bottle or Bag 5% 500 ml lasma and lasma Substitutes Albumin uman lasma rotien Solution Dextran (Dextran40) Bottle or Bag Sodium Chloride uman Fibrinogen Infusion 20-25% 50 ml/ Bottle 5% rotien (85% Albumin) 250 ml/ Bottle 10 % + 0.9% 500 ml 2 Gm in 100 ml/ NUTRITION AND BLOOD SUBSTITUTES Dextrose Ampoule 10% 10 ml N Dextrose Bottle or Bag 10% 250 ml Dextrose Bottle or Bag 10% 500 ml Ampoule or Dextrose Ampoule or Dextrose Ampoule or Dextrose otassium Acetate 25 % 250 ml Bottle 50 % 50 ml C Bottle 50% 500 ml 40 Mmol/ N 20ml Ampoule or 15 % 2Mmol/ otassium Chloride ml (10 ml) 3Mmol hosphate otassium hosphate N 4Mmol otasium Sodium Bicarbonate Bottle or Bag 5% 250 ml Intravenous Nutrition 15 % 500 ml/ Amino Acids for Adult Bottle Glass Bottle Amino Acids for 10% 100 ml/ Bottle Childeren Glass Bottle Fat Emulsion Glass Bottle or lastic 20 % 250 ml Bag Fat Emulsion Glass Bottle or lastic 20 % 500 ml N Bag Multivitamins (Adult) - (One or Two Ampoules) A, D, E, B1, B2, B3, B6 and B12 Ampoule 10 ml

54 NUTRITION AND BLOOD SUBSTITUTES NUTRITION AND BLOOD SUBSTITUTES Multivitamins (ediatric) A, D, E, B1 Ampoule 10 ml, B2, B3, B6 and B Trace Elements Additive 10 ml (ediatric Dose) Trace Elements 10 ml Additive (Adult Dose) Minerals Calcium, Magnesium and hosphate Magnesium Sulfate Ampoule 50 % 2 ml N Vitamins Thiamine (Vitamin B1) Tablet 100 mg Thiamine (Vitamin B1) Ampoule 100 mg yridoxine cl Tablet mg C (Vitamin B6) yridoxine cl Tablet 10mg N (Vitamin B6) Ascorbic Acid Tablet 500 mg (Vitamin C) 2 Mcg/ ml Alfacalcidol Oral Dropper C ml/ Bottle Magnesium Oxide Tablet 400 mg Alfacalcidol Capsule 0.25 Mcg C NUTRITION AND BLOOD SUBSTITUTES mg/5 ml Magnesium Citrate Syrup 300 ml /Bottle Ampoule or Magnesium Sulfate 10 % (20 ml) C hosphate Salt Tablet 500 mg N 10 % ( 10 ml Calcium Chloride Ampoule Ampoule) refilled Calcium Chloride 10% (10ml) C Syringe Alfacalcidol Capsule 1 Mcg C Alfacalcidol Ampoule 1 Mcg Calcitriol Capsule 0.25 Mcg N Calcitriol Capsule 0.5 Mcg N Calcitriol Ampoule 1 Mcg N Calcitriol Drops 2,000-5,000U/ C ml Cholecalciferol Capsule 1000 Iu (Vitamin D3) NUTRITION AND BLOOD SUBSTITUTES Calcium Gluconate Ampoule 10 % (10 ml) C Not Less Cholecalciferol (Vitamin D3) Capsule 5000 Iu Calcium (Gluconate or Lactate) Syrup Than 2.27 Mmol/ C Cholecalciferol Capsule Iu Cholecalciferol Capsule Iu 5 ml Vitamin E Suspension 500 mg/ 5 ml N Calcium Lactate Tablet 300 mg C hosphate-binding Agents Menadiol Sodium hosphate Tablet 10 mg N ure Aluminum ydroxide ure Aluminum ydroxide 400 mg - Capsul 500 mg Gel 0.04 N hytomenadione Tablet 10 mg hytomenadione Ampoule 2 mg C hytomenadione Ampoule 10 mg mg Multivitamins Tablet C Calcium Carbonate Tablet Elemental C Multivitamins for Calcium Sevelamer Tablet 800 mg Children According to (Recommended Daily Syrup ml C Zinc Allowances) Zinc Tablet mg Vitamin B1 & B6 & B12 Tablet 100 mg mg + 200Mcg C

55 NUTRITION AND BLOOD SUBSTITUTES MUSCULOSKELETAL SYSTEM Vitamin B Complex Tablet Complex Retinol (Vitamin A) Capsule Iu p C Metabolic Disorders 300 mg/ ml L-Carnitine Oral Solution 30% 20 ml Chapter 10 Drugs Used in The Treatment of Musculoskeletal And Joint Diseases NUTRITION AND BLOOD SUBSTITUTES mg L-Carnitine Tablet 500 mg L-Carnitine Ampoule 200 mg/ ml ydroxytryptophan Tablet or 50 mg Capsule Arginine cl Oral owder Jar 100 Gm owder 100 Gm Arginine cl 10% Iv Bottle or 100 mg / ml 300 ml Glycine owder 1 Kg Bottle henyl Butyrate Tablet 500 mg Carglumic Acid Tablet 200 mg Sod henyl Ampoule 10% Acetate+Sod Benz 10% Sodium Benzoate Oral owder 500 Gm p Bottle Riboflavine B2 Tablet 100 mg p Biotin Tablet 10 mg Code No. Item Specification Dosage Form Strength 10. Drugs Used in The Treatment of Musculoskeletal and Joint Diseases Drugs Used in Rheumatic Diseases and Gout Nonsteroidal Antiinflammatory Drugs Ibuprofen Tablet 400 mg C Ibuprofen Syrup 100 mg/ 5ml C Diclofenac Tablet 50 mg C Diclofenac Iv, Im 75 mg C Ampoule Diclofenac Suppository 12.5 mg C Diclofenac Suppository 50 mg C Diclofenac Gel 1-3% C Indomethacin Capsule 25 mg Indomethacin Suppository 100 mg Indomethacin Ampoule 50 mg Indomethacin Ampoule 1M g Mefenamic Acid Syrup 50 mg/5 ml N Sulindac Tablet 100 mg N MUSCULOSKELETAL AND JOINT DRUGS Celecoxib Capsule 200 mg Meloxicam Tablet 7.5 mg C Meloxicam Tablet 15 mg Lornoxicam Tablet 8 mg Non Steroidal Anti Inflammatory Drugs (Im,Iv) or Ampoule Naproxene Tablet or Capsule 250 mg C Local Corticosteroid Injections Triamcinolone Acetonide 40 mg/ ml Drugs Suppressing Rheumatic Disease rocess Sodium Aurothiomalate Tablet 10mg N

56 MUSCULOSKELETAL SYSTEM DRUGS ACTING ON TE EYE Sodium Injection 50 mg N Aurothiomalate Abatacept 250 mg Tocilizumab 80 mg Chapter 11 Drugs Acting on The Eye MUSCULOSKELETAL AND JOINT DRUGS 10 Tablet or enicillamine 250 mg Capsule Drugs for Gout Allopurinol Tablet 300 mg C Allopurinol Tablet 100 mg C Rasburicase 1.5 mg ydroxychloroquine Tablet 200 mg Sulphate Colchicine Tablet 500 Mcg Tumour Necrosis Factor ( Tnf) Antagonist Infliximab 100 mg Etanercept refilled 50 mg Syringe Adalimumab refilled 40 mg /0.8 ml Syringe B Cell Depation Agent Rituximab 100 mg Rituximab 500 mg Alemtuzumab 300 mg N Drugs Used in Neuromuscular Disorders Anticholinesterases Botulinum Toxin 100 Unit/ Ampoule Type A Injection yridostigmine Tablet 60mg Skeletal Muscle Relaxants Baclofen Tablet 10 mg C/ Baclofen Syrup 5 mg/ 5 ml Chlorzoxazone Capsule 250 mg N Drugs for The Relife of Soft Tissue Inflammation Enzymes and Chemical Code No. Item Specification Dosage Form Strength Drugs Acting on The Eye Antiinfective Eye reparations Antibacterials Bacitracin Zinc + Eye 500 I.U I.U./ olymixin B Sulphate Ointment Gm 2-5 Gm/ Tube Eye 1% (3-5 Gm/ Chloramphenicol Ointment Tube) 0.5% (10 ml/ Chloramphenicol Eye Dropper C Bottle) Chloramphenicol Eye Dropper % N Erythromycin Eye Ointment 0.5% N 0.3 % ( Gentamicin Eye Ointment C Gm/ Tube) Gentamicin Eye Drops 0.03% Minims N Eye/ Ear 0.3 % ( Gentamicin C Dropper ml/ Bottle) Sulfacetamide Eye Ointment 10% N 1 % 3-5 mg Tetracycline cl Eye Ointment C Tube 0.3% ml/ Moxifloxacin cl Eye Dropper Tube Ofloxacin Eye Dropper N Ciprofloxacin Eye Dropper 0.3% Bottle C/ Fusidic Acid Eye Drops or 1 % 5 Gm/ Gel Tube Tobramycin + Eye Ointment 0.3% + 0.1% 3 N Dexamethasone - 5 Gm/ Tube EYE ACTING DRUGS yaluronidase Ampoule or 1500 I.U Tobramycin + Dexamethasone Eye Suspension 0.3 % + 0.1% 5 ml/bottle N Sodium yaluronate Intra- Artircular (Mw Over 3 Million) refilled Syringe mg/ ml ( 2 ml) Antifungals Natamycin Eye Dropper 5% N

57 DRUGS ACTING ON TE EYE DRUGS ACTING ON TE EYE Antiviral 3 % 4.5 Gm/ Acyclovir Eye Ointment Tube 0.01 (5-10 ml Trifluridine Eye Dropper N Bottl Antinflammatory reparations Corticosteroids Dexamethasone Eye Dropper 0.1% N henylephrine cl Eye Dropper henylephrine cl Eye Dropper Treatment of Glaucoma Miotics ilocarpine Eye Dropper 2.5 % 5 ml/ Bottle 10 % 5-10 ml/ Bottle 2 % 10 ml/ Bottle N EYE ACTING DRUGS Betamethasone Eye Dropper 0.1% N rednisolone Eye Dropper 0.1% N Dexamethasone Eye Ointment 0.05% 3 N Gm Tube 0.1 % 5 ml Fluorometholone Eye Dropper Bottle Other Antiinflammatory reparations 0.1% 5 ml / Diclofenac Eye Dropper Bottle Ketotifen Eye Dropper 0.25 mg N Antihistamine Olopatadine cl Eye Dropper 0.10% C/ Olopatadine cl Eye Dropper 0.20% N Mydriatics and Cycloplegics Antimuscarinics 0.5 % Atropine Sulfate Eye Dropper (5-10 ml) Atropine Sulfate Eye Dropper 0.01 N Atropine Sulfate Ointment Cyclopentolate cl Eye Dropper Single Dose Cyclopentolate cl (Minims) Tropicamide Eye Dropper 1 % (3-5 Gm) 1 % ml/ Bottle 1% N 1 % ml/ Bottle omatropine Eye Dropper 2% N Sympathomimetics 0.1 % 15 ml/ Naphazoline Eye Dropper C Bottle Single Dose ilocarpine 2% N (Minims) Beta-Blockers Betaxolol cl Eye Dropper Carteolol cl Eye Dropper Timolol Eye Dropper Latanoprost Eye Dropper Bimatoprost Eye Dropper Apracloidine cl Eye Dropper Brimonidine Tartrate Eye Dropper Systemic Drugs Tablet or Acetazolamide Capsule 0.5 % 5 ml/ Bottle 1 % 5 ml/ N Bottle 0.5 % 5-10 ml/ Bottle % 2.5 ml/ Bottle 0.3 % 3 ml/ Bottle 0.5% 5 ml/ N Bottle 0.2% 5 ml/ N Bottle 250 mg Acetazolamide 500 mg Dorzolamide Eye Dropper Brinzolamide Eye Dropper Dorzolamide + Timolol Eye Dropper Local Anesthetics Amethocain Eye Dropper 2% 5 ml / Bottle 1% 5 ml / N Bottle % 5 ml N / Bottle 0.5% N ml/ Bottle EYE ACTING DRUGS Oxymetazoline Eye Dropper 0.025% N

58 DRUGS ACTING ON TE EYE DRUGS ACTING ON TE EAR, NOSE, AND OROARYNX roparacaine Eye Dropper Single Dose Amethocain (Minims) 0.5 % ml/ Bottle 0.50% N Chapter 12 Drugs Used in The Treatment of Disease of The Ear, Nose, and Oropharynx EYE ACTING DRUGS 11 Single Dose Oxybuprocaine 0.40% N (Minims) Lidocaine + Single Dose % % Fluorescein Sodium (Minims) Miscellaneous Ophthalmic reparations reparations for Tear Deficiency Artificial Tears Eye Eye Dropper ml C Dropper ydroxypropyl Eye Dropper 0.30% N Methylcelulose Carboxymethyl- Single Dose % N Cellulose (Minims) Liquid arafin Eye Ointment 42.50% N olyacrylic Acid Eye Gel 0.20% N Other reparations Acetylcholine Chloride 1% p Sterile Balanced Salt Sterile ml Solution (Bss) Solution 0.2% 5-15ml/ Sodium yaluronate Eye Dropper C/1 Bottle Sodium yaluronate Disposable 1% 10mg/ ml Intra Ocular Syringe ml (Mw Over 3 Million) Diagnostic reparations Single Dose 2% 0.5 ml/ Fluorescein (Minims) Dose Fluorescein Ampoule 10% N Rose Bengal Single Dose 1% N (Minims) Code No. Item Specification Dosage Form Strength 12. Drugs Used in The Treatment of Disease of The Ear, Nose, and Oropharynx Drugs Acting on The Ear Antinfective reparation 5% ( Chloramphenicol Ear Dropper ml/ Bottle) Ciprofloxacin Ear Dropper 3 mg/ ml (5-10 ml/ Bottle) Clotrimazole Ear Dropper 1% N Econazole Ear Dropper 1% N 1% (10 ml/ Imidazole Derivative Ear Dropper C/1 Bottle) Gentamicin + Eye/ Ear % C/1 Betamethasone Dropper ml/ Bottle Gentamicin Ear Dropper 0.3+1% N ydrocortisone olymyxin B Sulfate Iu Neomycin Sulfate + Ear Dropper 3400 Iu + 1% N ydrocortisone olymyxin B 0.10% + +Neomycin Ear Dropper 0.25% Aminacrine + %+ 0.02% ydrocortisone Other Ear reparations Wax Removal Ear Dropper 10 ml/ Bottle C Drugs Acting on The Nose Drugs Used in Nasal Allergy The EAR, NOSE, AND OROARYNX 12 50Mcg/ Mometasone Nasal Spray Metered Spray 50Mcg/ Beclomethasone Nasal Spray Metered N Spray

59 DRUGS ACTING ON TE EAR, NOSE, AND OROARYNX DRUGS ACTING ON TE SKIN Budesonide Nasal Spray 64 Mcg/ Metered Spray C Chapter 13 Drugs Acting on The Skin The EAR, NOSE, AND OROARYNX Fluticasone Nasal Spray 50Mcg/ Metered C/1 Spray Cromoglycate Sodium Nasal Spray 2% ( 5-10ml) Topical Nasal Decongestants Sodium Chloride Nasal Drops 0.9% ml Naphazoline cl Nasal Drops Chlorpheniramine Xylometazoline cl Nasal Drops 500 Mcg + C 500Mcg/ml 0.05 % ml/ Bottle Nasal 2% (3-5 Gm Mupirocin Ointment ) Tube Skin 2% ( Mupirocin Ointment Gm) Tube Drugs Acting on The Oropharynx Mouth Wash Chlorhexidine Mouth Wash 0.2% 150 ml C Gluconate Code No. Item Specification Dosage Form Strength 13.Drugs Acting on The Skin Emollient and Barrier reparation Urea Lotion 10%( ml) / Bottle Urea Cream 10 % (15-30 Gm) Tube Urea Cream 20 % (15-30 Gm) Tube Urea Cream 40 % (15-30 Gm) Tube Urea Ointment 10 % (15-30 h Gm) Tube Urea Ointment 20 % (15-30 Gm) Tube Urea Ointment 40 % (15-30 Gm) Tube Lubricant Tube Gm Calamine Lotion Lotion Bottle ml C Zinc Oxide Cream or 30 Gm/ Tube C Ointment araffin Wite Soft Tube Gm C etroleum SKIN ACTING DRUGS Surface Anaesthesia Lidocaine + rilocaine Cream 2.5% + 2.5% 15 Gm Tube Topical Corticosteroids ydrocortisone Cream 1% Gm Tube C Betamethasone Dipropionate Cream 0.05 %15-30Gm Tube Betamethasone Dipropionate Ointment 0.05 %,15-30Gm Tube ydrocortisone + Clioquinol Ointment 1% + 3% 5-10 Gm Tube

60 DRUGS ACTING ON TE SKIN DRUGS ACTING ON TE SKIN SKIN ACTING DRUGS 13 Calcipotriol+ 50 Mcg Betamethasone Scalp Gel C/1 0.5 mg / Tube Dipropionate Calcipotriol + Skin 50 Mcg Betamethasone C/1 Ointment 0.5 mg Dipropionate Betamethasone Scalp Lotion Valerate Clobetasol ropionate Cream Clobetasol ropionate Ointment Mometasone Furoate Cream Mometasone Furoate Ointment Triamcinolone Acetonide Betamethasone Valerate Betamethasone Valerate ydrocortisone Butyrate Triamcinolone Acetonide Triamcinolone Acetonide Betamethasone Dipropionate + Salicylic Acid Betamethasone Dipropionate + Salicylic Acid Fusidic Acid ydrocortison Acetate Fusidic Acid Betamethasone Ointment Ointment Cream Lipocream 0.1 % ml Bottle 0.05% 15-30Gm/ Tube 0.05% 15-30Gm/ Tube 0.1% 15-30Gm/ Tube 0.1% 15-30Gm/ Tube 0.1% 15-30Gm/ Tube 0.1 %,15 or C/1 30G Tube 0.1 %,15 or C/1 30G Tube 0.1 %,15 or 30G Tube 40 mg/ ml Dental aste Scalp Lotion Ointment Cream Cream 0.1 %, 10Gm Tube 0.05 % + 2 %, 30 ml 0.05 % + 3 %, 15-30Gm Tube 2 % + 1 %, 15-30Gm Tube 2 % %,15-30Gm Miconazol + 2 % + 1 %, Cream ydrocortison - 30Gm Tube reparation for Eczema and soriasis Topical reparations 2.5 %, Selenium Sulphide Shampoo ml Bottle 50Mcg/ Gm Calcipotriol Ointment (30 Gm/Tube) Oral Retinoids for soriasis Acitretin Capsule 10 mg reparation for Acne and irsutism Keratolytics 20 % 30 Gm/ Azelaic Acid Cream Tube Lotion or 5 % ( Benzoyl eroxide C Gel ml or Gm) 2.5 % ( Benzoyl eroxide Gel ml or Gm ) 0.7 %, 7 or Cantharidin Liquid N ml Bottle Topical Antibiotics Clindamycin or Topical Erythromycin for Acne Solution Metronidazole Gel Topical Retinoids Tretinoin Cream or Gel Tretinoin Liquid Tretinoin Gel Tretinoin Cream Adapalene Gel 10 mg/ml C 30 ml/ Bottle 0.75 %, 30-45Gm Tube 0.05 % C/1 Gm / Tube 0.05% ml /Bottle % Gm / N Tube 0.025% Gm / Tube 0.1 % Gm Tube SKIN ACTING DRUGS 13 Valerate Tube

61 DRUGS ACTING ON TE SKIN DRUGS ACTING ON TE SKIN Adapalene Gel 0.3 % G Tube N Ketoconazole Shampoo 2 %, ml C Tazarotene Gel 0.1 % ( 15 or 30 G ) N Miconazole Oral Gel 2 %, 20 or 30 G Tube C/ Tazarotene Gel 0.05 % ( 15 or 30 G) N Miconazole Solution Bottle 2 %, Gm SKIN ACTING DRUGS Oral Retinoids Tretinoin Capsule 10 mg N Isotretinoin Capsule 10 mg Isotretinoin Capsule 20 mg ormone Therapy for irsutism Cyproterone Acetate + 2 mg Tablet N Ethinyl Estradiol 35 Mcg Finasteride Tablet 1 mg Camouflagers Methoxsalen Lotion 15 ml/ Bottle N Ammidine Anti-Infective Skin reparations Topical Antibacterials Silver Sulfadiazine Cream (Sterile) Silver Sulfadiazine Cream (Sterile) Fusidic Acid Ointment Fusidic Acid Cream Topical Antifungals Imidazole Derivative (Clotrimazole, Econazole, Cream Miconazole, Ketoconazole) Clotrimazole Cream Nystatin Cream 1 % 50 C Gm/ Tube 1 % 500 Gm/ Jar 2% C Gm/ Tube 2% C Gm / Tube 1,1,2 or 2 % C (15 Gm/ Tube) 1% Gm/ Tube U/Gm Gm/ C Tube Miconazole owder Terbinafine Cream Amorolfine Nail Lacquer Topical Antiviral Acyclovir Cream enciclovir Cream Imiquimod Cream odofilox Gel odophyllin Lotion odophyllotoxin Solution odophyllotoxin Cream 2 %, Gm 1 %, G C Tube 5 %, 5 ml Tube 5% 10 Gm/ C Tube 1 %, 2-5 Gm Tube 5 %, 250 mg Each Sachet N Tube 0.5 %, 3.5 G N Tube 25 %, 15 ml N Bottle 0.5 %, 3 or 5 N ml Bottle 0.15 %, 5 G N Tube Miscellaneous for Skin, air Loss,Scars, yperhidrosis 0.25% 30 Gm/ B-Sitosterol Ointment Tube 1 %, 30 ml Methoxsalin Lotion N Tube 0.1 %, 30 G Tacrolimus Ointment Tube 0.03 %,30 G Tacrolimus Ointment Tube 1 %, 30 G imecrolimus Cream Tube SKIN ACTING DRUGS

62 DRUGS ACTING ON TE SKIN DRUGS ACTING ON TE SKIN Salicylic Acid Ointment 5 %, 30 G Tube Cortamiton Cream 10% (20-30 Gm) C 10 %, 30 G Salicylic Acid Ointment Tube 20 %, 30 G Salicylic Acid Ointment Tube Salicylic Acid ad 40 % atch Topical and Intralesional Cytotoxic Agent 0.5 %, 15 or Flurouracil Cream 30 G Tube N 5 %, 25 G Flurouracil Cream N Tube Salicylic Acid Topical / Scalp 2% ml Botle C Flurouracil Solution Injection 0.5%, 10ml 16.7% + Alicylic Acid + Lactic Lotion 16.7% (15 - Acid 30 ml) Silicon Gel 15 Gm Tube ydroquinone Cream 4 %, 30 Gm Tube Miscellaneous soralen Methoxsalen Tablet 10 mg Fluocinolone / ydroquinone / Tretinoin Cream 0.01 % + 4 % %, 30G SKIN ACTING DRUGS 13 Monobenzyl Ether of Cream ydroquinone Minoxidil Solution Minoxidil Solution Topical Aluminum Chloride Solution Eflornithine Cream 20 %, 35.4 G Tube 2 %, 60 ml Bottle 5 %, 60 ml Bottle 20 %, 40 ml Bottle 13.9 %, 30 G Tube N N SKIN ACTING DRUGS Diphenyl Cyclopropenone ( Dpcp ) White to Tan owder , 5 G N aromomycn Ointment N arasiticdal reparations (Anti Lice, Scabies) ermethrin Cream or Lotion 5%, 0.4% Gm C yrethrins Shampoo 0.3% ml/ Bottle N ermethrin Cream or Spray 1 %, 92%, Gm

63 VACCINS AND IMMUNOLOGIC RODUCTS VACCINS AND IMMUNOLOGIC RODUCTS VACCIN AND IMMUNOLOGIC RODUCTS 14 Chapter 14 Vaccin and Immunologic roducts Code No. Item Specification Unit acking 14. Vaccin and Immunologic roducts Vaccines and Antisera 5-10 Doses/ Ampoule or Bcg Vaccine C With Diluent Meningococcal olysaccharide Sero C Doses/ Group (A,C,Y,W-135 ) Meningococcal Group (A,C,Y & W135) olysaccharide 0.5ml Single Diphtheria Toxoic Conjugated Vaccine Dose s neumococcal olyvalent (23 Valent) 25 Mcg / 0.5 ml. / Vaccine. Ampoule neumococcal 0.5 ml Single C Conjugated Vaccine Dose / Influenza Virus Vaccine Mono Dose N Diphtheria and Tetanus Vaccine for Adults Dose/ Diphtheria and Tetanus C Vaccine for Children Dose/ Diphetheria,Tetanus, Ertussis Vaccine (Dtp) 5-10 Dose/ Tetanus Vaccine Single Dose N Measles Vaccine Tetanus Vaccine 10 Doses / 5-10 Dose/ C C N 25 Mcg /0.5ml Single Typhoid Vaccine Dose / Or Ampoule Measles Vaccine (3.7-4) 0.5 ml Measles Vaccine 0.5 ml Single Dose/ aemophilus Influenza Single Dose + Dpt Vaccine Type Ampule or "B" Conjugate Vacccine With D.t.p aemophilus A Single Dose, Vaccine for Adults and or Adolesent Syringe aemophilus B Single Dose, Vaccine for Adolescent and Adults aemophilus B Single Dose, Vaccine for Children aemophilus A Single Dose, Vaccine for Children aemophilus Influenza Vaccine Single Dose Type "B" of 0.5ml Conjugate Vaccine Dpt+epatitus B ib Ampoule Bib Vaccine (entavalent) 0.5 ml Children Injection 0.5 ml. Triple Virus Vaccine Single Dose/ (Mmr) Injectable olio Vaccines (Ipv) 0.5ml Single Injectable olio Dose Vaccines (Salk Vaccines). oliomyelitis Vaccine 5-10 Dose/ Live Oral: (Sabin Strain) C C C C C C C C Rabies Virus Vaccine Single Dose C VACCIN AND IMMUNOLOGIC RODUCTS 14

64 VACCINS AND IMMUNOLOGIC RODUCTS VACCINS AND IMMUNOLOGIC RODUCTS Yellow Fever Vaccine Varicella- Zoster Virus (Chicken ox Vaccine for Subcutaneous Injection ) 0.5 ml Single Dose Ampoul or Single Dose 0.5ml / With Diluent C uman Immunoglobulin for epatitis (B) uman Immunoglobulin For Rabies, U.(B) er 1ml 1-2 ml/amp or 150 I.U./ml 10 ml/amp epatitis B Vaccine ( uman 250 Units 1 VACCIN AND IMMUNOLOGIC RODUCTS for Adolescent and Adults ) epatitis(a) Vaccine for Children epatitis A Vaccine for Adults and Adolesent epatitis B Vaccine ( for Children ) Tuberculin pd Skin Test Tuberculin urified rotein Derivatives Containing 10 Tuberculin Anti Rabies Serum (orse Origin) Gas Gangrene Antitoxin for S.c. or I.m. Injections Diphtheria Antitoxin -orses Single Dose C Single Dose/ C Single Dose Single Dose/ C 2U-5U/0.1ml 0.1 ml of 5 ml 5-10ml/ p C Ampoul 10 ml / N Ampoule 5-10 ml/ Ampoul or N Immunoglobulin for Tetanus I.m. Injection (rophylaxis ) uman Normal Immunoglobulin for I.m Injection Anti- Rho (D) Immunoglobulin Anti- Rho (D) Immunoglobulin Anti- Rho (D) Immunoglobulin Antivenoms Scorpion Anti-Venin Snake Anti-Venin or 2 ml/ C Ampoule or 16.5% or 165 mg/ml 2ml / Ampoule Ampoule or Mcg C Ampoule or Ampoule or 1 ml/ Ampoule or 20 ml/ Ampoule or 1500 I.U. 300 Mcg 2500 I.U. 500 Mcg C olyvalent C Snake Unit Sea Snake Antivenin Ampoule 1000 Unit N VACCIN AND IMMUNOLOGIC RODUCTS Tetanus Antitoxin 1500 I.U. / 1 ml C 5-10ml./ Tetanus Antitoxin Ampoule or N Immunoglobulis uman Normal Immunoglobulin for I.v. Injection. 2-5 Gm./ With Diluent

65 DRUGS USED IN ANESTESIA DRUGS USED IN ANESTESIA Chapter 15 Drugs Used in Anesthesia Vecuronium Bromide Injection 10 mg N Anticholinesterases Used in Surgery Edrophonium Chloride Injection 10 mg N DRUGS USED IN ANESTESIA 15 Code No. Item Specification Dosage Form Strength 15. Drugs Used in Anesthesia General Anesthesia Intravenous Anesthetics Ampoule Thiopental Sodium 500 mg Or 2 mg/ ml Etomidate Ampoule 10 ml 10 mg/ ml Ketamine cl (20 ml) 10 mg/ ml ropofol (20 ml) Inhalational Anesthetics Inhalation Isoflurane 100 ml/ Bottle Inhalation Sevoflurane 250 ml/ Bottle Antimuscarinic remedication Drugs mg/ Atropine Sulfate Ampoule, C ml (5-10ml) 0.1 mg/ml Atropine Sulfate Syringe C (5ml) refilled 0.1 mg/ml Atropine Sulfate Syringe (10ml) Glycopyrrolate Ampoule 200 Mcg Bromide Muscle Relaxants 10 mg/ ml Atracurium Besylate Ampoule (25 mg) 2 mg/ ml ancuronium Bromide Ampoule (2ml) Rocuronium Bromide Ampoule 10 mg Succinylcholine Ampoule 100 mg Chloride Or Neostigmine Injection 12.5 mg N Methylsulfate Neostigmine Ampoule 500 Mcg Methylsulfate Antagonists for Central and Respiratory Depression 100 Mcg/M Flumazenil Ampoule L(5 ml) 0.02 mg/ml Naloxone cl Ampoule ( 2 ml) Naloxone cl Ampoule 0.4mg/ ml C Antagonists for Malignant yperthermia Dantrolene Sodium 20 mg Local Anesthesia Lidocaine cl 1 % (20 ml) Lidocaine cl 2% (20-50 ml) 2% 20 mg / refilled Lidocaine cl ml 100 mg / C Syringe 5ml remixed 2G/500ml Lidocaine cl C Bag D5w Lidocaine cl + 1% Adrenaline 1:100,000 Lidocaine cl + 1% N Adrenaline 1:200,000 2 % + Lidocaine cl Cartridge 1:80,000 Adrenaline 1.8 ml 5% Lidocaine cl Ointment Gm/ Tube Lidocaine cl (Water 2% Gel C Miscible Sterile Tube) Gm/ Tube Aerosol 10% 50 ml/ Lidocaine cl C Spray ack Bupivacaine cl 0.25% (20 ml) DRUGS USED IN ANESTESIA Bupivacaine cl 0.5% (20 ml)

66 DRUGS USED IN ANESTESIA Bupivacaine cl (eavy for Spinal Ampoule 0.50% Anaesthesia) Ropivacaine cl ml N 30 mg + rilocaine cl Cartridge 0.03% C Felypressin (1.8 ml) Code No. SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS Chapter 16/ Appendix I Solutions (Concentrates) used for ERITONEAL DIALYSIS / EMODIALYSIS Item Specification Dosage Form Strength 16. Solutions (Concentrates) used for eritoneal Dialysis/ emodialysis eritoneal Dialysis Solutions eracetic acid (Free aldehyde Disinfectant) Solution 3% ERITONEAL DIALYSIS FLUID WIT ADATOR WIT 1.5% DEXTROSE FOR ACUTE DIALYSIS DRUGS USED IN ANESTESIA ONE LITER of TE SOLUTION CONTAINS TE FOLLOWING:- 131 MMOL (MEQ) of Na+, 2.0 MMOL (4.0 MEQ) of Ca++, 1.0 MMOL (2.0 MEQ) of mg++, MMOL (MEQ) of CL-, 35.0 MMOL (MEQ) of ACETATE, MMOL (MOSM) of DEXTROSE, TOTAL OSMOLARITY = MOSM / LITER ERITONEAL DIALYSIS FLUID WIT ADATOR WIT % DEXTROSE, 250 ML. FOR CAD, CONTAINING TE FOLLOWING:- Na MMOL, Ca MMOL, mg 0.75 MMOL, CL 102 MMOL, LACTATE MMOL / LITER, 250 ML. / LASTIC BAG. Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or Solution Solution ONE LITER BAG. ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over lactate

67 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS RENAL DIALYSIS (RD) WIT ADATOR ERITONEAL DIALYSIS FLUID WIT ADATOR ERITONEAL DIALYSIS FLUID WIT % WIT % DEXTROSE, 2000 ML. FOR DEXTROSE, 500 ML. FOR CAD, CONTAINING CAD, CONTAINING TE FOLLOWING:- Na 131 TE FOLLOWING :- Na MMOL, Ca MMOL, Ca MMOL, mg 0.75 MMOL, MMOL, mg 0.75 MMOL, CL 102 MMOL, CL 102 MMOL, LACTATE MMOL / LITER, LACTATE MMOL / LITER, 500 ML. / 2000 ML. / LASTIC BAG Bags are connected LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and Solution with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each Solution catheter extention for each 450 bags for adult and 450 bags for adult and for each 200 bags for for each 200 bags for pediatrics.note when the pediatrics.note when the price is equal biofine is price is equal biofine is prefered over plastic as prefered over plastic as the content of the bags the content of the bags and tubes and and tubes and bicarbonate M MOL \liter is bicarbonate M MOL \liter is preferd over preferd over lactate lactate ERITONEAL DIALYSIS FLUID WIT ADATOR ERITONEAL DIALYSIS FLUID WIT ADATOR WIT % DEXTROSE, 250 ML. FOR CAD WIT % DEXTROSE, 500 ML. FOR CAD, CONTAINING TE FOLLOWING:- Na , CONTAINING TE FOLLOWING :- Na MMOL, Ca MMOL, mg 0.75 MMOL, CL MMOL, Ca MMOL, mg 0.75 MMOL, CL 102 MMOL, LACTATE MMOL / LITER, 250 ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS MMOL, LACTATE MMOL / LITER, 500 ML. / LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate M MOL \liter is preferd over lactate Solution ML. / LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over lactate ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS

68 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS ERITONEAL DIALYSIS FLUID WIT ADATOR ERITONEAL DIALYSIS FLUID WIT ADATOR WIT % DEXTROSE, 500 ML. FOR CAD WIT % DEXTROSE, 250 ML. FOR, CONTAINING TE FOLLOWING :- Na CAD, CONTAINING TE FOLLOWING:-Na 131 MMOL, Ca MMOL, mg 0.75 MMOL, CL MMOL, Ca MMOL, mg 0.75 MMOL, 102 MMOL, LACTATE MMOL / LITER,500 CL 102 MMOL, LACTATE MMOL / LITER, ML. / LASTIC Bags are connected with stay 250 ML. /LASTIC Bags are connected with stay safe system which should incl}de disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor Solution safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor Solution and catheter extention for each 450 bags for adult and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic the price is equal biofine is preferred over plastic as the content of the bags and tubes and as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over bicarbonate M MOL \liter is preferd over lactate lactate ERITONEAL DIALYSIS FLUID WIT ADATOR ERITONEAL DIALYSIS FLUID WIT ADATOR WIT % DEXTROSE, 1000 ML. FOR CAD WIT % DEXTROSE, 500 ML. FOR CAD, CONTAINING TE FOLLOWING :- Na , CONTAINING TE FOLLOWING:- Na MMOL, Ca MMOL, mg 0.75 MMOL, CL MMOL, Ca MMOL, mg 0.75, MMOL, CL 102 MMOL, LACTATE MMOL / LITER, 102 MMOL, LACTATE MMOL / LITER, 500 ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS ML. / LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over lactate Solution ML. / LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over lactate ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS

69 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS ERITONEAL DIALYSIS FLUID WIT ADATOR (ERITONEAL DIALYSIS SET FOR OME COICE WIT % DEXTROSE, 1000 ML. FOR MACINE) CYCLER MACINE OME CICE CAD, CONTAINING TE FOLLOWING:- Na MMOL, Ca MMOL, mg 0.75 MMOL, CL 102 MMOL, LACTATE MMOL / LITER CASSETTE-LINE 4 RONGS- LUER, LOCK MINCA WIT OVADINE TITANIUM ADATOR. TRANSFER SET WIT TWIST CLAM. TE Solution 1000 ML. / LASTIC Bags are connected with DIALYSATE BAG CONTAINS 1.36% DEXTROSE, stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or Solution 5000ML, LOW CALCIUM. (ERITONEAL DIALYSIS SET FOR OME COICE MACINE) CYCLER MACINE OME CICE biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is CASSETTE-LINE 4 RONGS- LUER, LOCK MINCA WIT OVADINE TITANIUM ADATOR. TRANSFER SET WIT TWIST CLAM. TE Solution prefered over plastic as the content of the bags DIALYSATE BAG CONTAINS 3.86% DEXTROSE, and tubes and bicarbonate MMOL \liter is 3000ML, LOW CALCIUM. preferd over lactate (ERITONEAL DIALYSIS SET FOR OME COICE ERITONEAL DIALYSIS FLUID WIT ADATOR MACINE) CYCLER MACINE OME CICE WIT % DEXTROSE, 2000 ML. FOR CAD, CONTAINING TE FOLLOWING:- Na MMOL, Ca MMOL, mg 0.75 MMOL, CASSETTE-LINE 4 RONGS- LUER, LOCK MINCA WIT OVADINE TITANIUM ADATOR. TRANSFER SET WIT TWIST CLAM. TE Solution CL 102 MMOL, LACTATE MMOL / LITER, DIALYSATE BAG CONTAINS 2.27% DEXTROSE, ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS ML. / LASTIC Bags are connected with stay safe system which should include disinfection cap and stay safe disc.organizer and organizer holder for each patient.titanum or biofine adaptor and catheter extention for each 450 bags for adult and for each 200 bags for pediatrics.note when the price is equal biofine is prefered over plastic as the content of the bags and tubes and bicarbonate MMOL \liter is preferd over lactate ERITONEAL DIALYSIS FLUID WIT ADATOR WIT 4.25% DEXTROSE FOR ACUTE ERITONEAL DIALYSIS ONE LITER of TE SOLUTION CONTAINS TE FOLLOWING:- 131 MMOL (MEQ) of Na+, 2.0 MMOL (4.0 MEQ) of Ca++, 1.0 MMOL (2.0 MEQ) of mg++, MMOL (MEQ) of CL-, 35.0 MMOL (MEQ) of ACETATE Solution Solution ML, LOW CALCIUM. (ERITONEAL DIALYSIS SET FOR OME COICE MACINE) CYCLER MACINE OME CICE CASSETTE-LINE 4 RONGS- LUER, LOCK MINCA WIT OVADINE TITANIUM ADATOR. TRANSFER SET WIT TWIST CLAM. TE DIALYSATE BAG CONTAINS 1.36% DEXTROSE, 3000ML, LOW CALCIUM. (ERITONEAL DIALYSIS SET FOR OME COICE MACINE )CYCLE MACINE OME COICE CASSETTE - LINE 4 RONGS - LUER -LOCK MINICA WIT OVADINE TITANIUM ADATER. TRANSFER SET WIT TWIST CLAM. TE DIALYSATE BAG CONTAINS 3.86% DEXTROSE, 5000ML,LOW CALCIUM. Solution Solution ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 (EQUIVALENT TO CO3 -), MMOL (MOSM) of DEXTROSE, TOTAL OSMOLARITY = MOSM / LITER IN ONE LITER CONTAINER

70 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS (ERITONEAL DIALYSIS SET FOR OME COICE ERITONEAL DIALYSIS SET FOR SLEE SAFE MACINE )CYCLE MACINE OME COICE MACINE+DEXTROSE 2.3% 3000ml (RENAL CASSETTE - LINE 4 RONGS - LUER -LOCK MINICA WIT OVADINE TITANIUM ADATER. TRANSFER SET WIT TWIST CLAM. TE Solution DIALYSIS SOLUTION 3000 ml WIT DEXTROSE 2.3% FOR SLEE SAFE CYCLER MACINE,SOULD INCLUDE A..D SET DIALYSATE BAG CONTAINS 2.27% DEXTROSE, ORGANIZER, ORGANIZER OLDER,ORGANIZER 5000ML,LOW CALCIUM. CLI ER ATIENT,TITANUM OR BIOFINE ERITONEAL DIALYSIS SET FOR SLEE SAFE MACINE+DEXTROSE 1.5% 3000ml (RENAL DIALYSIS SOLUTION 3000 ml WIT DEXTROSE ADATOR AND CATETR EXTENTION ER 450 BAG FOR ADULT AND ER 200 FOR EDIATRIC,ONE SLEE SAFE SET (LINES Solution 1.5% FOR SLEE SAFE CYCLER CASSETTLE) A..D.DRAINAGE BAG, MACINE,SOULD INCLUDE A..D SET DISINFECION CA FOR ADULT ER 3 BAGS;AND ORGANIZER, ORGANIZER OLDER,ORGANIZER FOR EDIATRICS ER 2 BAGS NOTE;WEN TE CLI ER ATIENT,TITANUM OR BIOFINE RICE IS EQUAL BIOFINE IS REFERD OVER ADATOR AND CATETR EXTENTION ER 450 BAG FOR ADULT AND ER 200 FOR EDIATRIC,ONE SLEE SAFE SET (LINES Solution LASTIC as TE CONTENT of TE BAGS AND TUBES AND BICARBONATE M MOL\LITRE IS REFERD OVER LACTATE) CASSETTLE) A..D.DRAINAGE BAG, ERITONEAL DIALYSIS SET FOR SLEE SAFE DISINFECION CA FOR ADULT ER 3 BAGS;AND MACINE+DEXTROSE 2.3% 5000ml(RENAL FOR EDIATRICS ER 2 BAGS NOTE;WEN TE DIALYSIS SOLUTION 5000 ml WIT DEXTROSE ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 RICE IS EQUAL BIOFINE IS REFERD OVER LASTIC as TE CONTENT of TE BAGS AND TUBES AND BICARBONATE M MOL\LITRE IS REFERD OVER LACTATE) % FOR SLEE SAFE CYCLER MACINE,SOULD INCLUDE A..D SET ORGANIZER, ORGANIZER OLDER,ORGANIZER CLI ER ATIENT,TITANUM OR BIOFINE ADATOR AND CATETR EXTENTION ER 450 BAG FOR ADULT AND ER 200 FOR EDIATRIC,ONE SLEE SAFE SET (LINES CASSETTLE) A..D.DRAINAGE BAG, DISINFECION CA FOR ADULT ER 3 BAGS;AND FOR EDIATRICS ER 2 BAGS NOTE;WEN TE RICE IS EQUAL BIOFINE IS REFERD OVER LASTIC as TE CONTENT of TE BAGS AND Solution ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 TUBES AND BICARBONATE M MOL\LITRE IS REFERD OVER LACTATE )

71 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS ERITONEAL DIALYSIS SET FOR SLEE SAFE EMODIALYSIS ACID COCENTRATE FOR MACINE+DEXTROSE 4.25% 3000ml (RENAL BICARBONATE DIALYSIS, IN DILUTION ( 1 :44 ) DIALYSIS SOLUTION 3000 ml WIT DEXTROSE 4.25% FOR SLEE SAFE CYCLER MACINE,SOULD INCLUDE A..D SET GIVES TE FOLLOWING CONCENTRATIONS:- IN M MOL / 1L,Na 100, Ca 1.5, mg 0.375, CL , OTASSIUM 1MMOL/L, ACETATE 2.00, Solution ORGANIZER, ORGANIZER OLDER,ORGANIZER DEXTROSE 1.1GM/L, TOTAL OSMOLARITY = CLI ER ATIENT,TITANUM OR BIOFINE MOSM /L IN 5 LITERS ADATOR AND CATETR EXTENTION ER 450 BAG FOR ADULT AND ER 200 FOR EDIATRIC,ONE SLEE SAFE SET (LINES CASSETTLE) A..D.DRAINAGE BAG, DISINFECION CA FOR ADULT ER 3 BAGS;AND Solution EMODIALYSIS ACID COCENTRATE FOR BICARBONATE DIALYSIS, IN DILUTION ( 1 : 44 ) GIVES TE FOLLOWING CONCENTRATIONS:- IN M MOL / 1L, DEXTROSE 1.1G/L, Na 100, K 2.00, Ca 1.5 mg 0.375, CL , ACETATE 2.00, Solution FOR EDIATRICS ER 2 BAGS NOTE;WEN TE TOTAL OSMOLARITY = MOSM / L IN 5 RICE IS EQUAL BIOFINE IS REFERD OVER LITERS LASTIC as TE CONTENT of TE BAGS AND TUBES AND BICARBONATE M MOL\LITRE IS REFERD OVER LACTATE) ICODEXTRAN 7.5% 2LITRE SINGLE BAG FOR A..D Solution EMODIALYSIS ACID COCENTRATE FOR BICARBONATE DIALYSIS, IN DILUTION ( 1:34 ) GIVES TE FOLLOWING CONCENTRATIONS:- IN MMOL / L, Na 103, K 2.00, Ca 1.5, mg 0.5 ACETATE 2.97, CL 109, DEXTROSE 1.1 GM/L, TOTAL OSMOLARITY = 225 MOSM / L IN 5 Solution ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS emodialysi Concentrates and Related Materials YROGEN FREE EMOFILTRATION SOLUTION IN 4.5 LITRES BI-CAMBER BICARBONATE BAG WIT TE FOLLOWING:- Na 138 MMOL / L, K = MMOL / L, CA = 2 MMOL / L, MG = 0.75 MMOL / L, CL=111.5 MMOL / L,BICARBONATE =25-40 meq / L. EMODIALYSIS ACID COCENTRATE FOR BICARBONATE DIALYSIS, IN DILUTION ( 1 :44 ) GIVES TE FOLLOWING CONCENTRATIONS:- IN M MOL / 1L,Na 100, K 2.00, Ca 1.75, mg 0.375, CL , ACETATE 2.00, DEXTROSE 1.1GM/L, Solution Solution LITERS CONTAINER. EAMODIALYSIS ACID CONCENTRATE FOR BICARBONATE DIALYSIS FORMULA (FF2) AFTER DILUTING 1 LITER CONCENTRATE WIT 34 LITERS of WATER, TE FOLLOWING CONCENTRATIONS of IONS/LITER ARE OBTAINED:Na 103 MMOL, ACETATE 2.97 Ca 1.5 MMOL, CL 108MMOL, mg 0.5 MMOL,DEXTROSE 1.1GM/L MMOL,K 1 MMOL, WIT AN OSMOLARITY of 223 MOSM/L, 5 LITERS/LASTIC CONTANER. Solution ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 TOTAL OSMOLARITY = MOSM / L IN 5 LITERS

72 SOLUTIONS FOR ERITONEAL DIALYSIS/ EMODIALYSIS ANTIDOTES EAMODIALYSIS ACID CONCENTRATE FOR BICARBONATE DIALYSIS FORMULA (FF3) AFTER DILUTING 1 LITER CONCENTRATE WIT 34 LITERS of WATER, TE FOLLOWING Chapter 17 / Appendix Ii Drugs Used As Antidotes CONCENTRATIONS of IONS/LITER ARE OBTAINED: Na 103 MMOL, K 2MMOL, Ca 1.25MMOL, mg 0.5MMOL, CL MMOL, ACETATE 2.97MMOL, DEXTROSE 1.1GM/L WIT AN OSMOLARITY of 223MOSM/L, 5 LITERS/ LASTIC CONTAINER Sodium Bicarbonate for heamodialysis owder Sacht Solution 650 gm/ Sacht N Code No. Item Specification Dosage Form Strength Drugs Used as Antidotes 1.Removal and Elimination Ipecacuanha Syrup 30ml/Bottel p C 2.revention of Absorption owder or G/ Activated Charcoal p C Suspension Container 3. Specific Drugs 200 mg/ ml Sodium Bicarbonate for heamodialysis owder Sacht 840 gm/ Sacht N Acetylcysteine Ampoule 10 ml/ Ampoule Deferoxamine Mesylate 500 mg Digoxin Immune Fab Injection 40 mg/ p Methylene Blue Injection 100 Mcg/ Amp N ERITONEAL DIALYSIS / EMODIALYSIS SOLUTIONS 16 hysostigmine Injection 2 mg/amp Salicylate Sodium Thiosulphate Injection 0.05 N 100 mg/ml Dimercaprol (Bal) Ampoule ( 2ml) Sodium Injection 1G/Amp N Calciumedetate or ralidoxime Chloride 1-6 Gm Ampoule Deferiprone Tablet 500 mg Deferasirox Tablet 125 mg ANTIDOTES Deferasirox Tablet 250 mg Deferasirox Tablet 500 mg Trimethylglycine Scoop 1 Gm/ Scoop N

73 ANTIDOTES CEMICALS (334 mg+ olycitra (Citric Acid+ 500 mg+ Reconstitution Sodium Syrup 550 mg) /5 N Citrate+ otassium ml 480 ml/ Citrate) Bottle Dmsa (Succimer) Capsule 100 mg Chemet entetate Calcium Gm N Trisodium 1.5 ml Fomepizole N (1Gm/ ml) russian Blue Cap 500 mg N Botulism Immune Injection owder for 100 mg N Globulin ediatrics Reconstitution Sea Snake Antivenin Ampoule 1000 Unit N Chapter 18 / Appendix Iii Chemicals Code No. Item Specification Dosage Form Strength Solids Bentonite Benzoic Acid Borax (Sodium Borate) Boric Acid owder Citric Acid Comphor Crystals owder Container owder Container owder Container owder Container owder Container owder Container 1 Kg N 250 Gm N 500 Gm 500 Gm 1 Kg N 500 Gm N Iodine Crystals owder Container 500 Gm Glass Bottle Magnesium Sulfate owder Container 500 Gm N Menthol owder Container 50 Gm ANTIDOTES 17 Mercurochrome Amber Gm N Crystals Colored Bottle owder Methylene Blue 100 Gm N Container otassium Iodide owder Kg Crystals Container otassium owder Gm ermanganate Crystals Container Silver Nitrate Styptics ack 10 Sticks CEMICALS Soda Lime Granules Container 250 Gm Sodium Chloride owder Container 500 Gm N Sodium Citrate owder Container 500 Gm N Sodium ypochloride Tablets Gm N

74 CEMICALS CEMICALS Sucrose owder Container 1 Kg N Alcohol Gel Desk Top Dispensers Gel Sulphur owder Container 500 Gm N Alcohol Gel Bed Mounted Dispensers Gel Talc urified owder owder Container Gm Clove Oil (Amber Colored Bottle) Container 100 ml/ Container Thymol owder Container 100 Gm N Eucalyptus Oil, 100 ml/ Container N Zinc Iodide Zinc Sulfate owder Container owder Container 100 Gm N 500 Gm N Orthophthaldehyde Container 55% 1 Gallon 60 Strips/ Bottle N CEMICALS 18 Semisolids Adeps-Lanae Container 5 Kg (Anhydrous Lanolin) Emulsifying Wax Container 1000 Kg Liquids Acetic Acid Container 1 Liter/ Bottle Benzoin Tincture Container 1 Liter/ Bottle Benzyl Benzoate Container C Castor Oil Bottle 60 ml Chlorhexidine 0.5% and Alcohol 70% Chlorhexidine 2 % in Aqueous Solution Chlorhexidine 2 % and Alcohol 70% Chlorhexidine Gluconate 4% in A Surfactant Solution, 1 Liter/Container With Dispenser Chlorhexidine Gluconate Alcohol Gel Wall Mounted Dispensers Solutions 500 (0.5 & ml With N 70%)500 ml Dispenser Stick 2% N Stick 2% & 70% N N 19-21% Container 1 Liter/ C Container Gel C Glycerol (Glycerin) Bottle ydrogen eroxide Solution Without Sliver Nitrate ydrogen eroxide Spray Without Sliver Nitrate Ichthammol Container Spray Ready Isopropyle Alcohol to Use Didecyl Dimethyl Spray Ready Ammonium Bromide to Use Didecyl Dimethyl Concentrated Ammonium Bromide Solutions Methyl Salicylate Bottle Orange Syrup, 100 ml/ Container araffin, Liquid Container (rotected From Light) eppermint Oil, 100 ml/ Container eracetic Acid Solution Container ovidone (Iodine) With Surgical Scrub Dispenser 60 ml/ Bottle 6% 1-2 N Liter 3% N ml 500 G/ N Container 70% 250ml 70% ml 70% 2-5 L 1 Liter/ Bottle N 5 Liters/ Container N (3-5 %) 1-2 L 7.5% ml/ Container CEMICALS

75 CEMICALS RADIOLOGY ovidone (Iodine) Container Iodophor 7,5 % & Isopropyle Alcohol Solution 70% Triethanolamine Liquid Container 10% ml/ Container 7.5% & 70% ( ml) 500 ml/ Container C N N Code No. Chapter 19 / Appendix Iv Contrast Media Used In Radiology Item Specification Dosage Form Strength Contrast Media Used in Radiology Iodine- Based Water Soluble Contrast Medium for G.i.t Examination (Oral & Rectal) Concentratio mg Iodine/ml, Bottle 100ml/Bottle. Iodine-Based Isosmolar,Water Soluble Non- Ionic Contast Medium for Iv&1A Injection and for Body Cavities,Concentration mg Iodine ml,50ml/s Iodine-Based Low Osmolality,Water Soluble Non- Ionic Contast Medium for Iv&1A Injection and for Body Cavities, Also Suitable for ediatric,concentration 300mg Iodine ml,50ml/s Gadolinium-Based Water Soluble Contrast Medium for Iv Injection,Concentration 0.5M CEMICALS Mol/ml, 20ml/ Gadolinium-Based Water Soluble Contrast Medium for Injection,Concentration 0.5M Mol/10ml/s Gadolinium-Based Water Soluble Contrast Medium for Injection,Concentration 1. 0 M Mol/ml, ml s or fs(re Filled Syringe) Iodine- Based Low Osmolality Water CONTRAST MEDIA FOR RADIOLOGY 19 Soluble Non-Ionic Contrast Medium for Iv & Ia Injection and Body Cavities, Concentration mg Iodine/ml, 50ml/

76 RADIOLOGY RADIOLOGY Barium-Based Enema Kit W/ Barium Sulfate Barium -Based,Enema Kit W/Barium Sulfate for Suspension for Double Contrast Colon Suspension for Ct Examinations of The Examinations.650 ml of Low Viscosity Gastrointestinal Tract.400 ml of Barium (Rapid Flow),Ready to Use Suspension of Sulfate Suspension 1.3% W/V in Abag With Barium Sulfate Density 100% to 105% W/V Screw Cap Fittings, 60 of1/2 Tubing With KIT With Dispersing Agent, erservatives and Cap Assebly and Attached Safety End Anti-Foaming Agent in A Bottle-Bag With Flexable Enema Tip With Non-Latex Screw Cap Fittings, 60 of1/2 Tubing With Retention Cuff. Each Case Includes 1 Cap Assembly and Attachedsafety End Single-uff Inflator. Flexable Enema Tip With Non-Latex Retention Cuff With Anti-Reflux Valve. 1Multi-uff Insufflator and 1 Airline Extension. Barium-Based,Barium Sulfate Suspention for Computed Tomography of Gastrointestinal Tract.450 ml Barium KIT Sulfate Suspension % W/V Flavored, Ready-To Use,Unit Dose Bottle. Barium -Based.barium Sulfate Suspension for Double Contrast Colon Examinations ml Barium Sulfate Suspension 105% W/V, igh Density,Low Viscosity,Bubble- Free,Uniform,Non recipating Suspension. GALLON 1900 ml/gallon. Low Density Barium Sulfate (2-5%) Suspention or Water Soluble Iodine CONTRAST MEDIA FOR RADIOLOGY Containing Contrast Medium (2-3%) With Flavoring Agent for Opacification of Stomach & Bowel Loops in Computed Tomographic Examination,Approx,1000ml Bottle. Bottle CONTRAST MEDIA FOR RADIOLOGY

77 RADIO ARMACEUTICALS RADIO ARMACEUTICALS Chapter 20 / Appendix V Radio harmaceuticals Mtc-Technetium 99M Sterile Generator (600 Mci) iece Code No Item Specification 123 I-Diag. Capsules 400Uci 5Capsules/ ackage Capsule Dosage Form Strength Cardiolate (Mibi) for Cardiac, Breast and arathyroid Imaging (5 /Kit). Ceretec (mpao) for Cerebral Blood Flow Study.(5 /Kit) Colloid for Lymphoscintgraphy (5/Kit) Kit Kit Kit Dmsa Kits (For Labelling With 99Mtc to I-Mibg 5 Mci (Solution ) Evaluate Renal Kit Coritcal Imaging) I-Iodine Therapy Dose 50Mci (Solution) Dmsa (V) (entavalent Dmsa), 5 / Kit. Kit I-Mibg 1 Mci (Solution) Dtpa Kits (For Labelling With 99Mtc) 5 / Kit Kit I-Sodium Iodine Diag. Capsules (10 Capsule/ack) 100Uci Capsule ida (Disida) Kits (For Labelling With 99Mtc to Evaluate epatobilliary Kinetics) 5 / Kit Kit I-Therapy Capsules 10 Mci Capsule Liver Kits (For Labelling With 99Mtc Silver Coloide to Evaluate epatic and Spleen Imaging) 5 /Kit Kit RADIO ARMACEUTICALS I-Therapy Capsules 50 Mci 201Tl-Thallium for Cardiac Imaging, 5 Mci (Solution) Ga-Gallium 5Mci (Solution) 89 Sr-Strentium 4Mci (Theraputic) for Bone alliation 99M Tc. Bicidate,Ecd (Neurolite) for Cerebral Imaging. 5 /Kit. 99Mtc-Technetium 99M Sterile Generator (270.3Mci iece Kit Ampoule Capsule Maa Kits (For Labelling With 99Mtc to Evaluate Lung erfusion) 5 /Kit Medronate Ii (Mdp) Bone Kik (5/Kit) Myouview Kit (For Labelling With 99Mtc) /Kit yp Kits for (Cardiac Imaging), 5 /Kit Stannous or Other Agents for 99Mtc Labelling of Red Blood Cells (5 /Kit) 111In-Chloroide Octreotide (111 in Radiolabled Somatostatin), 3-6 Mci 111In-Capromab endetide (rostascint), 3-6 Mci (153Sm (Edtmp)- Samarium Lexidronam (Quadramet), 50 Mci.(1 Mci/Kg Kit Kit Kit Kit Kit Kit Kit Kit RADIO ARMACEUTICALS

78 RADIO ARMACEUTICALS INSECTICIDES Smarium Chloride recursor for Labeling Multibone in Vivo on e Kit 99M Tc- Technetium 99M Sterile Generator (400Mci) Mag3 Kits (For Labelling With 99Mtcto Evaluate Renal Execretory Function), 5/ Kit. Kit Kit Kit Code No. Chapter 21 / Appendix Vi Insecticides Item Specification Dosage Form Strength hosphorus 5 Mci. (Solution). ig Kits (For Labelling With 99Mtc), for Joint Imaging 5/Kit Radic Wash Spray Mist Kit Kit Solution Deltamethrin Wg 25% :(250G/L) Water Dispersible Granule Formulation (Wg) Water Dilutable Insecticide for Surface Application (Residual Sprying) ack Size Should Be in Unit Dose Aluminum Sachet 20mg. in Carton of 4Kg/Carton (200 Sachets). SACETS Co- Cobalt oint Source (Spot Maker). Kit The roduct Should Comply With Who Specification M Tc- Sesta 2-Methoxyisobutyl Isonitrile (Mibi) Dosae Mbq Kit Juvenile ormore Analogue (J.h.a) Contains yriproxyfen 0.5 %.Affects Mosquito Development From Egg to Adult ackage 20 Kg in Thick Nylon Sacks Inside A ard aper Sac. SAC. The roduct Should Comply With Who Specification. Micro Encapsulated Lambda-Cyhalothrin RADIO ARMACEUTICALS Micro Encapsulated yrethroid Insecticide Active Ingredient Lambda-Cyhalothrin 100Gm/Liter Capsule Size Micron to Keep Its Residual Effector Long Time acking Special lastic With Self Measuring (1)Liter In A ard Carton Kg The roduct Must Comply With Who Specifications Liter INSECTICIDES

79 INSECTICIDES INSECTICIDES Molluscicide Wettable owder Containing at Least 70% Niclosamide, Active Ingredient urity Not Less Than 960Gm/Kg (96%), Whopes Certificated and Who Approved. acking 500Gm in A igh Density olyethylene Bottle (0.4Gm/Cm) Natural Colour,Uv Stabilized for Sun rotection and Anti-Dust Leakage Bottle Neck for uman Safety & Environment rotection Sealed By BOTTLES yrethroid Insecticide for Knock Down and Killing Flying Insects Like Mosquitoes and Sand Flies in Aform of Ulv and Fogging Containing A Combination of Bifenthrin 5% + Zeta - Cypermethrin 0.5%+Sbioallethrin 0.5%+iperonyl Butoxide 6%. Can Be Dilluted With Water, Diesel or Kerosene. acking in Rust Resistance Drums of 20 Liters. The rouduct Must Be Comply With Who Specifications.(Whopes) Liter Chromo Duplex Carton Wax Disk, Each 20 Bottles 5 in A eavy Duty Carton, The roduct Should Comply With Who Specifiaction. yrethroid Insecticide for Knock Down and Killing Used in Form of Uly and Thermal Fogg Containing at Least D.d Trans - Cyphenothrin 5% as Active Ingredient, Can Mosquito Igr Effervescent 6% Diflubenzuron Tablet. Weight About 2Gm/ Tablet. acking in 3-5Kg lastic Bucket With andle for Easy Carrying. The roduct Tablet Be Diluted With Water, Diesel or Kerosine in ackage of Rust Resistance Drums of Liters. The roduct Should Comply With Who Specification. Liter Must Comply With Who Specification. Etofenprex 20% Wb for Residual Spray of Mosquito Larvicide owder Containing 25% Diflubenzuron acking : Kg. The roduct Should Comply With Who Specification. ack Low Mammalian Toxicity Not More Than 42000mg/Kg. acking in Sachets of 250 mg. Carton of 10 Kg. The ruduct Must Comply With Who Specification. ack INSECTICIDES ress acked Aerosol for Flying Insect 350 ml. The roduct Should Complay With W.h.o. Specification. ack Juvenile ormone Analogue (J.h.a) Contains yriproxyfen 0.5%,Wdg Could Be Diluted By Water Affects Mosquito Development From Egg to Adult.acking 20Kg in Thick Nylon Sacks Inside A ard aper Sac.The roduct Should Comply With Who Specifications. (Whopes) ack INSECTICIDES

80 INSECTICIDES INSECTICIDES Natural and Biological Insecticide for A Biological Larvicide of Bacillus Mosquito Larvae Control,Containing Thurengiensis Isralensis -14 Strain 164 Spinosad 7.48% as Active Ingredient in The Form of Tablets (1.4Gm) Each.packing otency 5000 Iu/mg in The Form of Dispersible Wettable owder acked in 1 ack Made of Mylar olymer and olyethylene Liner,Outer ack Is A Fiber Board Box.250 ack Kg lastic Jar. roduct Should Comply With Who Specifications. Tablet ouch,16 och/case (4000)Tablets. weight About 5.6Kg.the roduct Must Comply With Who Specification (Whopes) Igr of Diflubenzuron 10% Sc,Free of Solvent for Control of Mosquito Larvae. ack yrethroid esticide,for Knock Down of Insects Composed of D.d. Trans Cyphonethrin(S) 6% and 4% D.tetramethrin Could Be Used as Thermal Fogg,Ulv and Residual Spray Soluble in Water and Kerosene.acking in esticide Resistant Stainless Steel Drums Liter. The ack Micro Emulsion esticide Composed of D. henothrin 10% for Rapid Knock Down of Insects,To Be Diluted on ly With Water for Application as Ulv,Thermal Fog and Residual Spray. The roduct Must Comply With Who Specification. Residual Spray roduct Should Comply With Who Specifications (Whopes) Neonicotinoids and yrethroids.rapid Knock Down and Killing of Insects,Active Ingredients Dinoterfuran 0.5% S-Bioallethrin 0.5% Etofenprox 10% and bo 10%.acking in esticide Resistant ack olyethylene Containers of 5 Liters.Each Carton Contains 4 acks. The roduct Must Comply With Who Specification Mosquito Larvicide and upicide INSECTICIDES Composde of oly ( Oxy-1.2-Ethanediy Alpha-C16-20 Brached and Linear Alkyl- W Alpha-ydroxy ( 100% ).acking in ard lastic Gallons of 10 Liter. The ruduct Must Comply With Who Specification. ack INSECTICIDES

81 AENDIX rimary ealth Care Centers Medication List 1- ANALGESIC ANTIYRETICS & ANTIMIGRAINE DRUGS No Code No. Item Therapeutic ower Center aracetamol Tabs 500 mg aracetamol (Alcohol Free) aracetamol Syrup 120 mg/5ml ml/ Bottle Suppository mg Sumatriptan 100 mg aracetamol aracetamol + Codeine + Caffeine Dropper 500 mg / 5 ml 15 ml Tablet 300mg + 8 mg + 30 mg 2 - ANAESTETICS (LOCAL) No Code No. Item Therapeutic ower Center Lidocaine cl (Water Miscible Sterile Tube) Lidocaine cl Lidocaine cl rilocaine cl + Felypressin Gel 2% Gm/ Tube Aerosol Spray 10% 50 ml/ ack refilled Syringe 1% 100 mg 10 ml/ Syringe Cartridge 30 mg % (1.8 ml) AENDIX Oral Drops 40mg/ Simethicone 0.6ml 30ml/ Bottle 4- ANTIETIC ULCER DRUGS No Code No. Item Therapeutic ower Center Ranitidine Tablet 150 mg Tablet or Capsule Omeprazole 20 mg 5- ANTIAMOEBICS No Code No. Item Therapeutic ower Center Metronidazole Tabs 500 mg Suspension Metronidazole 125 mg/5 ml 100 ml Diloxanide Furoate Tablet 500 mg 6- ANTIBACTERIALS No Code Classification Item Therapeutic ower No. Center Amoxicillin Trihydrate + Tablet 250 mg Clavulanate otassium 125 mg Amoxicillin Trihydrate + Suspension 125mg Clavulanate otassium 31 mg/ 5 ml 100 ml Amoxicillin Trihydrate Capsule 250 mg Amoxicillin Trihydrate Susp 250 mg/5ml 3 - ANTACIDS No Code No. Item Therapeutic ower Center Aluminum hydroxide + Tablet Magnesium hydroxide Aluminum ydroxide + Magnesium ydroxide Suspension 100 ml (Low Sodium) Simethicone Tablets mg enicillin Benzathine (enicillin G) Trimethoprim Sulfamethoxazole Trimethoprim Sulfamethoxazole Azithromycin 1,000,000 I.U. Tablet 160 mg mg Suspension 40 mg mg/5 ml 50 ml Bottle Suspension 200 mg / 5 ml 15 ml

82 AENDIX Tablet or Capsule Clarithromycin 250 mg henoxymethyl enicillin (enicillin V Tablet 250 mg otassium) henoxymethyl enicillin (enicillin V Suspension 250 mg / 5 ml 100 ml/ Bottle otassium) Doxycycline cl Tablet or Capsule 100 mg Ciprofloxacin Tablet 500 mg Cloxacillin or Capsule 250 mg Flucloxacillin Sodium Tabs or Nitrofurantion Capsule 100 mg Erythromycin Ethylsuccinate or Tablet 250 mg Stearate Erythromycin Suspension 200 mg/ 5 ml 100 ml Ethylsuccinate 7-ANTIVIRALS No Code No. Item Therapeutic ower Center Acyclovir Tablet 200 mg Syrup 100 mg / 5 ml Rifampicin 100 ml 9-ANTIELMINTICS No Code No. Item Therapeutic ower AENDIX Center Mebendazole Tablet 100 mg Mebendazole Suspension 100 mg/ 5 ml 30 ml raziquantel Tablet 600 mg 10-LEISMANIASIS (DRUGS USED IN) No Code No. Item Therapeutic ower Center Stibogluconate Sodium Ampoule or (Organic entavalent hc/1 600 mg Antimony) 11- ANTIMALARIALS No Code No. Item Therapeutic ower Center Chloroquine hosphate Chloroquine hosphate Tablet 250 mg (150 mg Base) Syrup 50 mg/ 5 ml ml rimaquine hosphate Tablet 7.5mg Acyclovir Cream 5% 10 Gm/ Tube yrimethamine + Sulfadoxine Tablet 25 mg mg 8-ANTITUBERCULOSIS DRUGS No Code No. Item Therapeutic ower Center Isoniazid Tablet 100 mg Rifampicin Capsule 300 mg Ethambutol cl Tablet 400 mg yrazinamide Tablet 500 mg Streptomycin Sulfate 1 Gm Artesunate Suppository 50 mg hc/ Artemether + Tablet 20 mg + hc/1 Lumefantrine 120 mg 12-NON STEROIDALS ANTI-INFLAMMATORY No Code No. Item Therapeutic ower Center Ibuprofen Tablet 400 mg Ibuprofen Syrup 100 mg / 5ml Diclofenac Tablet 50 mg

83 AENDIX AENDIX Diclofenac Suppository 50 mg Diclofenac Suppository 12.5 mg Diclofenac Gel 1-3% Diclofenac Iv, Im Ampoule 75 mg Naproxen Tablet or Capsule 250 mg Meloxicam Tablet 7.5 mg 13-ANTIEILETICS No Code No. Item Therapeutic ower Center Diazepam Rectal Tube 5 mg Diazepam Ampoule 10 mg Carbamazepine Tablet 200 mg henytoin Sodium Capsule 100 mg Sodium Valproate Tablet 200 mg Sodium Valproate (Slow Tablet 500 mg Release) regabalin Capsule 75 mg 14-ANTIDERESSANT DRUGS No Code No. Item Therapeutic ower Center Imipramine cl Tablet 10 mg Imipramine cl Tablet 25 mg Fluoxetine Maleate Tablet 50 mg Citalopram Tablet 20 mg hc/1 ydrobromide Escitalopram Tablet 10 mg hc/ Amitriptyline cl Tablet 10 mg aloperidol Tablet 1.5 mg hc/ aloperidol Ampoule 5 mg hc/1 15-ANTIDIABETICS No Code No. Item Therapeutic ower Center Glibenclamide Tablet 5 mg Metformin cl Tablet 500 mg Gliclazide Tablet 80 mg uman Isophane 100 I.U./ ml (10 ml) Insulin (Nph) uman Soluble Insulin 100 I.U./ ml (10 ml) (Regular) Mixed uman Insulin 30% Soluble, 70 % Isophane 100 I.U./ml (10 ml) Metformin cl Xr Tablet 750 mg (Modified Released) Gliclazide Mr (Modified Tablet 30 mg Released) refilled en 100 I.U Insulin Glulisine hc/1 /ml (3 ml) refilled en 100 I.U Insulin Aspart hc/1 /ml (3 ml) Insulin Glargine 100 I.U./ ml (10 ml) hc/ Insulin Lispro 100 I.u/ ml (10 ml) hc/ Insulin Aspart 100 I.u/ ml (10 ml) hc/ Insulin Detmir 100 I.u/ ml (10 ml) hc/ Insulin Lispro refilled en hc/1 100 I.U./ml (3 ml) Insulin Detmir refilled en 100 I.U./ hc/1 ml (3 ml) Insulin Glargine refilled en100 I.U./ hc/1 ml (3 ml) Amitriptyline cl Tablet 25 mg

84 AENDIX Insulin Mixed (50% Lispro, 50 % rotamine Lispro) Insulin Mixed (25% Lispro, 75 % rotamine Lispro) Insulin Mixed (30% Aspart,70 % rotamine Aspart) refilled en 100 I.U./ hc/1 ml (3 ml) refilled en 100 I.U./ hc/1 ml (3 ml) refilled en 100 I.U./ hc/1 ml (3 ml) Glimepiride Tablet 2mg hc/ Sitagliptin hosphate Tablet 100 mg hc/1 16-ANTITYROID DRUGS&TYROID ORMONES No Code No. Item Therapeutic ower Center Carbimazole Tablet 5 mg Thyroxine Sodium Tablet 50 Mcg Thyroxine Sodium Tablet 100 Mcg Thyroxine Sodium Tablet 25 Mcg 17- DRUGS USED IN CARDIOVASCULAR DISEASES No Code No. Item Therapeutic ower Center Acetyl Salicylic Acid Tablet mg (Enteric Coated) Atenolol Tablets 100 mg Captopril Tablets 25 mg Enalapril Maleate Tablets 10 mg Amlodipine Besilate Tablet or Capsule 5 mg AENDIX Methyldopa Tablets 250 mg Losartan otassium Tablets 50 mg Clopidorgel Tablets 75 mg Nifedipine Retard Tablet or Capsule (Modified Release) 30 mg Carvedilol Tablets 6.25 mg Carvedilol Tablets 25 mg Indapamide (Sustainad Tablet 1.5 mg Release) erindopril Tablets 4-5 mg Valsartan Tablets 80 mg razosin cl Tablets 1 mg razosin cl Tablets 5 mg Telmisartan Tablets 40 mg Irbesartan Tablets 150 mg Candesartan Tablets 8 mg Candesartan Tablets 16 mg Bisoprolol Fumarate Tablets 5 mg Olmesartan Tablets 20 mg 18 - LIID LOWERING DRUGS No Code No. Item Therapeutic ower Center Simvastatin Tablet 10 mg Rosuvastatin Tablet 10 mg Nitroglycerin Sublingual Tablet mg Gemfibrozil Capsule or Tablet 600 mg hc/ Isosorbide Dinitrate (Sustainad Release) Tablet or Capsule 20 mg ropranolol cl Tablets 40 mg

85 AENDIX AENDIX 19 - DIURETICS No Code No. Item Therapeutic ower Center Ampoule10 mg/ml Frusemide (20 mg/ 2 ml) Frusemide Tablets 40 mg ydroclorothiazide Tablets 25 mg Spironolactone Tablets 25 mg 20 -ANTIASTMATICS No Code No. Item Therapeutic ower Center Salbutamol Metered Dose Inhalations Salbutamol Budesonide Turbuhaler Salmeterol + Inhaler 100 Mcg/uff (200 Doses) Nebulization Solution 0.5% 20 ml/ Bottle Inhaler 200 Mcg 200 hc/1 Doses Fluticasone ropionate Inhaler 25 Mcg Metered Dose Mcg 120 Doses Inhalations rednisolone Tablet mg Salbutamol Fluticasone ropionate Ipratropium Bromide, Metered Dose Inhalation Ipratropium Bromide Budesonide Syrup 2 mg/5 ml, ml Inhaler 125 Mcg 120 hc/1 Doses Inhaler 20 Mcg/uff hc/1 200 Doses Nebulization Solution (Unit Dose Ampoule) hc/ % 2 ml 500 Mcg Nebulization Solution hc/1 500 Mcg / 2 ml Montelukast Sodium Chewable Tablet 5 mg hc/1 21-ANTIDIARROEALS No Code No. Item Therapeutic ower Center Electrolyte Oral Sachet Rehydration Salt (Ors) 22-ANTIEMETICS No Code No. Item Therapeutic ower Center Metoclopramide cl Ampoule 10 mg Metoclopramide cl Tablet 10 mg Metoclopramide cl Suppository 10 mg 23-LAXATIVES No Code No. Item Therapeutic ower Center Bulk Forming Laxative ack 7 or 15 Gm Glycerin ediatric Suppository 900 mg Suppository Bisacodyl Tablets 5 mg Bisacodyl Suppository 10 mg Senna Tablets 5-10 mg Lactulose Syrup Gm/ ml (300 ml) 24-ANTISASMODICS No Code No. Item Therapeutic ower Center yoscine Butylbromide Ampoule 20 mg for Injection yoscine Butylbromide Tablet 10 mg Mebeverine cl Tablet 200 mg yoscine Butylbromide Syrup 5 mg /5 ml rednisolone Syrup 15 mg/ 5ml

86 AENDIX AENDIX 25-ANTI-AEMORROIDS No Code No. Item Therapeutic ower Center Simethicone Tablets mg Antihemorrhoida Suppository Without Steroids 26-DRUGS USED IN YERURICEMIA No Code No. Item Therapeutic ower Center Allopurinol Tablet 100 mg Allopurinol Tablet 300 mg 27-ANTIISTAMINICS No Code No. Item Therapeutic ower Center Non Sedating Antihistamine Tablet (Cetirizine, or Loratadine, or Astemizole) Tablet 10 mg Chlorpheniramine Maleate Chlorpheniramine Maleate seudoephedrine cl mg + Antihistamine Syrup 2 mg / 5 ml (100 ml/ Bottle) Tablet 4 mg Capsule or Tablet 28-COUG SYRU No Code No. Item Therapeutic ower Center Cough Syrup ediatric Syrup ml Expectorant Bottle Syrup 15 mg/ 5 ml Dextrometheorphan ml/ Bottle seudoephedrine cl Syrup 60 ml -100 ml 30 mg + Antihistamine 29-DRUGS FOR SKIN CONDITIONS No Code No. Item Therapeutic ower Center Lotion or Gel Benzoyl eroxide 5 % (30-60 ml or Gm) Cream 1% Gm ydrocortisone Tube Benzyl Benzoate Container Silver Sulfadiazine Cream 1% 50 (Sterile) Gm Tube Zinc Oxide Cream or Ointment 30 Gm/ Tube Nystatin Suspension 100,000 I.U. / 1 ml ml Imidazole Derivative (Clotrimazole, Cream 1,1,2 or 2 % Econazole, Miconazole, Ketoconazole) (15 Gm/ Tube) Tretinoin Cream or Gel 0.05 hc/1 % Gm / Tube Nystatin Cream U/Gm Gm/ Tube Miconazole MOral Gel 2% hc/1 (20-40 Gm) Fusidic Acid Ointment 2% Gm/ Tube Betamethasone Oint 0.1% hc/1 Betamethasone Valerate Clindamycin or Erythromycin for Acne ermethrin Cream 0.1 %,15 or hc/1 30G Tube Topical Solution 10 mg/ml 30 ml/ Bottle Cream or Lotion 5%, 0.4% Gm Terbinafine Tablet 250 mg hc/ Terbinafine Cream 1 %, G Tube Calamine Lotion Lotion Bottle ml

87 AENDIX araffin Wite Soft Tube Gm etroleum Topical / Scalp 2% Salicylic Acid ml Botle Alcohol Gel Wall Gel Mounted Dispensers Cortamiton Cream 10% Ketoconazole Shampoo 2 %, ml 30-EYE, EAR & NOSE DRUGS No Code No. Item Therapeutic ower Center Eye Ointment 1 % Tetracycline cl mg Tube Eye Dropper 0.1 % Naphazoline ml/ Bottle Eye/ Ear Dropper 0.3 % Gentamicin (5-10 ml/ Bottle) Eye Dropper 0.5% Chloramphenicol (10 ml/ Bottle) Eye Ointment 0.3 % Gentamycin (3-5 Gm/ Tube) Artificial Tears Eye Eye Dropper ml Dropper Gentamicin + Eye/ Ear Dropper hc/1 Betamethasone % 5 ml/ Bottle Ear Dropper 10 ml/ Wax Removal Bottle Naphazoline cl + Nasal Drops 500 Mcg Chlorpheniramine 500Mcg/ml Fluticasone Nasal Spray 50 Mcg hc/ Budesonide Nasal Spray 64 Mcg/ Metered Spray Imidazole Derivatives Ear Dropper 1% (10 ml/ hc/1 Bottle) romethazine cl Tablet 10 mg romethazine cl Syrup 5 mg / 5 ml 100 ml Ciprofloxacin Eye Dropper 0.3% Bottle 31-DRUGS USED IN OBSTETRICAL & GYNAICOLOGICAL CONDITIONS AENDIX hc/1 No Code No. Item Therapeutic ower Center Methylergonovine Maleate Anti- Rho (D) Immunoglobulin Ampoule 200 Mcg Ampoule or Mcg hytomenadione Ampoule 2 mg Norethisterone Tablet 5 mg essary or Vaginal Nystatin Tablet 100,000 I.U. Imidazole Derivative Vaginal Tablet (Clotrimazole, mg Econazole, Miconazole) Medroxyprogesterone Tablet 5 mg Acetate Iodine Vaginal Dish Vaginal Dish 10% Dydrogesterone Tablet 10 mg hc/1 32-ANTISETICS & DISINFECTANTS No Code No. Item Therapeutic ower Center Chlorhexidine Gluconate ovidone (Iodine) ydrogen eroxide Without Sliver Nitrate ydrogen eroxide Without Sliver Nitrate Chlorhexidine Gluconate Container 19-21% 1 Liter/ Container Container 10% ml/ Container Solution 6% 1-2 Lite Spray 3% ml Mouth Wash 0.2% 150 ml

88 AENDIX 33-VITAMINS, MINERALS & NUTRITIONAL SULEMENTS No Code No. Item Therapeutic ower Center yridoxine cl (Vitamin B6) Tablet mg Retinol (Vitamin A) Capsule 50,000 I.u Calcium (Gluconate or Lactate) Syrup Not Less Than 2.27 Mmol/ 5 ml Calcium Lactate Tablet 300 mg Ferrous Salt Tablet or Capsule mg Elemental Iron Ferrous Sulphate Drops 75 mg15-30ml Folic Acid Tablet 1 mg Multivitamins for Children According to (Recommended Daily Allowances) Syrup ml AENDIX 34-VACCINES & SERA No Code No. Item Therapeutic ower Center oliomyelitis Vaccine 5-10 Dose/ Live Oral: (Sabin Strain) Diphetheria,Tetanus, 5-10 Dose/ Ertussis Vaccine (Dtp) Diphtheria and Tetanus 5-10 Dose/ Vaccine for Children aemophilus Influenza + Dpt Vaccine Type Single Dose "B" Conjugate Vacccine Ampule or With D.t.p Dpt+epatitus B ib Vaccine(entavalent) 0.5ml Injection Children Dose Ampoule Bib Dpt+epatitus B ib Ampoule Bib 0.5 ml Vaccine (entavalent) Injection Children Tetanus Antitoxin 1500 I.U. / 1 ml Multivitamins Tablet uman Immunoglobulin Tablet mg Calcium Carbonate Elemental Calcium Oral Dropper 2 Mcg/ ml Alfacalcidol 20 ml/ Bottle Alfacalcidol Capsule 0.25 Mcg Alfacalcidol Capsule 1 Mcg Calcitriol Capsule 0.25 Mcg for Tetanus I.m Injection (rophylaxis ) Bcg Vaccine neumococcal Conjugated Vaccine njectable olio Vaccines (Ipv) 250 Units 1 or 2 ml/ Ampoule or 5-10 Doses/ Ampoule or With Diluen 0.5 ml Single Dose / Disodium Etidronate Ampoule 300 mg Calcitriol Drops 2,000-5,000U/ml Injectable olio Vaccines (Salk Vaccines). 0.5ml Single Dose Meclozine + Vitamin B6 Tablet 25 mg + 50 mg Vitamin B1 & B6 & B12 Tablet 100 mg mg + 200Mcg Varicella- Zoster Virus (Chicken ox Vaccine for Subcutaneous Injection ) Single Dose 0.5ml / With Diluent

89 AENDIX Triple Virus Vaccine ml.single Dose/ (Mmr) Measles Vaccine 10 Doses / aemophilus B Vaccine Single Dose, for Children aemophilus B Vaccine for Adolescent and Single Dose, Adults aemophilus A Vaccine Single Dose for Children 25 Mcg/0.5ml Single Typhoid Vaccine Dose / Or Ampoule Scorpion Anti-Venin 1 ml/ampoule or Snake Anti-Venin 20 ml/ Ampoule or olyvalent Snake Unit Rabies Virus Vaccine Single Dose Anti Rabies Serum 5-10ml/ Ampoul (orse Origin) aemophilus Influenza Single Dose of Vaccine Type "B" 0.5ml Conjugate Vaccine 35-Miscellaneous No Code No. Item Therapeutic ower Center Betahistine Tablet 8 mg hc/1 Dihydrochloride Betahistine Tablet 16 mg hc/1 Dihydrochloride Domperidone Tablet 10 mg Tamsulosin cl Tablet 400 Mcg hc/1 (Modified Release) AENDIX Multienzyme (ancreatic Enzymes : Capsule or Enteric rotease U ; Coated Tablet Lipase 5,000-10,000 U I.u hc/1 and Amylase 5, ,000 U) /Capsule or I.u I.u Enteric Coated Tablet Calcipotriol/ Oint 50 Mcg / Betamethasone hc/1 0.5 mg Dipropionate Eye Dropper 0.2% Sodium yaluronate hc/1 5-15ml/ Bottle Alendronate Sodium Tablet 70 mg hc/ Baclofen Tablet 10 mg hc/1 36-INTRAVENOUS SOLUTIONS: No Code No. Item Therapeutic ower Center Bottle or Bag 5% Dextrose 250 ml Ampoule or 50 % Dextrose 50 ml Bottle Sodium Chloride Bottle Or Bag 0.9 % (Normal Saline) 500 ml Dextrose + Sodium BottleOr Bag 5% Chloride (Normal % 500 ml Saline) Ringer s Lactate Bottle or Bag 500 ml Solution Water for Injection Ampoule 5-10 ml (Sterile) 37-DRUGS USED IN EMERGENCY: Olopatadine cl Eye Dropper 0.10 % hc/1 No Code No. Item Therapeutic ower Center Nicotine (24-our Transdermal atch hc/1 Effect Dose) 7 mg Nicotine (24-our Effect Transdermal atch hc/1 Dose) 14mg Nicotine (24-our Effect Transdermal atch hc/1 Dose) 21 mg Morphine Sulphate Ampoule 10mg Activated Charcoal owder or Suspension G/Container Ipecacuanha Syrup 30ml/Bottel Atropine Sulfate Syringe 0.1 mg/ml (5ml)

90 AENDIX Atropine Sulfate Ampoule,refilled Syringe mg/ 1 ml,0.05mg/ml 5ml ADVERSE DRUG REACTION FORM AENDIX Dexamethasone Ampoule 5 mg refilled Syringe 10% Calcium Chloride (10ml) refilled Syringe Adrenalin (Epinephrine) 1:10,000 (1mg/ml) refilled Syringe 8.4 % Sodium Bicarbonate 50 ml refilled Syringe 2%, Lidocaine cl 100 mg 5 ml/ Syringe Ampoule or ydrocortisone 100 mg Naloxone cl Ampoule 0.4mg/ ml Methylprednisolone Ampoule Or 500 mg Amiodarone cl for Ampoule 50mg/ml (3ml Injection Ampoule) romethazine cl Ampoule 50 mg/ 1ml Dobutamine cl remixed Bag 500 mg in 250 ml D5w Bag Dopamine cl remixed Bag 800 mg in 250 ml D5w Bag Noradrenaline Acid Ampoule 1mg/ml (4mg/ Tartrate Amp (4ml) rocainamide cl 1 Gm (10 ml) Vasopressin Ampoule 20 U/ml 1ml Lidocaine cl remixed Bag 2 Gm in 500 ml D5w Calcium Gluconate Ampoule 10 % (10 ml) For a printable form check attached CD or visit Isoprenaline cl (Isoproterenol cl) Nitroglycerin Magnesium Sulfate Ampoule 200 Mcg/ ml (5 ml) Ampoule or 5mg/ ml (10ml) Ampoule or 10 % (20 ml)

91 AENDIX MEDICATION ERROR REORT FORM AENDIX For a printable form check attached CD or visit For a printable form check attached CD or visit

92 AENDIX AENDIX Drug Quality Report Form For a printable form check attached CD or visit FORMULARY ADDITION REQUEST FORM DRUG EVALUATION & ECONOMIC ANALYSIS المملكة العربية السعودية وزارة الصحة إدارة الرعاية الصيدلية نموذج طلب دواء لدليل األدوية بوزارة الصحة Formulary Addition Request Form Drug Evaluation & Economic Analysis Important:- All information requested on this form must be filled out completely and referenced by published scientific articles or it will be returned to requesting health care professional of pharmaceutical company promotional literature is not acceptable. No action will be taken on forms that are submitted incomplete. Full Drug evaluation should be attached. Drug Used Evaluation should be attached once the requisition is for addition. Requested by: Drug Name: roprietary Name: Therapeutic Classification: Manufacturer: Dosage Form: Clinical harmacology and harmacokinetics: FDA, (others) Approved Indications: (1) FDA, (others) Recommended Dose and Approved Route of Administration: Adverse Effects: For a printable form check attached CD or visit Drug Interactions: otential for Error: Include published medication safety literature

93 AENDIX AENDIX Rational for Addition / Change: ospital harmacy & Therapeutic Committee: Literature Review (cite major trials only): Include pharmacoeconomic literature and summarize findings (if available). (2) lace in Therapy: Comparison to Formulary agents including: therapeutic advantages over drugs currently on formulary/ safety advantages/ drugs that could be considered for deletion. Generic Name (Manufacturer) Requested drug Comparator drug # 1 Comparator drug # 2 rogram Comparative Therapy: Dose Cost/ Day Usage in revious Year Total Cost Indicate the estimated annual acquisition costs (savings) for this new drug by program (3) Estimated Cost (savings): SR اسم الطبيب مقدم الطلب :- التخصص:- التوقيع:- يعتمد من رئيس القسم المختص :- التوقيع:- For a printable form check attached CD or visit عضو اللجنة عضو اللجنة رئيس قسم الصيدلة رئيس اللجنة Regional harmacy &Therapeutic Committee عضو اللجنة عضو اللجنة عضو اللجنة رئيس اللجنة Corporate harmacy &Therapeutic Committee عضو اللجنة عضو اللجنة عضو اللجنة عضو اللجنة Recommendations: (4) عضو اللجنة رئيس اللجنة عضو اللجنة Conclusions: Include budget impact or other cost savings such as lab costs, decreased stay in hospital, labour, if applicable Disclosures : Include impact or other cost saving such as lab costs, decreased stay in hospital, labour, if applicable For a printable form check attached CD or visit

94 AENDIX AENDIX Utility Rank (for Corporate &T USE ONLY) : Therapeutic: AUTOMATIC STO of MEDICATION FORM Rank =1 if large randomized clinical trials demonstrate clear cut therapeutic advantage (enhanced efficacy and /or reduced toxicity ) over available modalities and use of drug will lead to clinically significant improvement in patient mortality, morbidity or quality of life. Rank =2 if clinical studies indicate therapeutic advantage over available modalities but there is questionable / marginal improvement in patient outcome, and /or efficacy advantage is some what offset by toxicity disadvantage. Rank =3 if no therapeutic advantage but secondary chrematistics confer some advantage (e.g dosage form, route / frequency of administration, pharmacocokinetics, convenience). Rank =4 if no demonstrated advantage over currently available modalities. Cost: Rank =A if addition of drug will significantly reduce direct cost to hospital. Rank =B if addition of drug will modestly reduce direct costs to hospital. Rank =C if addition of drug will have minimal direct cost impact (i.e., less than 20,000 per year). Rank =D if addition of drug will modestly increase direct costs to hospital (i.e., 20,000 SR to 60,000 SR per year). Rank =E if addition of drug will significantly increase direct cost to hospital (i.e., more than SR per year). For a printable form check attached CD or visit For a printable form check attached CD or visit

95 AENDIX DIRECT URCASE ORDER FORM For a printable form check attached CD or visit KEY WORD INDEX AENDIX CONTROLLED SUBSTANCE[ C ]AND NARCOTICS[ N ] alprazolam amobarbital benzhexol hcl buprenorphine chloral hydrate chlordiazepoxide hcl clonazepam codeine phosphate diazepam etomidate fentanyl citrate flumazenil lorazepam methadone hcl methylphenidate midazolam morphine sulphate nalbuphine hcl naloxone hcl nitrazepam paracetamol + codeine pethidine hcl phenobarbital (phenobarbitone) propofol temazepam thiopental sodium tramadol hcl

96 AENDIX AENDIX ALABETICAL DRUG GROUS INDEX Supraventricular and Ventricular Arrhythmias 58 Chapter Ventricular Arrhythmias Gastrointestinal System Beta-Adrenoceptor Blocking Drugs Antacids Antihypertensive Drugs Antispasmodics Vasodilator Antihypertensive Drugs Ulcer-ealing Drugs Centrally Acting Antihypertensive Drugs Receptor Antagonists Alpha-Adrenoceptor Blocking Drugs Chelates and Complexes heochromocytoma roton ump Inhibitors Angiotensin-Converting Enzyme Inhibitors Antidiarrheal Drugs Angiotensin Ii Receptor Antagonist Drugs for Inflammatory Bowel Diseases Nitrates, Calcium-Channel Blockers, and Laxatives 55 eripheral Vasodilators Bulk-Forming Laxative Nitrates Stimulant Laxatives Calcium-Channel Blockers Osmotic Laxatives eripheral Vasodilators Antiflatulent Drugs Sympathomimetics reparations for emorrhoids Inotropic Sympathomimetics Soothing reparations With Corticosteroids Vasoconstrictor Sympathomimetics Rectal Sclerosants Anticoagulants and rotamine Drugs Affecting Intestinal Secretions Low Molecular Wieght eparin Drugs Acting on The Gall Bladder 56 (Treatment Dose) Dvt, ulmonary Embolism 63 Chapter 2 Drugs Used in the Treatment of Diseases of The Low Molecular Wieght eparin (Treatment Dose) Cardiac Treatment Myocardial Infarction, Unstable Coronary Artery Disease, Acute Coronary Syndrome 63 Cardiovascular System Low Molecular Wieght eparin 02. Drugs Used in The Treatment of Diseases (rophylaxis Dose) igh Risk 63 of The Cardiovascular System Low Molecular Wieght eparin ositive Inotropic Drugs 57 (rophylaxis Dose)Moderate Risk Cardiac Glycosides Antiplatelet Drugs hosphodiesterase Type-3 Inhibitors Fibrinolytic Drugs Diuretics Antifibrinolytic Drugs and emostatics Thiazides and Related Diuretics Antifibrinolytic Drugs and emostatics Loop Diuretics Antihemophilic Agent otassium-sparing Diuretics and Combined Diuretics Lipid-Lowering Drugs Osmotic Diuretics Local Sclerosants Antiarrhythmic Drugs Antioxidant Agent Supraventricular Arrhythmias ulmonary Arterial ypertension

97 AENDIX Chapter 3 Drugs Used in The Treatment of Diseases of The Respiratory System Drugs Used in The Treatment of Diseases Of The Respiratory System Bronchodilators Selective Beta2-Adrenoceptor Stimulants Long Acting 2 Agonists (Laba) With Corticosteroids Antimuscarinic Theophylline Corticosteroids Cromoglycate Antihistamines and Allergic Emergencies Nonsedative Antihistamines Sedative Antihistamines Anaphylaxis Allergen Immunotherapy ulmonary Surfactants Cough Suppressants, Expectorants, Mucolytic and Decongestants Leukotriene Receptors Antagonist 69 Chapter 4 Drugs Acting on The Central Nervous System Drugs Acting on The Central Nervous System ypnotics and Anxiolytics ypnotics Anxiolytics Barbiturates Antipsychotic and Antimanic Drugs Antipsychotic Drugs Antimanic Drugs Antidepressant Drugs Tricyclic and Related Drugs Related Antidepressants Monoamine-Oxidase Inhibitors Selective Serotonin Re-Uptake Inhibitors Norepinephrine Serotonin Re-Uptake Inhibitors (Nsri) 73 AENDIX Central Nervous System Stimulants Drugs Used in Nausea and Vertigo Antihistamines Metoclopramide and Domperidone Specific 5-t3 Serotonin Antagonists Analgesics Nonopioid Analgesics Opioid Analgesics Antimigraine Drugs Antiepileptics Drugs Used in arkinsonism and Related Disorders Dopaminergic Drugs Antimuscarinic Drugs Drugs for Dementia N-Methyl-D-Aspartate Receptor Antagonist Drug for Smoking Cessation 77 Chapter 5 Drugs Used in The Treatment of Infections Drugs Used in The Treatment of Infections Antibacterial Drugs enicillins enicillinase-resistant enicillins Broad-Spectrum enicillins Antipseudomonal enicillins Cephalosporins and Cephamycins Carbapenem Tetracyclines Aminoglycosides Macrolides Clindamycin Other Antibiotics Sulfonamides and Trimethoprim Antituberculous Drugs Antileprotic Drugs Quinolones Antibiotics for Urinary Tract Infections

98 AENDIX AENDIX Antifungal Drugs Thyroid ormones olyene Antifungals Antithyroid Drugs Imidazole Antifungals yperparathyroidism Other Antifungals Corticosteroids Echinocandins Sex ormones Antiviral Drugs Estrogens for ormone Replacement Therapy Drugs for erpes Simplex and Varicella-Zoster Viruses rogestogens Drugs for uman Immunodeficiency Virus Androgens Nucleotide Reverse Transcriptase Inhibitors ypothalamic and ituitary Non-Nucleoside Reverse Transcriptase Inhibitors 85 ormones and Antiestrogens rotease Inhibitors (is) Antiestrogens Drugs for Fusion or Entry Inhibitors: Anterior ituitary ormones Drugs for Cytomegalovirus ypothalamic ormones Drugs for Respiratory Syncytial Virus osterior ituitary ormones Drugs for Viral epatitis Drugs Affecting Bone Metabolism Antiprotozoal Drugs Bisphosphonate and Other Drugs Affecting Bone Metabolism Antimalarials Amebicides, Trichomonacides and Antigiardial Drugs 87 Calcitonin and arathyroid ormone Leishmaniacides Other Endocrine Drugs Drugs for neumocystis neumonia Other Endocrine Drugs Anthelmintics ituitary Gonadotrophins Inhibitors Drugs for Threadworms, Roundworms and ookworms Gonadorelin Analogues Taenicides and Schistosomicides Drugs for ydatid Disease, Tapeworms 87 Chapter Filaricides (Elephantiasis) 87 Drugs Used in Disorders of The Obstetrics, Gynecology and Genitourinary Disorders 94 Chapter Drugs Used in Obstetrics, Gynecology Drugs Used in The Treatment of Disorders of The And Genitourinary Disorders 94 Endocrine System Drugs Used in Obstetrics Drugs Used in The Treatment of rostaglandins and Oxytocics 94 Disorders of The Endocrine System Myometrial Relaxants Drugs Used in Diabetes Drugs for Seizure revention in Eclampsia Insulin Treatment of Vaginal and Vulval Conditions Oral ypoglycemic Agents Antifungal Drugs Drugs for ypoglycemia Drugs for Genitourinary Disorders Thiazolidinedione Drugs for Urinary Retention Thyroid and Antithyroid Drugs Drugs for Urinary Frequency and Incontinence

99 AENDIX Chapter 8 Drugs Used in The Treatment of Malignant Disease and Immunosuppression Drugs Used in The Treatment of Malignant Disease and Immunosuppression Cytotoxic Drugs Alkylating Drugs Drugs for Urothelial Toxicity Cytotoxic Antibiotics Antimetabolites Folinic Acid Rescue Vinca Alkaloids and Etoposide Other Antineoplastic Drugs rotein Kinase Inhibitors ormone Antagonists Drugs Affecting The Immune Response Immunosuppressants Immunostimulants Sex ormones and ormone Antagonists in Malignant Disease rogestogens ormone Antagonists 100 Chapter 9 Drugs Affecting Nutrition and Blood Drugs Affecting Nutrition and Blood Anemias and Some Other Blood Disorders Iron Iron and Folic Acid reparations Used in regnancy Drugs Used in Megaloblastic Anemia Drugs Used in Renal Anemia Drugs Used in Neutropenia Fluids and Electrolytes Oral Electrolytes and otassium Removal Intravenous Solutions and Electrolytes lasma and lasma Substitutes Intravenous Nutrition 105 AENDIX Minerals Calcium, Magnesium and hosphate hosphate-binding Agents Zinc Vitamins Metabolic Disorders 108 Chapter 10 Drugs Used in The Treatment of Musculoskeletal And Joint Diseases Drugs Used in The Treatment of Musculoskeletal and Joint Diseases Drugs Used in Rheumatic Diseases and Gout Nonsteroidal Antiinflammatory Drugs Local Corticosteroid Injections Drugs Suppressing Rheumatic Disease rocess Drugs for Gout Tumour Necrosis Factor ( Tnf) Antagonist B Cell Depation Agent Drugs Used in Neuromuscular Disorders Anticholinesterases Skeletal Muscle Relaxants Drugs for The Relife of Soft Tissue Inflammation Enzymes and Chemical 110 Chapter 11 Drugs Acting on The Eye Antiinfective Eye reparations Antibacterials Antifungals Antiviral Antinflammatory reparations Corticosteroids Other Antiinflammatory reparations Antihistamine Mydriatics and Cycloplegics Antimuscarinics Sympathomimetics

100 AENDIX Treatment of Glaucoma Miotics Beta-Blockers Systemic Drugs Local Anesthetics Miscellaneous Ophthalmic reparations reparations for Tear Deficiency Other reparations Diagnostic reparations 114 Chapter 12 Drugs Used in The Treatment of Disease of The Ear, Nose, and Oropharynx Drugs Used in The Treatment of Disease of The Ear, Nose, and Oropharynx Drugs Acting on The Ear Antinfective reparation Other Ear reparations Drugs Acting on The Nose Drugs Used in Nasal Allergy Topical Nasal Decongestants Drugs Acting on The Oropharynx Mouth Wash 116 Chapter 13 Drugs Acting on The Skin Drugs Acting on The Skin Emollient and Barrier reparation Surface Anaesthesia Topical Corticosteroids reparation for Eczema and soriasis Topical reparations Oral Retinoids for soriasis reparation for Acne and irsutism Keratolytics Topical Antibiotics Topical Retinoids 119 AENDIX Oral Retinoids ormone Therapy for irsutism Camouflagers Anti-Infective Skin reparations Topical Antibacterials Topical Antifungals Topical Antiviral Miscellaneous for Skin, air Loss,Scars, yperhidrosis arasiticdal reparations (Anti Lice, Scabies) Topical and Intralesional Cytotoxic Agent Miscellaneous soralen 123 Chapter 14 Vaccin and Immunologic roducts Vaccin and Immunologic roducts Vaccines and Antisera Immunoglobulis Antivenoms 127 Chapter 15 Drugs Used in Anesthesia Drugs Used in Anesthesia General Anesthesia Intravenous Anesthetics Inhalational Anesthetics Antimuscarinic remedication Drugs Muscle Relaxants Anticholinesterases Used in Surgery Antagonists for Central and Respiratory Depression Antagonists for Malignant yperthermia Local Anesthesia 129 Chapter 16/ Appendix I Solutions (Concentrates) used for ERITONEAL DIALYSIS / EMODIALYSIS Solutions (Concentrates) used for eritoneal Dialysis/

101 AENDIX AENDIX emodialysis eritoneal Dialysis Solutions emodialysi Concentrates and Related Materials 140 Chapter 17 / Appendix Ii Drugs Used as Antidotes Removal and Elimination revention of Absorption Specific Drugs 143 Chapter 18 / Appendix Iii Chemicals 145 Solids 145 Semisolids 146 Liquids 146 Chapter 19 / Appendix Iv Contrast Media Used In Radiology 149 Chapter 20 / Appendix V Radio harmaceuticals 152 Chapter 21 / Appendix Vi Insecticides

102 ALABETICAL INDEX ALABETICAL DRUG INDEX abacavir sulfate + lamivudine + zidovudine 84 acetazolamide 113 acetylcholine chloride 114 acetyl salicylic acid (aspirin) 73 acitretin 119 acyclovir ( ) adalimumab 110 adefovir dipivoxil 86 adenosine 58 adrenaline hcl 68 adrenalin (epinephrine) (47-62) albendazole 87 albumin human 105 alemtuzumab 110 alendronate sodium 92 alfacalcidol 107 allopurinol ( ) alprazolam 70 alprostadil (prostaglandin e1) pediatric dose 94 alteplase 64 aluminum hydroxide + magnesium hydroxide 54 amantadine hcl 76 amethocain 113 amikacin sulfate 80 amiloride hcl + hydrochlorothiazide 58 amino acids for adult 105 aminocaproic acid 64 aminoglutethimide 100 aminophylline 67 amiodarone hcl (58-72) amlodipine besilate or felodepine 166 ammonium chloride 105 amobarbital 70 amoxicillin trihydrate (78-161) amoxicillin trihydrate + clavulanate potassium (78-79 ) ALABETICAL INDEX amphotericin b liposomal 83 ampicillin sodium 79 anagrelide 62 anastrozole 100 antihemorrhoidal /without steroids anti rabies serum (horse origin) 126 anti- rho (d) immunoglobulin 126 antithymocyte globulin (atg) 99 apracloidine hcl 113 aripiprazole 72 artemether + lumefantrine 86 artemisinin 86 artesunate (87-163) artesunate + sulfadoxine + pyrimehamine 86 artificial tears eye dropper 114 ascorbic acid (vitamin c) 65 asparaginase (crisantaspase) 97 atazanavir 85 atenolol 59 atorvastatin 65 atracurium besylate 128 atropine sulfate ( ) azathioprine 99 azelaic acid 119 azithromycin ( ) bacillus calmette-gue rin 100 bacitracin zinc + polymixin b sulphate 111 baclofen ( ) basiliximab 99 bcg vaccine (bacillus calmette - guérin) 124 beclomethasone 115 benzhexol hcl 76 benzoyl peroxide ( ) benztropine mesylate 76 beractant, phospholipid 68 betahistine dihydrochloride (46-73) betamethasone ( )

103 ALABETICAL INDEX betaxolol hcl 113 bevacizumab 98 bicalutamide 98 bimatoprost 113 bisacodyl (55-169) bisoprolol fumarate 59 bleomycin 96 bortezomib 98 bosentan 65 botulinum toxin type a 110 bretylium tosylate 58 brimonidine tartrate 113 brinzolamide 113 bromocriptine 92 b-sitosterol 121 budesonide ( ) budesonide 3mg capsules 55 budesonide turbuhaler 67 bulk-forming laxative 55 bupivacaine hcl ( ) buprenorphine 74 bupropion 77 busulfan 96 cabergoline 92 calcipotriol 119 calcipotriol + betamethasone dipropionate 118 calcitonin (salmon) - (salcatonin) 92 calcitriol ( ) calcium carbonate 106 calcium chloride ( ) calcium gluconate ( ) calcium lactate ) capecitabine 97 capreomycin 82 captopril (60-166) captopril 166 carbamazepine (75-164) ALABETICAL INDEX carbimazole (89-166) carboplatin 98 carboprost tromethamine 94 carboxymethyl-cellulose 114 carmustine 96 carteolol hcl 113 carvedilol (59-167) caspofungin acetate 83 cefaclor 49 cefepime hydrochloride 79 cefixime 79 cefotaxime sodium 79 ceftazidime pentahydrate 79 ceftriaxone sodium 79 cefuroxime 79 celecoxib 109 cephalexin monohydrate 79 cephradine 79 cetuximab 98 chloral hydrate 70 chlorambucil 96 chloramphenicol 111 chlordiazepoxide hcl 70 chlorhexidine gluconate ) chloroquine (86-163) chlorpheniramine maleate (68-170) chlorpromazine hcl (70-71) chlorthalidone 57 chlorzoxazone 110 cholecalciferol (vitamin d3) (46-107) cholestyramine 65 cinacalcet hydrochloride 89 cinnarizine 61 ciprofloxacin ( ) cisplatin 97 citalopram hydrobromide 72 clarithromycin (80-81)

104 ALABETICAL INDEX clindamycin 81 clindamycin or erythromycin for acne 119 clindamycin phosphate (81-118) clofazimin 82 clomiphene citrate 91 clomipramine hcl 72 clonazepam 76 clonidine hcl 59 clopidogral 64 clotrimazole ( ) cloxacillin or flucloxacillin sodium 78 clozapine 71 codeine phosphate 74 colchicine 110 colistin sulphomethate sodium 81 conjugated estrogen + norgestrel 90 corticorelin (corticotrophin-releasing factor, crf) 91 cromoglycate sodium 116 cyanocobalamin (vit b12) 101 cyclopentolate hcl 112 cyclophosphamide 96 cycloserine 81 cyclosporin 99 cyproterone acetate + ethinyl estradiol (120-98) cytarabine for injection 97 dabigatran (62-63) dacarbazine 97 dactinomycin 96 dalteparin 63 danazol 93 dantrolene sodium 129 dapsone 82 darbepoetin 102 darunavir 85 dasatinib monohydrate 98 daunorubicin hcl 96 desmopressin acetate 92 ALABETICAL INDEX dexamethasone (90-112) 90 dexamethasone 112 dextran (dextran40) + sodium chloride 105 dextromethorphan 69 dextrose ( ) diazepam (70-164) diazoxide 59 diclofenac 112 didanosine 84 diethylcarbamazine citrate 87 digoxin 57 dihydralazine mesilate or hydralazine hcl 59 diloxanide furoate (87-161) diltiazem hcl (sustainad release) 61 dimenhydrinate 73 dinoprostone 94 diphenhydramine hcl (46-68) diphetheria,tetanus, pertussis vaccine (dtp) 124 diphtheria and tetanus vaccine for adults 124 diphtheria and tetanus vaccine for children 124 diphtheria antitoxin 126 dipyridamol 64 disodium pamidronate 92 disopyramide phosphate 58 distigmine bromide 95 dobutamine hcl ( ) docetaxel 98 docusate sodium 55 domperidone (73-176) dopamine hcl (62-178) dorzolamide 113 doxorubicin hcl ( ) duloxetine 73 dydrogesterone (90-173) econazole nitrate 95 edrophonium chloride 129 efavirenz

105 ALABETICAL INDEX electrolyte oral rehydration salt (ors) 102 emtricitabine 85 enalapril maleate 60 enfuvirtide 85 enoxaparin 63 entecavir 86 ephedrine hydrochloride 62 epirubicin hcl 96 epoetin (recombinant human erythropoietins) 101 ergotamine tartarate 75 erlotinib hydrochloride 98 erythromycin (162-80) escitalopram (73-164) esmolol hcl 59 esomeprazole magnesium trihydrate 55 estradiol valerate 90 etanercept 110 ethambutol hcl (81-162) ethanolamine oleate 65 ethinyl estradiol 90 ethionamide 81 ethosuximide 75 etomidate 128 etoposide 97 etravirine 85 factor ix fraction for injection, which is sterile and free of hepatitis, hiv and any other infectious disease agent 65 factor viii (stable lyophilized concentrate) 64 fat emulsion 105 felodipine retard (modified release) 61 fentanyl citrate 74 ferrous salt ( ) ferrous sulfate or fumarate + folic acid 101 filgrastim g-csf 102 finasteride (90-120) flavoxate 95 fluconazole 83 ALABETICAL INDEX fludarabine phosphate 97 fludrocortisone acetate 90 flumazenil 129 fluorescein 114 fluorometholone 112 fluorouracil 97 fluoxetine (72-164) flupenthixol 71 fluphenazine decanoate 71 flutamide 100 fluticasone ( ) fluvoxamine maleate (72-73) formoterol + budesonide turbuhaler 66 foscarnet 85 fosinopril 60 furosemide 57 fusidic acid ( ) gabapentin 76 ganciclovir 85 gemcitabine 98 gemfibrozil 65 gentamicin ( ) glibenclamide (89-165) gliclazide (89-165) glipizide 89 glucagon 89 glycerin 169 glycopyrrolate bromide 128 gonadorelin (gonadotrophin-releasing hormone, lhrh) 92 goserlin acetate 93 granisetron 73 griseofulvin micronized 83 haemophilus influenza vaccine 125 haloperidol (71-164) heparin calcium for subcutaneous injection 48 heparin sodium (bovine) 62 hepatitis b vaccine (child) ( )

106 ALABETICAL INDEX homatropine 112 human chorionic gonadotrophin 91 human fibrinogen 105 human isophane insulin (nph) 88 human menopausal gonadotrophins, follicle stimulating hormone + luteinizing hormone 91 human normal immunoglobulin for i.m. injection 126 human soluble insulin (regular) 88 hyaluronidase 110 hydralazine hclmesilate 59 hydrochlorothiazide 57 hydrocortisone ( ) hydroxurea 97 hydroxychloroquine sulphate 110 hydroxyprogesterone hexanoate 90 hydroxypropyl methylcelulose 114 hyoscine butylbromide 54 ibuprofen ( ) ifosfamide 96 iloprost 65 imatinib mesilate 98 imidazole derivative ( ) imipenem + cilastatin 80 imipramine hcl (72-164) indapamide (sustainad release) 57 indinavir 85 indomethacin (47-109) infliximab 110 influenza virus vaccine 124 injectable polio vaccines (ipv) (salk vaccines) ( ) insulin aspart (88-165) insulin detmir (88-165) insulin glargine (88-165) insulin lispro (88-165) interferon alpha 99 interferon beta 1a 99 ipratropium bromide (67-168) ALABETICAL INDEX irbesartan (60-167) irintecan hydrochloride 98 iron saccharate 101 isoflurane 128 isoniazid (81-82) isoprenaline hcl (isoproterenol hcl) 62 isosorbide dinitrate (60-166) isotretinoin 120 itraconazole 83 ivabradine 61 ivermectin 87 kanamycin 82 kaolin + pectin 55 ketamine hcl 128 ketoconazole ( ) ketotifen 112 labetalol hcl 59 lactulose (55-169) lamivudine 84 lamotrigine 75 lansoprazole 54 latanoprost 113 l-carnitine 108 leflunomide 99 lenalidomide 97 letrozole 99 leucovorin calcium 97 leuprolide depo acetate 93 levamizole 87 levetiracetam 76 levofloxacin 82 levothyroxine sodium 89 lidocaine + fluorescein sodium 114 lidocaine hcl ( ) linezolid 81 liquid parafin 114 lisinopril

107 ALABETICAL INDEX lithium carbonate 72 lomustine 98 loperamide hcl 55 lopinavir + ritonavir 85 lorazepam 70 losartan potassium 60 lubricant 117 magnesium oxide ( ) mannitol 58 maprotiline hcl 72 measles vaccine ( ) mebendazole (87-162) mebeverine hcl (169-54) mechlorethamine hcl 96 meclozine + vitamin b6 (68-174) medroxyprogesterone acetate (90-173) mefenamic acid 109 mefloquine hcl 86 megestrol acetate 100 meloxicam ( ) melphalan 96 memantine hcl 77 meningococcal polysaccharide sero group (a,c,y,w-135 ) 124 mercaptopurine 97 meropenem 80 mesalazine 55 mesna 96 metformin hcl 89 methadone hcl 74 methotrexate 97 methoxsalen + ammidine 120 methoxy polyethylene glycol-epoetin beta 102 methyldopa (166-60) methylergonovine maleate 94 methylphenidate 73 methylprednisolone 90 metoclopramide hcl 73 ALABETICAL INDEX metolazone 57 metoprolol tartrate 59 metronidazole ( ) mexiletine hcl 59 micafungin sodium 83 miconazole ( ) midazolam 70 miltefosine 98 minocycline hcl 80 mirtazapine 73 misoprostol 94 mitomycin 96 mitoxantrone hydrochloride 97 mixed gas gangrene antitoxin 126 moclobemide 72 mometasone furoate ( ) montelukast sodium 69 morphine sulfate 74 moxifloxacin hydrochloride 82 multienzyme (pancreatic enzymes : protease u ; lipase 5,000-10,000 u and amylase 5,000-10,000 u) /capsule or enteric coated tablet 56 multivitamins 107 mupirocin 116 muromonab-cd3 99 mycophenolate mofetil 99 mycophenolate sodium 99 nafarelin 93 nalbuphine hcl 74 naloxone hcl 129 naphazoline ( ) naproxene 109 natalizumab 69 natamycin 112 nateglinide 89 nelfinavir 85 neomycin sulfate

108 ALABETICAL INDEX neostigmine methylsulfate 129 niclosamide 87 nicotine (24-hour effect dose) 77 nifedipine retard (modified release) 61 nilotinib 98 nimodipine 61 nitrazepam 70 nitrofurantoin (82-83) nitroglycerin (46-60) isosorbide dinitrate 166 non sedating antihistamine tablet (cetirizine, or loratadine) ( ) noradrenalin acid tartrate (62-46) norethisterone (90-173) norfloxacin 83 nystatin ( ) octreotide 100 ofloxacin (82-111) oily phenol injection 56 olanzapine 71 olopatadine hcl 112 omeprazole sodium 55 ondansetron 73 orlenograstim (g-csf) 102 oxaliplatin 98 oxybuprocaine 114 oxybutynin hcl xl 95 oxymetazoline 113 oxytocin 94 paclitaxel 98 paliperidone 72 palivizumab 86 pancuronium bromide 128 pantoprazoole sodium sesquihydrate 55 papaverin 61 para-amino salicylate sodium 82 paracetamol ( ) pegaspargase 97 ALABETICAL INDEX pegylated interferon alpha 2 a 100 pemetrexed 97 penicillamine 110 penicillin benzathine (penicillin g) 78 pentamidine isethionate 87 pentavalent vacc.(hbv+hib+dtp) 175 pentoxifylline 61 perindopril 60 permethrin ( ) pethidine hcl 74 phenobarbital (phenobarbitone) 75 phenoxymethyl penicillin (penicillin v potassium) 78 phentolamine mesylate 60 phenylephrine hcl (62-113) phenytoin sodium ( ) phosphate enema 55 phosphate salt 106 phytomenadione 107 pilocarpine 113 pioglitazone 89 piperacillin + tazobactam 79 plasma protien solution 105 pneumococcal polyvalent (23 valent) vaccine. 124 poliomyelitis vaccine live oral: (sabin strain) 125 polyacrylic acid 114 polyethylene glycol, g oral powder, sodium bicarbonate mg, sodium chloride 350 mg, potassium chloride 46.6 mg /sachet 56 polymyxin b sulfate + neomycin sulfate + hydrocortisone 115 polystyrene sulphonate resins (calcium) 102 potassium salt 102 pramipexole 76 pravastatin 65 praziquantel (87-163) prazosin hcl (167-60) prednisolone ( ) pregabalin (76-164)

109 ALABETICAL INDEX prilocaine hcl + felypressin 130 primaquine phosphate (86-163) primidone 75 procainamide hcl (46-58) procarbazine 97 procyclidine hydrochloride 76 progesterone 90 proguanil hcl 86 promethazine hcl (46-68) proparacaine 114 propofol 128 propranolol hcl ( ) propylthiouracil 89 protamine sulfate 62 prothionamide 82 protirelin (thyrotrophin-releasing hormone, trh) 92 pseudoephedrine hcl 30 mg + antihistamine (69-171) pumactant phospholipid 68 pure aluminum hydroxide 106 pyrazinamide (82-162) pyrethrins 122 pyridostigmine 110 pyridoxine hcl (vitamin b6) 107 pyrimethamine 86 quetiapine 72 quinidine sulfate 58 quinine dihydrochloride 86 quinine sulphate 86 rabies immunoglobulin for i.m. injection 126 rabies virus vaccine 125 racemic epinephrine 62 raltegravir ( ) ranitidine 54 rasburicase 110 recombinant factor viia 64 follitropin 91 repaglinide 89 ALABETICAL INDEX reteplase 64 tretinoin 119 retinol (vitamin a) 108 ribavirin 86 rifabutine 82 rifampicin (82-162) riluzole 70 ringer s lactate solution 104 risperidone 71 ritonavir 85 rituximab 110 rivaroxaban 62 rocuronium bromide 128 ropivacaine hcl 130 rose bengal 114 rosuvastatin (65-167) salbutamol (66-168) salmeterol + fluticasone propionate 66 scorpion anti-venin 127 selegiline hcl 76 senna (55-169) sevelamer 106 sevoflurane 128 sildenafil 65 silver sulfadiazine (sterile) 120 simethicone 56 simvastatin (65-167) sirolimus 99 sitagliptin phosphate 89 snake anti-venin 127 sodium acetate 102 sodium aurothiomalate 109 sodium bicarbonate ( ) sodium chloride ( ) sodium cromoglycate 67 sodium hyaluronate ( ) sodium hyaluronate intra- artircular (mw over 3 million) ( )

110 ALABETICAL INDEX sodium nitroprusside (46-59) sodium phosphate 104 sodium valproate (65-76) somatropin (human growth hormone) 91 sorafenib 98 sotalol hydrochloride 59 spectinomycin hcl 81 spiramycin 81 spironolactone (58-168) sterile balanced salt solution (bss) 114 sterile water for injection 177 stibogluconate sodium (organic pentavalent antimony) 87 streptokinase 64 streptomycin sulfate 82 strontium ranelate 92 succinylcholine chloride 128 sucralfate 54 sulfacetamide (48-111) sulfadiazine 81 sulfadoxin500mg+ pyrimethamine25mg 163 sulfasalazine, 500 mg/tablet 55 sulindac 109 sulpiride 71 sumatriptan succinate (160-75) tacrolimus (99-121) tamoxifen citrate 100 tamsulosin hcl (modified release) 60 telmisartan (46-60) telmisartan 167 temazepam 70 tenofovir disoproxil fumurate 84 terbinafine ( ) teriparatide 92 terlipressin acetate 100 tetanus antitoxin 126 tetanus immunoglobulin for i.m. injection 126 tetanus vaccine 124 ALABETICAL INDEX tetracosactrin (corticotrophin) 91 tetracycline hcl ( ) thalidomide 96 theophylline 67 thiacetazone 82 thiamine (vitamin b1) 107 thioguanine 97 thiopental sodium ( ) tigecycline 80 timolol 113 tinzaparin sodium 63 tiotropium 67 tirofiban hydrochloride 64 tobramycin + dexamethasone 111 tobramycin sulfate 80 tolterodine tartrate 95 topiramate 76 trace elements additive (pediatric dose) 106 tramadol hcl 74 tranexamic acid 64 trastuzumab 98 trazodone 72 triamcinolone acetonide ( ) triamterene + hydrochlorothiazide 58 trifluoperazine hcl 71 trifluridine 112 trimetazidine dihdrochloride (modified release) 65 trimethoprim + sulfamethoxazole 81 triple virus vaccine ( measles-mumps-rubella ) 125 triptorelin acetate 91 tropicamide 112 tuberculin ppd skin test 126 typhoid vaccine 125 urea 117 urofollitrophine f.s.h 91 ursodeoxycholic acid 56 valaciclovir hcl

111 ALABETICAL INDEX valganciclovir hcl 85 Valsartan (60-167) Vancomycin CL 81 VARICELLA- ZOSTER VIRUS (CICKEN OX VACCINE) 125 Vasopressin ( ) Vecuronium bromide 128 Venlafaxine CL (Sustained Release) 73 Verapamil CL 61 Verapamil CL (Sustainad Release) 61 Vigabatrin 76 Vinblastine sulfate 97 Vincristine sulfate 97 Vinorelbine 98 Vitamin B1 & B6 & B Vitamin B Complex 108 Vitamin E 107 Voriconazole 83 Warfarin sodium 62 Water For Injection (Sterile) 105 Wax removal ( ) Xylometazoline CL 116 YELLOW FEVER VACCINE 125 Zidovudine (Azidothymidine, AZT) 84 Zidovudine + Lamivudine 84 Zinc Sulfate 146 Zoledronic acid 92 Zolpidem tartrate 70 Zuclopenthixol Acetate (I.m) 72 ALABETICAL INDEX

112 Notes

113 Notes

114 Notes

115 Notes